CYCLOAKYLUREA DERIVATIVE

Abstract

The present invention relates to a medicament for the treatment or prevention of a disease related to the orexin receptor, especially the orexin receptor type 2, comprising a novel compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient; more specifically, the present invention relates to a medicament for the treatment or prevention of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.

Description

DERIVED FROM CYCLOALOUILUREA TECHNICAL FIELD The present invention relates to a medicament for the treatment or prevention of a disease related to the orexin receptor, especially the orexin receptor type 2, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as a active principle. In more detail, the present invention relates to a medicament for the treatment or prevention of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc. BACKGROUND OF THE INVENTION Orexin is a neuropeptide that is specifically produced in a specific neuron that spreads throughout the lateral hypothalamus and its adjacent region. Orexin is an endogenous ligand of the orexin receptor which is a G protein-coupled receptor that exists primarily in the brain, which binds to the orexin receptor. The orexin receptor is known to have two subtypes, type 1 and type 2 (Non-Patent Reference 1). It was reported that a narcolepsy-like symptom could be improved in a transgenic mouse whose orexin neuron was denatured by the intraventricular injection of an orexin peptide (Non-Patent Reference 2), and that a narcolepsy-like symptom could be initiated by the inactivation of a prepro-orexin which is a precursor protein of orexin (Reference No. Patent 3), in addition the concentration of orexin in the cerebrospinal fluid of patients with narcolepsy was notably reduced (Reference No. Patent 4). Therefore, it is suggested that narcolepsy may be initiated due to lack of orexin. Furthermore, it was reported that there was a mutation of the orexin 2 receptor in a dog suffering from hereditary narcolepsy (Non-Patent Reference 5), suggesting that the orexin 2 receptor is involved in sleep-wake function. Furthermore, it was revealed that the narcolepsy-like symptom was initiated in an orexin 2 receptor KO mouse (Non-Patent Reference 6), strongly suggesting that stimulation at the orexin 2 receptor is involved in sleep-wake function. Therefore, an orexin 2 receptor agonist is expected to be a promising therapy for a patient presenting with hypersomnia-type symptoms such as narcolepsy. Recently, a compound has been reported that has agonist action at the orexin 2 receptor (Patent Reference 1). PRIOR ART (Patent Reference) [Patent Literature 1] WO 2017 / 135306 (Non-Patent Reference) [Non-Patent Literature 1] Cell, Vol.92, 573-585, 1998 [Non-Patent Literature 2] Proc. Nati. Academic Sci. USA, Vol. 101, 4649-4654, 2004 [Non-Patent Literature 3] Cell, Vol. 98, 437-451, 1999 [Non-Patent Literature 4] THE LANCET, Vol. 355, 39-40, 2000 [Non-Patent Literature 5] Cell, Vol. 98, 365-376, 1999 [Non-Patent Literature 6] Neuron, Vol. 38, 715-730, 2003 [Non-Patent Literature 7] Brain, Vol. 130, 1577-1585, 2007 [Non-Patent Literature 8] Neuroscience Letters, Vol. 569, 68-73, 2014 BRIEF DESCRIPTION OF THE INVENTION (Technical Problem) The purpose of the present invention may be to provide a medicament for the treatment or prevention of an orexin type 2 receptor-related disease, for example, narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc. (Solution to the problem) The present inventors have studied extensively to achieve the above purpose, and therefore have found that a compound of the following formula (1) or a pharmaceutically acceptable salt thereof (hereinafter, may be referred to as the present compound) has a therapeutic and preventive effect for orexin type 2 receptor related disease, for example, narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc. Based on the new findings, the present invention has been completed. The present invention can be shown as follows. (Point Al) A compound of the formula (1): (1) or a pharmaceutically acceptable salt thereof wherein R1 is optionally substituted Ce-ium aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, optionally substituted 4- to 10-membered saturated heterocyclyl group, or cyano; L1 and L2 are each independently single bond, -CH2-, or oxygen atom; R2 is hydrogen atom, hydroxy group, halogen atom, cyano, or optionally substituted C1-4 alkyl; or when L1 is single bond, R1 and R2 can combine together as a spiro ring to form optionally substituted C3-6 saturated carbon ring or optionally substituted saturated 4 to 10 membered heteroring; R3 and R4 are each independently hydrogen atom, halogen atom, cyano, -(C=O)NR5R6, carboxy group, -(C=O)O-R7, optionally substituted C1-4 alkyl, or C1-4 alkoxy optionally substituted, where R3 and R4 can be attached to the same carbon atom if chemically possible; or when R3 and R4 are attached to different carbon atoms, R3 and R4 can be taken together via a C1-6 alkylene to form a fused ring or a bridged ring; R5 to R7 are each independently hydrogen atom, halogen atom, or optionally substituted C1-4 alkyl; n is an integer of 1 or 2; Ring G is optionally substituted Ce-ium aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, or optionally substituted 4- to 10-membered saturated heterocyclyl group; A1 is oxygen atom or sulfur atom; A2is oxygen atom or -NH-; A3es -CH-, nitrogen atom, or carbon atom; and the bond accompanied by a dashed line is each independently a single bond or a double bond. (Point A2) The compound of Point Al or a pharmaceutically acceptable salt thereof, wherein in R2-R7, the optionally substituted C1-4 alkyl substituent is the same or different from one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkoxy, and C3-7 cycloalkyl; and the optionally substituted C1-4 alkoxy substituent is the same or different from one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C3-7 cycloalkyl; in R1, the optional substituent of the optionally substituted Ce-ium aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and optionally substituted 4- to 10-membered saturated heterocyclyl group is each independently having at least one substituent selected from the group consisting of hydrogen atom, halogen atom, hydroxy group, Ce-ium aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), Ci-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkoxy, and C3-7 cycloalkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C37 cycloalkyl), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl optionally substituted with the same or different one or more halogen atoms, and C3-7 cycloalkyl), and aromatic heterocyclyl group from 5 to 10-membered (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl); and on ring G, the optional substituent of optionally substituted Cs-io aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and 4- to 10-membered saturated heterocyclyl group. optionally substituted is each independently at least one substituent selected from the group consisting of halogen atom, Ci-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom , hydroxy group, Ci-4 alkoxy, and C3-7 cycloalkyl), aromatic carbocyclyl group of Ce-ium (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of atom halogen, hydroxy group, C1-4 alkyl, and C3-7 cycloalkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Cu alkyl, C1-4 alkoxy, and C37 cycloalkyl), and C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl); or when there are plural optional substituents, two of them can be taken together via a Ci 6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring. (Point A3) The compound of Point Al or A2 or a pharmaceutically acceptable salt thereof, wherein in R2-R7, the optionally substituted C1-4 alkyl substituent is the same or different one or more substituents selected from the group consisting of atom of halogen and C1-4 alkoxy; and the optionally substituted C1-4 alkoxy substituent is the same or different from one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl; in R1, the optional substituent of optionally substituted Ce-ίο aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and optionally substituted 4- to 10-membered saturated heterocyclyl group is each independently having at least one substituent selected from the group consisting of hydrogen atom, halogen atom, hydroxy group, Ce-ium aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkoxy, and C3-7 cycloalkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C37 cycloalkyl), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl optionally substituted with the same or different one or more halogen atoms, and C3-7 cycloalkyl), and 5- to 10-membered aromatic heterocyclyl group ( which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl); and in ring G, the optional substituent of the optionally substituted Cs-io aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and optionally substituted 4- to 10-membered saturated heterocyclyl group. substituted is each independently at least one substituent selected from the group consisting of halogen atom, C1-6 alkyl (which may optionally be substituted with the same or different one or more substituents selected from the group consisting of halogen atom and Ci 4 alkoxy), Ce 10 aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy) , C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), and C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); or when there are plural optional substituents, two of them can be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring. (Point A4) The compound of any of Points Al to A3 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the following formulas (la-1) to (la-4): (1a-3) where X1- X7 are each independently nitrogen atom or CRa6; Q1 and Q2 are oxygen atom, -NRa7-, or sulfur atom; Ral_ ^7are box one independently (if there is plural of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, aromatic carbocyclyl group of Ceium (which may be optionally substituted with the same or different one or more substituents selected from the group that consists of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, group hydroxy, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, alkyl C1-4, and C1-4 alkoxy), or 5- to 10-membered aromatic heterocyclyl group; where Ra4 and Ra5 can bond to the same carbon atom if chemically possible; and when X1 and and q1 is an integer of 1 or 2. (Point A5) The compound of any of Items Al to A4 or a pharmaceutically acceptable salt thereof, wherein the ring G is selected from the following (lb-1) to (lb-4): (1b-1) (1b-2) (1b-3) (1b-4) where W1, W3, W5, W6, and W7 are each independently nitrogen atom or CRb4; W2, W4, and W8 are NRb5, oxygen atom, or CRb6Rb7; Rbl_ Rb7are each independently (if plural of CRb4, each Rb4is also independently), hydrogen atom, Ci-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), Ce-ium aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1 alkoxy -4), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); where Rb and Rb2 can bond to the same carbon atom if chemically possible; or Rb and Rb2 can be taken together via Ci6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring. (Point A6) The compound of any of Points Al to A5 of formula (2): or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the following formulas (la-1) to (la-4): where X1- X7 are each independently nitrogen atom or CRa6; Q1 and Q2 are oxygen atom, -NRa7-, or sulfur atom; Ral-Ra7are each independently (if plural of CRa6, each Ra6is also independently), hydrogen atom, halogen atom, aromatic carbocyclyl group of Ce-ium (which may be optionally substituted with the same or different one or more selected substituents from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group that consists of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-6 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, group hydroxy, C1-4 alkyl, and C1-4 alkoxy), or 5- to 10-membered aromatic heterocyclyl group; where Ra4 and Ra5 can bond to the same carbon atom if chemically possible; and when X1 and ; and q1 is an integer of 1 or 2; L1 and L2 are each independently single bond, -CH2-, or oxygen atom; R2 is hydrogen atom, hydroxy group, halogen atom, cyano, or optionally substituted C1-4 alkyl; R3 and R4 are each independently hydrogen atom, halogen atom, C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci4 alkoxy, and C3-7 cycloalkyl), or C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and cycloalkyl). from C3-7); where R3 and R4 can bond to the same carbon atom if chemically possible; and when R3 and R4 are attached to different carbon atoms in the ring, R3 and R4 can be taken together via a Ci-e alkylene to form a fused ring or bridged ring; The G ring is selected from the following (lb-1) to (lb-4): (1b-1) (1b-2) (1b-3) (1b-4) where W1, W3, W5, W6, and W7 are each independently nitrogen atom or CRb4; W2, W4, and W8 are NRb5, oxygen atom or CRb6Rb7; Rbl_Rb7are cac|a independently (if plurals of CRb4, each Rb4is also independently), hydrogen atom, C1-6alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen and C1-4 alkoxy), Ce-ium aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy). C1-4), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); where Rb and Rb2 can bond to the same carbon atom if chemically possible; or Rb and Rb2 can be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring; A1 is oxygen atom or sulfur atom; A2is oxygen atom or -NH-; and A3es -CH-, nitrogen atom, or carbon atom. (Point A7) The compound of Item A6 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the following formulas (la-1), (la-2), and (la-3-1): where X1- X6 are each independently nitrogen atom or CRa6; Q1 and Q2 are oxygen atom, -NRa7-, or sulfur atom; and Ral- Ra3, Ra6, and Ra7 are each independently (if plural of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, aromatic carbocyclyl group of Ce-ium (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Cu alkyl, and C1-4 alkoxy), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), or 5- to 10-membered aromatic heterocyclyl group; wherein when X1 and X3. (Point A8) The compound of Items A6 or A7 or a pharmaceutically acceptable salt thereof, wherein the ring G is selected from the following (lb-1), (lb-2), and (lb-4): (1b-4) where W1, W3, W5, W6, and W7 are each independently nitrogen atom or CRb4; W2and W4are NRb5o CRb6Rb7; and Rbl, Rb2, and Rb4-Rb7 are each independently (if plural of CRM, each Rb4 is also independently), hydrogen atom, Ci-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), aromatic carbocyclyl group of Ce-ίο (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1 alkyl -4, and C1-4 alkoxy), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), cycloalkyl C3-7 (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); where Rb and Rb2 can bond to the same carbon atom if chemically possible; or Rb and Rb2 can be taken together via a C1-6 alkylene to form a bridged bicyclic structure. (Point A9) The compound of any of Items A6 to A8 or a pharmaceutically acceptable salt thereof, wherein the ring G is selected from the following (lb-1) and (lb-2): where W1 and W3 are nitrogen atom or CRb4; W2and W4are NRb5o CRb6Rb7; and Rbl, Rb2, and Rb4-Rb7 are each independently hydrogen atom, Ci-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy ), Cs-10 aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), Cs-10 alkoxy C1-4 (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), C3-7 cycloaIkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); where Rb and Rb2 can bond to the same carbon atom if chemically possible; or Rb and Rb2 can be taken together via a C1-6 alkylene to form a bridged bicyclic structure. (Point A10) The compound of any of Points Al to A9 of formula (3): (3) or a pharmaceutically acceptable salt thereof, wherein R1 is the following formula (la-1), (la-2), or (la-3-1): where X1- X6 are each independently nitrogen atom or CRa6; Q1 and Q2 are oxygen atom or sulfur atom; Ral- Ra3 and Ra6 are each independently (if they are plurals of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, and C1-4 alkoxy), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, group hydroxy, C1-4 alkyl, and C1-4 alkoxy), cyano, or C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, group hydroxy, C1-4 alkyl, and C1-4 alkoxy); wherein when X1 and X3; L1 and L2 are each independently single bond or oxygen atom; R2 is hydrogen atom, halogen atom, or C1-4 alkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and hydroxy group; R3 and R4 are each independently halogen atoms; the G ring is as follows (lb-1), (lb-2-1), (lb-2-2), or (lb-2-3): (1b-1-1) (1b-2-1) (1b-2-2) (1 b-2-3) where Rb5 is hydrogen atom, or C1-6 alkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy; and A1is oxygen atom or sulfur atom. (Point All) The compound of any of Items A4 to A10 or a pharmaceutically acceptable salt thereof, wherein R1 is the formula (la-2), and Rales hydrogen atom, halogen atom, C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), C3-cycloalkyl 7 (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), or C1-4 alkoxy ( which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl). (Point A12) The compound of Item A10 or All or a pharmaceutically acceptable salt thereof, wherein R1 is the formula (la-2), and X4 and X5 are both nitrogen atoms. (Point A13) The compound of any of Items A10 to A12 or a pharmaceutically acceptable salt thereof, wherein the ring G is the formula (lb-1-1), and Rb5 is C1-4 alkyl which may be optionally substituted with the same or different one or more halogen atoms. (Point A14) The compound of any of Items A10 to A12 or a pharmaceutically acceptable salt thereof, wherein the ring G is the formula (lb-2-1), and Rb5 is hydrogen atom, or Ci-4 alkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy. (Point A15) The compound of any of Points Al to A12 of formula (4): or a pharmaceutically acceptable salt thereof, where R1 is as follows (la-2-1): where Q2is oxygen atom or sulfur atom; Ra2 is a C3-7 cycloalkyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy) or cycloalkoxy group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); R2 is C1-4 alkyl; the G ring is as follows (lb-1-1) or (lb-2-1): (1b-1-1) (1b-2-1) where Rb5 is C1-4 alkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and Ci-alkyl. 4; and L2 is a single bond or oxygen atom. (Point A16) The compound of Item A15 or a pharmaceutically acceptable salt thereof, wherein Ra2 is a C3-7 cycloalkyl group that may be optionally substituted with the same or different one or more substituents selected from halogen atoms, and R2 is methyl group. (Point A17) The compound of Item A15 or A16 or a pharmaceutically acceptable salt thereof, wherein Ra2 is a cyclopropyl group which may be optionally substituted with the same or different one or more substituents selected from halogen atoms, and R2 is methyl group. (Point A18) The compound of any of Points A15 a acceptable thereof, wherein the ring G is the formula (lb-2-1), and Rb8 is isopropyl group. A17 0 a pharmaceutically salt (Item A19) The compound of any acceptable thereof, wherein the ring G is the formula (lb-1-1), Rb5 is isopropyl group, and L2 is oxygen atom. Points A15 to A17 0 a pharmaceutically acceptable salt (Point A20) The compound of any of Points A15 to acceptable thereof, where Q2 is oxygen atom. A19 0 a pharmaceutical salt (Point A21) The Point Al compound or a pharmaceutically acceptable salt thereof, which is selected from the following compound names or structures: Example 22: 4-(5-cyclopropíl-1,2-oxazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2íl) p¡peraz¡n-l-¡l]cyclohex¡l}-4-methylp¡peradina-l-carboxamide Example 23: 4-(5-cycloprop¡l-l,2,4-oxadiazol-3-¡l)-N-{(lSz6R)-2,2-difluoro-6-[4(propan-2-¡l)piperazin -l-yl]cyclohex¡l}-4-methylp¡perina-l-carboxamide Example 24: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-l)-N-{(lR,6S)-2,2-difluoro-6-[4( propan-2-¡l)p¡perazin-l-¡l]cyclohex¡l}-4-met¡lp¡per¡dina-l-carboxam¡da Example 25: 4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2¡l) p¡peraz¡n-l-¡l]cyclohex¡l}-4-methylp¡perdina-l-carboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 62: 4-(5-cyclopropyl-1,2,4-oxadíazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3(propan -2-¡l)-3,8-d¡azabic¡clo[3.2.1]octane-8-¡l]cyclohex¡l}-4-methylpiperid¡na-l-carboxamide Example 63: N-{(lR,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan8-yl]cyclohex¡l}-4-met¡l-4-(4-met¡lfen¡l)p¡per¡dina-l-carboxamide Example 65: 4-(5-cyclopropyl-l,2-oxazol-3-il)-N-{(lR,6S)-2,2-difluoro-6-[3-(propan-2yl)- 3,8-d¡azab¡cyclo[3.2.1]octane-8-¡l]cyclohex¡l}-4-met¡lpiper¡dina-l-carboxamide Example 66: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-yl]cyclohexyl}-4-{5[(lS,2S) )-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡perína-l-carboxamide Example 68: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4methyl-4 -{5-[(lS,2R)-2-met¡lc¡clopropyl]-l,2,4-oxad¡azol-3-yl}piperidine-l-carboxamide Example 69: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-yl]cyclohexyl}-4methyl-4-{5- [(lR,2S)-2-met¡lc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}p¡perina-l-carboxamide Example 79: r5C-4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-¡l)-N-{(lR,6S)-2,2-difluoro-6-[ 4(propan-2-yl)piperaz¡n-l-¡l]cyclohexyl}-4-methylp¡perina-l-carbot¡oamide Example 80: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-yl)-N-{(lR,6S)-2,2-difluoro-6-[45 (propan-2 -¡l)p¡peraz¡n-l-il]cyclohex¡l}-4-met¡lp¡per¡dina-l-carbot¡oam¡da. (Point A22) The Point Al compound or a pharmaceutically acceptable salt thereof, which is selected from the following compound names or structures: Example 64: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-l)-N-[(lR,6S)-2,2-difluoro-6-{[( 3R)-l(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidina-l-carboxamide Example 67: N-[(lR,6S)-2,2-difluoro-6-{[(3R)-l-(propan-2-yl)pyrrolidin-315 ¡l]ox¡}c¡clohexyl] -4-methyl·4-(4-methylphenyl)pyridine-l-carboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 71: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-yl)-N-[(lR,6S)-2 / 2-difluoro-6-{[(3S )-l(propan-2-¡l)pyrrolidin-3-¡l]oxy}cyclohexyl]-4-methylpiperidina-l-carboxamide Example 72: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-¡l)pyrrolidin-3yl]ox¡}c¡clohex¡l ]-4-{5-[(lS,2S)-2-fluorocíclopropyl]-1,2,4-oxadíazol-3-yl}-4-methyllpéndin-lcarboxamide Example 73: N-[(lR,6S)-2,2-difluoro-6-{[(3R)-l-(propan-2-¡l)pyrrolídin¡n-310yl]oxy}cyclohex ¡l]-4-{5-[(lS,2S)-2-fluoroc¡clopropyl]-l,2,4-oxad¡azol-3-yl}-4-methylpipendine-lcarboxamide Example 74: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-¡l)pyrrolidin-3¡l]ox¡}cyclohexyl]-4- methyl-4-{5-[(lR,2S)-2-methylcyclopropyl]-l,2,4-oxadilazole-3-l}piperidine-lcarboxamide Example 75: 4-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-N-[(lR,6S)-2,2-difluoro-6-{[(3S,4S)4-fluoro -l-(propan-2-¡l)pyrrolidin-3-yl]oxy}cyclohex¡l]-4-methylpiperidina-l-carboxamide Example 76: 4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-6-{[(3R)-4,4-difluorO-10 ( propan-2-¡l)pyrrolidin-3-¡l]ox¡}-2,2-difluorocyclohex¡l]-4-methylpiper¡dine-l-carboxamide. (Point A23) A medicament for the treatment of a disease related to the orexin receptor, comprising the compound of any of Points Al to A22 or a pharmaceutically acceptable salt thereof. (Point A24) A medication for the treatment of narcolepsy, idiopathic hypersominus, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, hypersomnia associated with dementia with Lewy body, hypersomnia syndrome involving hypersomnia during the day (e.g. Kleine-Levin syndrome, major depression accompanied by hypersomnia, dementia with Lewy body, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen encephalitis, Wernicke encephalopathy, limbic encephalitis, Hashimoto encephalopathy), coma, loss of consciousness, obesity (e.g. malignant mast cells, extrinsic obesity, hyperinsulin obesity, hyperplasmic obesity, pituitary obesity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, childhood obesity, upper body obesity, alimentary obesity, gonadal obesity, systemic mastocytosis, primary obesity , central obesity), insulin resistance syndrome, Alzheimer's, impaired consciousness such as coma, side effect or complication caused by anesthesia, sleep disturbance, sleep problems, insomnia, intermittent sleep, nocturnal myoclonus, interruption of REM sleep, decompensation jet lag syndrome, shift worker sleep disorder, dyssomnia, sleep terror, depression, major depression, sleepwalking, enuresis, sleep disorder, Alzheimer's sundown syndrome, disease associated with the circadian rhythm, fibromyalgia , condition resulting from decreased sleep quality, bulimia, obsessive eating disorder, obesity-related diseases, hypertension, diabetes, elevated plasma insulin level / insulin resistance, hyperlipidemia, hyperlipidemia, endometrial cancer, cancer breast, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart rhythm, arrhythmia, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disease, sudden death, polycystic ovary, craniopharyngioma, Prader-Willi syndrome, Froehlich syndrome, growth hormone deficiency, variant short stature, Turner syndrome, children suffering from acute lymphoblastic leukemia, syndrome reproductive hormone abnormality, decreased fertility, infertility, hypogonadism in men, dysfunction of sexual / reproductive function such as hirsutism in women, fetal defect associated with obesity in motherhood, gastrointestinal motility disorder such as gastroesophageal reflux related to obesity, obesity hypoventilation syndrome (Pickwickian syndrome), respiratory disease such as respiratory distress, inflammation such as systemic vascular inflammation, arteriosclerosis, hypercholesterolemia, hyperuricemia, lower back pain, gallbladder disease, gout, kidney cancer, secondary risk of obesity such as risk of left ventricular hypertrophy, migraine, headache, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweats, disease in the genital / urinary system, disease associated with sexual function or fertility, persistent depressive disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder , separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorder such as brain deficiency developed after cardiac bypass surgery or heart transplant, stroke, ischemic stroke, cerebral ischemia, spinal column trauma, head injury, periparturient hypoxia, cardiac arrest, hypoglycemic nerve injury, Huntington's disease,amyotrophic lateral sclerosis, multiple sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorder associated with muscle spasm, delirium, amnestic disorder, age-related cognitive decline, schizoaffective disorder, paranoia, drug addiction, movement disorder, chronic fatigue syndrome, fatigue, drug-induced parkinsonian syndrome, Giles de la Tourette syndrome, chorea, myoclonus, tic, restless leg syndrome, dystonia, dyskinesia, attention deficit hyperactivity disorder (ADHD), behavioral disorder, urinary incontinence, withdrawal syndrome, trigeminal neuralgia, hearing loss, ringing in the ears, nerve injury, retinopathy, macular degeneration, vomiting, cerebral edema, pain, bone pain, arthralgia, dental pain, cataplexy, or traumatic brain injury, comprising the compound of any of Items Al to A22 or a pharmaceutically acceptable salt thereof. (Point A25) A medication for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy body, comprising the compound of any of Points Al to A22 or a pharmaceutically acceptable salt thereof. (Point A26) A method for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy body, comprising administering a therapeutically effective of the compound of any of Items Al to A22 or a pharmaceutically acceptable salt thereof to a patient in need thereof. (Point A27) The use of the compound of any of Items Al to A22 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving type symptoms narcolepsy, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy body. The present invention may also be shown as follows. (Point 1) A compound of the formula (1): (1) or a pharmaceutically acceptable salt thereof wherein R1 is optionally substituted Ce-ium aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, optionally substituted 4- to 10-membered saturated heterocyclyl group, or cyano; L1 and L2 are each independently single bond, methylene (which may be optionally substituted with the same or different one or more C1-4 alkyl), -NR8-, -C(=O)-, OC(=O)-, - SO-, -SO2-, -S-, or oxygen atom; R2 is hydrogen atom, hydroxy group, halogen atom, cyano, or optionally substituted C1-4 alkyl; or when L1 is single bond, R1 and R2 may combine together as a spiro ring to form optionally substituted C3-6 saturated carbon ring or optionally substituted saturated 4 to 10 membered heteroring; R3 and R4 are each independently hydrogen atom, halogen atom, cyano, -(C=O)NR5R6, carboxy group, -(C=O)O-R7, optionally substituted C1-4 alkyl, or C1-4 alkoxy optionally substituted, where R3 and R4 can be attached to the same carbon atom if chemically possible; or when R3 and R4 are attached to different carbon atoms, R3 and R4 can be taken together via a Ci-e alkylene to form a fused ring or a bridged ring; R5 to R7 are each independently hydrogen atom, halogen atom, or optionally substituted C1-4 alkyl; R8 is each independently hydrogen atom or optionally substituted C1-4 alkyl; n is an integer of 1, 2, 3, or 4; Ring G is optionally substituted C6-10 aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, or optionally substituted 4- to 10-membered saturated heterocyclyl group; A1 is oxygen atom or sulfur atom; A2is oxygen atom or -NR8-; A3es -CH-, nitrogen atom, or carbon atom; and the bond accompanied by a dashed line is each independently a single bond or a double bond. (Point 2) The compound of item 1 or a pharmaceutically acceptable salt thereof, wherein in R2-R8, the optionally substituted C1-4 alkyl substituent is the same or different from one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkoxy, Ce-io aromatic carbocyclyl group, and C3-7 cycloalkyl; and the optionally substituted C1-4 alkoxy substituent is the same or different from one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C3-7 cycloalkyl; in R1, the optional substituent of Ce-ium aromatic carbocyclyl group optionally substituted ζζίταηη / ζζηζ / Ε / γίΛΐ, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and saturated heterocyclyl group 4 to 10 members optionally substituted is each independently at least one substituent selected from the group consisting of hydrogen atom, halogen atom, hydroxy group, aromatic carbocyclyl group of Ce-ίο (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkoxy, and C3-7 cycloalkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Cu alkyl, C1-4 alkoxy, and C37 cycloalkyl), C1-6 alkylamino (the alkyl group of which may be optionally substituted with halogen atom, hydroxy group, or C3-7 cycloalkyl), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, alkyl Ci 4, Ci 4 alkoxy, and C 3 cycloalkyl 7), cyano, Ci 4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, alkyl C1-4 optionally substituted with the same or different one or more halogen atoms, and C3-7 cycloalkyl), and 5- to 10-membered aromatic heterocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkyl, Ci-4 alkoxy, and C3-7 cycloalkyl); and on ring G, the optional substituent of optionally substituted Cs-io aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally-substituted C3-6 saturated carbocyclyl group, and 4 to 10 saturated heterocyclyl group. optionally substituted members are each independently at least one substituent selected from the group consisting of halogen atom, C1-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom halogen, hydroxy group, C1-4 alkoxy, and C3-7 cycloalkyl), aromatic carbocyclyl group of Ce-ium (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom , hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C3-7 cycloalkyl), C1-6 alkylamino (the alkyl group of which may be optionally substituted with halogen atom, hydroxy group, or C3-7 cycloalkyl ), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more ζζίταηη / ζζηζ / Ε / γίΛΐ substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkyl, alkoxy C1-4, and C3-7 cycloalkyl), and C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-alkyl 4, C1-4 alkoxy, and C3-7 cyclolakyl); or when there are plural optional substituents, two of them can be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring. (Point 3) The compound of item 1 or 2 or a pharmaceutically acceptable salt thereof, wherein in R2-R7, the optionally substituted C1-4 alkyl substituent is the same or different from one or more substituents selected from the group consisting of halogen and C1-4 alkoxy; and the optionally substituted C1-4alkoxy substituent is the same or different from one or more substituents selected from the group consisting of halogen atom and Ci4alkyl; in R1, the optional substituent of optionally substituted Ce-ium aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and optionally substituted 4- to 10-membered saturated heterocyclyl group is each independently having at least one substituent selected from the group consisting of hydrogen atom, halogen atom, hydroxy group, Ce-ium aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkyl, Ci-4 alkoxy, and C3-7 cycloalkyl), Ci-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkoxy, and C3-7 cycloalkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C37 cycloalkyl), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkyl optionally substituted with the same or different one or more halogen atoms, and C3-7 cycloalkyl), and 5- to 10-membered aromatic heterocyclyl group ( which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl); and on the G ring, the optional substituent of the optionally substituted C5-10 aromatic carbocyclyl group ζζίταηη / ζζηζ / Ε / γίΛΐ, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and optionally substituted 4- to 10-membered saturated heterocyclyl is each independently at least one substituent selected from the group consisting of halogen atom, Ci-e alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), Ce-ium aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1 alkyl -4, and C1-4 alkoxy), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), cycloalkyl C3-7 (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), C1-6 alkylamino (the group alkyl of which may be optionally substituted with halogen atom, hydroxy group, or C3-7 cycloalkyl), and C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, Ci 4 alkyl, and Ci 4 alkoxy); or when there are plural optional substituents, two of them can be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring. (Point 4) The compound of any of Items 1 to 3 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the following formulas (la-1) to (la-4): ζζίταηη / ζζηζ / Ε / γίΛΐ where X1- X7 are each independently nitrogen atom or CRa6; Q1 and Q2 are oxygen atom, -NRa7-, or sulfur atom; Ral. Ra7 are each independently (if plural of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, aromatic carbocyclyl group of Ce-ίο (which may be optionally substituted with the same or different one or more substituents selected from the group that consists of halogen atom, hydroxy group, C1-4 alkyl, and alkoxy Ci-4), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy ), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, 5-hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cycloalkoxy C3-7 (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), or heterocyclyl group aromatic 5 to 10 members; where Ra4 and Ra5 can bond to the same carbon atom if chemically possible; and when X1 and ; and q1 is an integer of 1 or 2. (Point 5) The compound of any of Items 1 to 4 or a pharmaceutically acceptable salt thereof, wherein the ring G is selected from the following (lb-1) to (lb-14): ζζίταηη / ζζηζ / Ε / γίΛΐ ζζίταηη / ζζηζ / Ε / γίΛΐ (1b-13) where W1, W3, W5, W6, W7, W11, W12, W13, W15, W16, W17, W19, and W25 are each independently nitrogen atom or CRb4; W2, W4, W8, W9, W10, W14, W18, W20, W21, W22, W23, and W24 are NRb5, oxygen atom, or CRb6Rb7; Rbl- Rb7 are each independently (if plural of CRb4, each Rb4 is also independently), hydrogen atom, -N(Rb8)Rb9, Ci-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C3-7 cycloalkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl (said C1-alkyl 4 may be substituted with halogen atom), and alkoxy of Cm), aromatic carbocyclyl group of Ce-ίο (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, alkyl of C1-4, and C1-4 alkoxy), 5- to 10-membered aromatic heterocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl , and C1-4 alkoxy), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), C3-cycloalkyl 7 (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, Ci 4 alkyl, and Ci 4 alkoxy); where Rb and Rb2 can bond to the same carbon atom if chemically possible; or Rb and Rb2 can be taken together via a Ci 6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring; and Rb8 and Rb9 are each independently hydrogen atom, C1-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, Ci-4 alkoxy, C3-7 cycloalkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl (said C1-4 alkyl may be substituted with halogen atom), and aromatic heterocyclyl group of 5 to 10 members), Ci-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), aromatic heterocyclyl group of 5 to 10 members (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), or C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy); or Rb8 and Rb9 can be taken together with the nitrogen atom to which they are attached to form 3- to 7-membered saturated nitrogen-containing heterocycle. (Point 6) The compound of any of Points 1 to 5 of formula (2): ζζίταηη / ζζηζ / Ε / γίΛΐ ζζίταηη / ζζηζ / Ε / γίΛΐ or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the following formulas (la-1) to (la-4): where X1- X7 are each independently nitrogen atom or CRa6; Q1 and Q2 are oxygen atom, -NRa7-, or sulfur atom; Ral-Ra7are each independently (if plural of CRa6, each Ra6is also independently), hydrogen atom, halogen atom, aromatic carbocyclyl group of Ce-ium (which may be optionally substituted with the same or different one or more selected substituents from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group that consists of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-6 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, group hydroxy, C1-4 alkyl, and C1-4 alkoxy), or 5- to 10-membered aromatic heterocyclyl group; where Ra4 and Ra5 can bond to the same carbon atom if chemically possible; and when X1 and ; and q1 is an integer of 1 or 2; L1 and L2 are each independently single bond, -CH2-, or oxygen atom; R2 is hydrogen atom, hydroxy group, halogen atom, cyano, or optionally substituted Ci-4 alkyl; R3 and R4 are each independently hydrogen atom, halogen atom, Ci-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci4 alkoxy, and C3-7 cycloalkyl), or C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and cycloalkyl). from C3-7); where R3 and R4 can bond to the same carbon atom if chemically possible; and when R3 and R4 are attached to different carbon atoms in the ring, R3 and R4 can be taken together via a Ci-e alkylene to form a fused ring or bridged ring; The G ring is selected from the following (lb-1) to (lb-4): (1b-1) (1b-2) (1b-3) (1b-4) where W1, W3, W5, W6, and W7 are each independently nitrogen atom or CRb4; W2, W4, and W8 are NRb5, oxygen atom or CRb6Rb7; Rbl. pb7are cac|a one independently (if plural of CRb4, each Rb4is also independently), hydrogen atom, C1-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen and C1-4 alkoxy), Ce-ίο aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy). C1-4), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); where Rb and Rb2 can bond to the same carbon atom if chemically possible; or Rb and Rb2 can be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring; A1 is oxygen atom or sulfur atom; A2is oxygen atom or -NH-; and A3es -CH-, nitrogen atom, or carbon atom. ζζίταηη / ζζηζ / Ε / γίΛΐ (Point 7) The compound of item 6 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the following formulas (la-1), (la-2), and (la-3-1): where X1- X6 are each independently nitrogen atom or CRa6; Q1 and Q2 are oxygen atoms, -NRa7-, or sulfur atoms; and Ral. Ra3, Rae, and Ra7 are each independently (if they are plurals of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, aromatic carbocyclyl group of Ce-ium (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group that consists of halogen atom, hydroxy group, Cu alkyl, and C1-4 alkoxy), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom , hydroxy group, C1-4 alkyl, and C1-4 alkoxy), or 5- to 10-membered aromatic heterocyclyl group; wherein when X1 and X1, X2, and X3. (Point 8) The compound of Items 6 or 7 or a pharmaceutically acceptable salt thereof, wherein the ring G is selected from the following (lb-1), (lb-2), and (lb-4): ζζίταηη / ζζηζ / Ε / γίΛΐ (1b-1) (1b-2) (1b-4) where W1, W3, W5, W6, and W7 are each independently nitrogen atom or CRb4; W2and W4are NRb5o CRb6Rb7; and Rbi, Rb2, and Rb4. Rb7 are each independently (if plural of CRM, each Rb4 is also independently), hydrogen atom, Ci-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), Ce-10 aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-alkoxy 4), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl), C3-7 cycloalkyl (which may optionally be substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); where Rb and Rb2 can bond to the same carbon atom if chemically possible; or Rb and Rb2 can be taken together via a C1-6 alkylene to form a bridged bicyclic structure. (Point 9) The compound of any of Items 6 to 8 or a pharmaceutically acceptable salt thereof, wherein the ring G is selected from the following (lb-1) and (lb-2): ζζίταηη / ζζηζ / Ε / γίΛΐ (1b-1) where (1b-2) W1 and W3 are nitrogen atom or CRb4; W2and W4are NRb5o CRb6Rb7; and Rbl, Rb2, and Rb4-Rb7 are each independently hydrogen atom, Ci-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy ), Cs-10 aromatic carbocyclic group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), alkoxy C1-4 (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and Ci 4 alkyl), C3 7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, Ci 4 alkyl, and C 14 alkoxy), or C 3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy); where Rb and Rb2 can bond to the same carbon atom if chemically possible; or Rb and Rb2 can be taken together via a Ci-e alkylene to form a bridged bicyclic structure. (Point 10) The compound of any of Points 1 to 9 of formula (3): (3) or a pharmaceutically acceptable salt thereof, where R1 is the following formula (la-1), (la-2), or (la-3-1): X<y2 ζζίταηη / ζζηζ / Ε / γίΛΐ where X1- X6 are each independently nitrogen atom or CRa6; Q1 and Q2 are oxygen atom or sulfur atom; Ral- Ra3 and Ra6 are cac|a un0independently (if they are plurals of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, Ci-4 alkyl (which may be optionally substituted with the same or different one or more selected substituents from the group consisting of halogen atom, hydroxy group, and C1-4 alkoxy), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, or C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy); wherein when X1 and X3; L1 and L2 are each independently single bond or oxygen atom; R2 is hydrogen atom, halogen atom, or C1-4 alkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and hydroxy group; R3 and R4 are each independently halogen atoms; the G ring is as follows (lb-1), (lb-2-1), (lb-2-2), or (lb-2-3): Rh5 Rb5 Rt>5 Rb5 (1 b-2-1) (1b-2-2) (1b-2-3) where Rb5 is hydrogen atom, or C1-6 alkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and Ch alkoxy; and A1is oxygen atom or sulfur atom. (Point 11) The compound of any of Items 4 to 10 or a pharmaceutically acceptable salt thereof, wherein R1 is the formula (la-2), and Rales hydrogen atom, halogen atom, C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), C3-cycloalkyl 7 (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkyl, and C1-4 alkoxy), or Ci-4 alkoxy ( which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl). (Point 12) The compound of Item 10 to 11 or a pharmaceutically acceptable salt thereof, wherein R1 is the formula (la-2), and X4 and X5 are both nitrogen atoms. (Point 13) The compound of any of Items 10 to 12 or a pharmaceutically acceptable salt thereof, wherein the ring G is the formula (lb-1-1), and Rb5 is C1-4 alkyl which may be optionally substituted with the same or different one or more substituents selected from halogen atoms. (Point 14) The compound of any of Items 10 to 12 or a pharmaceutically acceptable salt thereof, wherein the ring G is the formula (lb-2-1), and Rb5 is hydrogen atom, or C1-4 alkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy. (Point 15) The compound of any of Points 1 to 12 of formula (4): ζζίταηη / ζζηζ / Ε / γίΛΐ or a pharmaceutically acceptable salt thereof, wherein R1 is the following (la-2-1): (1a-2-1) where Q2is oxygen atom or sulfur atom; Ra2 is a C3-7 cycloalkyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, Ci 4 alkyl, and Ci 4 alkoxy) or cycloalkoxy group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, Ci 4 alkyl, and Ci 4 alkoxy); R2 is C1-4 alkyl; the G ring is as follows (lb-1-1) or (lb-2-1): (1b-1-1) (1b-2-1) where Rb5 is C1-4 alkyl which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy; and L2 is a single bond or oxygen atom. (Point 16) The compound of item 15 or a pharmaceutically acceptable salt thereof, wherein Ra2 is a C3-7 cycloalkyl group that may be optionally substituted with the same or different one or more substituents selected from halogen atoms, and R2 is methyl group. (Point 17) The compound of item 15 or 16 or a pharmaceutically acceptable salt thereof, wherein Ra2 is a cyclopropyl group which may be optionally substituted with the same or different one or more substituents selected from halogen atoms, and R2 is methyl group. ζζίταηη / ζζηζ / Ε / γίΛΐ (Item 18) The compound of any acceptable thereof, wherein the ring G is the formula (lb-2-1), and Rb5 is isopropyl group. Points 15 to 17 0 a pharmaceutically acceptable salt (Point 19) The compound of any of the acceptable thereof, wherein the ring G is the formula (lb-1-1), and Rb5 is isobutyl group. Points 15 to 17 0 a pharmaceutically acceptable salt (Point 20) The compound of any of the acceptable thereof, wherein the ring G is the formula (lb-1-1), Rb5 is isopropyl group, and Points 15 to 17 0 a salt pharmaceutically L2is oxygen atom. ζζίταηη / ζζηζ / Ε / γίΛΐ (Point 21) The compound of any of Items 15 to 20 or a pharmaceutically acceptable salt thereof, wherein Q2 is an oxygen atom. (Point 22) The compound of Item 1 or a pharmaceutically acceptable salt thereof, which is selected from the following compound names or structures: Example 22: 4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2¡l) p¡peraz¡n-l-¡l]cyclohex¡l}-4-methylpiper¡dina-l-carboxamide I. ^Me Example 23: 4-(5-cyclopropíl-1,2,4-oxadíazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4(propan-2 -¡l)piperazin-l-yl]cyclohexyl}-4-met¡lp¡per¡dina-l-carboxamide I. ^Me Example 24: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-yl)-N-{(lR,6S)-2,2-difluoro-6-[4(propan -2-yl)p¡peraz¡n-l-yl]cyclohex¡l}-4-met¡lpiper¡na-l-carboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 25: 4-(5-cyclopropyl-l,2-oxazol-3-yl)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2¡l)piperaz¡ n-l-¡l]cyclohex¡l}-4-methylp¡perina-l-carboxamide Example 62: 4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3(propan-2-íl) -3,8-d¡azab¡cyclo[3.2.1]octan-8-yl]cyclohex¡l}-4-methylp¡per¡dina-l-carboxamide Example 63: N-{(lR,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan8-¡l]c¡ clohex¡l}-4-methyl¡l-4-(4-met¡lfen¡l)p¡perídine-l-carboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 65: 4-(5-cyclopropyl-1,2-oxazol-3-íl)-N-{(:LR,6S)-2,2-difluoro-6-[3-(propan-2yl) -3,8-d¡azab¡cyclo[3.2.1]octane-8-¡l]cyclohex¡l}-4-metllp¡per¡dina-l-carboxam¡da Example 66: N-{(lR,6S)-2,2-difluoro-6-[4-(piOpan-2-yl)p¡peraz¡n-l-yl]cyclohex¡l}-4-{5[ (lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-l-carboxamide Me. Example 68: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)piperaz¡n-l-yl]cyclohex¡l}-4methyl- 4-{5-[(lS,2R)-2-met¡lc¡cloprop¡l]-l,2,4-oxad¡azol-3-yl}p¡perina-l-carboxamide Example 69: N-{(lR,6S)-2,2-d¡fluorO-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4methyl -4-{5-[(lR,2S)-2-methylcycloprop¡l]-l,2,4-oxadiazol-3-¡l}p¡peridana-l-carboxam¡da ζζίταηη / ζζηζ / Ε / γίΛΐ Example 79: fac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(lR,6S)-2,2-difluoro-6-[4 (propan-2-¡l)p¡peraz¡n-l-il]cyclohex¡l}-4-met¡lp¡per¡d¡na-l-carbot¡oam¡da Example 80: 4-(5-cyclopropyl-1,2,4-oxadíazol-3-íl)-N-{(1R,6S)-2,2-difluoro-6-[4(propane- 2-yl)piperazin-l-yl]cyclohexyl}-4-methylpiperidina-l-carbothioamide. (Point 23) The compound of Item 1 or a pharmaceutically acceptable salt thereof, which is selected from the following compound names or structures: Example 64: 4-(5-cyclopropyl-l,2,4-oxadíazol-3-yl)-N-[(lR,6S)-2,2-difluoro-6-{[(3R)-l( propan-2-¡l)pyrrol¡din-3-¡l]oxy}c¡clohex¡l]-4-met¡lp¡perid¡na-l-carboxamide F Example 67: N-[(lRz6S)-2z2-d¡fluoro-6-{[(3R)-l-(propan-2-yl)pyrrol¡n-3ζζίταηη / ζζηζ / Ε / γίΛΐ ¡l]ox¡}cyclohexyl]-4-methyl-4-(4-methylphenyl)pyridine-l-carboxamide F Example 71: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-l)-N-[(lR,6S)-2z2-difluoro-6-{[(3S) -l(propan-2-¡l)pyrrolidin-3-yl]oxy¡}c¡clohexyl]-4-met¡lp¡perid¡na-l-carboxamide Example 72: N-[(lRz6S)-2z2-d¡fluoro-6-{[(3S)-l-(propan-2-¡l)p¡nOlidin-3yl]ox¡}cyclohexyl]-4-{5 -[(lSz2S)-2-fluoroc¡cloprop¡l]-lz2z4-oxad¡azol-3-yl}-4-methylpiperidine-l carboxamide AND. I 73: Example N-[(lR,6S)-2,2-difluoro-6-{[(3R)-l-(propan-2-yl)pyrrol¡n-3ζζίταηη / ζζηζ / Ε / γίΛΐ ¡ l]ox¡}cyclohexyl]-4-{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-methylp¡peridine -lcarboxamide E, ✓ F 74: Example N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-yl)pyrrolídin-3yl]ox¡}cyclohex¡l]- 4-methyl-4-{5-[(lR / 2S)-2-met¡lc¡clopropyl]-l,2,4-oxadiazol-3-¡l}piper¡dina-lcarboxamide I F Example 75: 4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-2,2-difluoro-6-{[( 3S,4S)4-fluoro-l-(propan-2-yl)pyrrolídin-3-¡l]ox¡}cyclohexyl]-4-methyl¡lp¡perídine-l-carboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 76: 4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-yl)-N-[(lR,6S)-6-{[(3R)-4,4-d¡ fluorO-l(propan-2-íl)pyrrolidin-3-íl]oxy}-2,2-difluorocyclohexíl]-4-methylpiperídine-l-carboxamide. (Point 24) The compound of Item 1 or a pharmaceutically acceptable salt thereof, which is selected from the following compound names or structures: Example 82: N-{(lS,6R)-2,2-difluoro-6-[4-(propan-2-yl)p¡perazin-l-¡l]cyclohex¡l}-4-{510 [( lR,2R)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡perídine-l-carboxamide I. .I Example 95: N-[(lR,6S)-2,2-difluoro-6-{methyl[(3S)-l-(propan-2-yl)pyrrolidin-3¡l]amino}c¡clohex¡ l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡pendenna- lcarboxamide I ζζίταηη / ζζηζ / Ε / γίΛΐ Example 96: N-[(lR,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-yl)amino]pyrrolidin-l¡l}cyclohex¡l]-4 -{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperididine-l-carboxamide Example 97: 4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4(propan-2-íl) piperazin-l-yl]cyclohexyl}-4-methylpiperdina-l-carboxamide Example 99: 4-(5-cycloprop¡l-1,2,4-oxad¡azol-3-yl)-N-[(lR,6S)-2,2-difluoro-6-{(3S)-3[met ¡l(propan-2-yl)amino]pyrrolidin-l-yl}cyclohexyl]-4-methylpiperidine-l-carboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 110: N-{(lR,6S)-2,2-difluoro-6-[(2S)-2-methyl-4-(propan-2-yl)p¡perazin-lyl]cyclohex¡l} -4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol·3-¡l}-4-methylpi¡perina-l- carboxamide Example 111: N-{(lR,6S)-2,2-difluoro-6-[(2R)-2-methyl-4-(propan-2-yl)piperazin-l¡l]cyclohex¡l} -4-{5-[(lS,2S)-2-fluoroc¡clopropyl]-l,2,4-oxad¡azol·3-¡l}-4-met¡lp¡per¡na-l- carboxamide Example 112: N-[(lR,6S)-2,2-difluoro-6-{(3R)-3-[methyl(propan-2-¡l)amino]pyrrolidin-l¡l}cyclohex¡l]-4-{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-methylp¡peridin-l -carboxamide I Example 114: N-[(lR,6S)-2,2-difluoro-6-{4-[met¡l(propan-2-¡l)am¡no]p¡perid¡n-l¡l}cyclohex¡l ]-4-{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxadiazol-3-yl}-4-met¡lp¡perídine-l-carboxamide I Example 115: N-[(lR,6S)-6-{(3S)-3-[c¡cloprop¡l(met¡l)amino]pyrrol¡n-l-¡l}-2, 25 difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 128: N-[(lR,6S)-2,2-difluoro-6-{(3S)-3-[methyl(2-methylpropyl)amino]pyrrolidine-l}cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp ¡per¡dina-l10 carboxamide Example 134: N-[(lR,6S)-2,2-difluoro-6-(4-{met¡l[(l-methylcycloprop¡l)methyl]amino} p¡perídin-l-¡ l)cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡ lp¡perína-lcarboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 136: N-[(lR,6S)-2,2-difluoro-6-(4-{[(l-fluorocyclopropyl)methyl](methyl)amino} p¡perídin¡n-l-¡l)cyclohex¡ l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-methylpiperid¡na-lcarboxamide Example 137: N-[(lR,6S)-6-{(3S)-3-[(cycloprop¡lmethyl)(methyl)amino]p¡nOl¡d¡n-l-yl}-2,2difluorocyclohex¡l]- 4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2 / 4-oxadiazol-3-yl}-4-methylpyridine-lcarboxamide Example 138: N-[(lR,6S)-6-{(3S)-3-[(cyclopropylmethyl)(methyl)amino]pyrrolidin-l-¡l}-2,2d¡ fluoroc¡clohex¡l]-4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-yl)-4-methylp¡perid¡na-l-carboxamide Example 139: rac-4-(5<¡clopropyl-1,2,4-oxad¡azol-3-yl)-N-{(lR,2R,6S)-2-fluoro-6-[4(propan- 2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4-met¡lp¡per¡dina-l-carboxamide Example 152: N-{(lR,6S)-2,2-difluoro-6-[4-(prOpan-2-yl)-l,4-diazepan-l-yl]cyclohexyl}4 -{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxadiazol-3-¡l}-4-methylpiperidine-l-carboxamide Example 156-A: 4-{5-[(lS,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N{(lR,2S,6S)-2-fluoro-6 -[4-(propan-2-yl)piperazin-l-¡l]cyclohexyl}-4-met¡lp¡perídina-l-carboxamide Example 156-B: 4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-1,2,4-oxad¡azol-3-¡l}-N{(lS,2R,6R )-2-fluoro-6-[4-(propan-2-yl)p¡peraz¡n-l-¡l]cyclohex¡l}-4-methylpiper¡na-l-carboxam¡da ζζίταηη / ζζηζ / Ε / γίΛΐ Example 157: N-[(lR,6S)-2,2-difluoro-6-{4-[methyl(2-methylpropyl)amino]píperídin-15 ¡l}cyclohex¡l] -4-{5-[(lS,2S)-2-fluorocyclopropíl]-1,2,4-oxadíazol-3-íl}-4-methylperídine-l-carboxamide Example 158: N-[(lR,6S)-6-{4-[(cycloprop¡lmethyl)(methyl)amino]piperid¡n-l-yl}-2,2d¡fluoroc¡clohex¡l ]-4-{5-[(lS,2S)-2-fluoroc¡clopropyl]-l,2,4-oxad¡azol-3-¡l}-4-methylp¡per¡na-lcarboxamide Example 159: N-[(lR,6S)-6-{4-[cyclobut¡l(methyl)amino]piper¡din-l-yl}-2,2difluorocyclohex¡l]-4-{5-[ (lS,2S)-2-fluoroc¡clopropyl]-l,2 / 4-oxad¡azol-3-yl}-4-methylpi¡perina-lcarboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 161: N-[(1R,65)-2,2-difluoro-6-{[(3S)-l-(propan-2-yl)pyrrolídin-3¡l]amino}c ¡clohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-methylpiper¡dine -lcarboxamide (Point 25) The compound of Item 1 or a pharmaceutically acceptable salt thereof, which is selected from the following compound names or structures: Example 83: N-[(lR,6S)-2,2-difluoro-6-{[l-(propan-2-¡l)píperid¡n-4-yl]ox¡}c¡clohex ¡l]-4{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡períd¡ na-l-carboxamide I F Example 84: 4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,65)-2,2-difluoro-6-{[l(propan-2-íl )piperidin-4-¡l]ox¡}c¡clohexyl]-4-met¡lp¡per¡dina-l-carboxamide I F ζζίταηη / ζζηζ / Ε / γίΛΐ Example 102: 4-(5-cyclobutyl-l,2,4-oxadilazole-3-yl)-N-[(lR,6S)-2,2-difluoro-6-{[(3S )-l(propan-2-¡l)pyrrolidin-3-yl]oxy¡}cyclohexyl]-4-met¡lp¡perídina-l-carboxamide I Example 103: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-¡l)pyrrolidin-3yl]ox¡}c¡clohex¡l ]-4-ethyl-4-{5-[(lS,2S)-2-fluorOCycloprop¡l]-l,2,4-oxad¡azol-3-¡l}p¡pendena-lcarboxamide Example 107: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(2-methylprop¡l)pyrrolidin-310 il]ox¡}cyclohex¡l ]-4-{5-[(lS,2S)-2-fluoroc¡clopropyl]-l,2,4-oxad¡azol-3-yl}-4-methylpiper¡dina-lcarboxamide I ζζίταηη / ζζηζ / Ε / γίΛΐ Example 116: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-yl)-N-[(lR,6S)-2 / 2-difluoro-6-{[(3S )-l(2-methylpropyl)pyrrolidin-3-l]oxyl]-4-methylpiperdina-l-carboxamide I F Example 118: N-[(lR,6S)-6-{[(3S)-l-(cycloprop¡lmet¡l)pyrrol¡din-3-¡l]ox¡}-2,2d¡ fluorocyclohexyl]-4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-l}-4-methylpiperidine-lcarboxamide F Example 119: 4-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-N-[(lR,6S)-6-{[(3S)-l-(2.210 dimethylprop) l)pyrrolidin-3-¡l]ox¡}-2,2-difluorocyclohex¡l]-4-methylpiperidine-l-carboxamide Example 120: N-[(lR,6S)-6-{[(3S)-l-(2,2-dimethylpropyl)pyrrolídin-3-¡l]ox¡}-2,2d¡fluoroc¡ clohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡per¡ dna-lcarboxamide Example 121: N-[(lR,6S)-2,2-difluoro-6-({(3S)-l-[(l-methylcycloprop¡l)methyl]pyrrolidin3-¡l}oxy)cyclohexyl]-4-{5-[(lS,2S)-2-fluorocyclopropíl]-1,2,4-oxadiazol-3-íl}-4-methylpiperidine-lcarboxamide Example 122: N-[(lR,6S)-6-{[(3S)-l-(cycloprop¡lmethyl)pyrrolidin-3-yl]oxy}-2,210 difluoroc¡clohex ¡l]-4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-¡l)-4-met¡lp¡perína-l-carboxamide Example 126: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-l)-N-[(lR,6S)-2z2-difluoro-6-({(3S) -l[(l-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-methylpiperidine-l-carboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ Example 133: N-[(lR,6S)-2,2-difluoro-6-({(3S)-l-[(l-fluoroc¡cloprop¡l)methyl]pyrrolidin3-¡l}ox¡)cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4- methylperidine-lcarboxamide Example 134: N-[(lR,6S)-2,2-difluoro-6-(4-{methyl[(l-methylcyclopropyl)methyl]amino} piperidin-l-¡l)cyclohex¡l] -4-{5-[(lS / 2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-met¡lp¡perína-lcarboxamide Example 143: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(2-fluoro-2-methylpropyl)pyrrolidin-3yl ]ox¡}cyclohexyl]-4-{5-[(lS,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide. (Point 26) A medicament for the treatment of an orexin receptor-related disease, comprising the compound of any of Items 1 to 25 or a pharmaceutically acceptable salt thereof. (Point 27) A medication for the treatment of narcolepsy, idiopathic hypersominus, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, hypersomnia associated with dementia with Lewy body, hypersomnia syndrome involving hypersomnia during the day (e.g. Kleine-Levin syndrome, major depression accompanied by hypersomnia, dementia with Lewy body, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen encephalitis, Wernicke encephalopathy, limbic encephalitis, Hashimoto encephalopathy), coma, loss of consciousness, obesity (e.g. malignant mast cells, extrinsic obesity, hyperinsulin obesity, hyperplasmic obesity, pituitary obesity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, childhood obesity, upper body obesity, alimentary obesity, gonadal obesity, systemic mastocytosis, primary obesity , central obesity), insulin resistance syndrome, Alzheimer's, impaired consciousness such as coma, side effect or complication caused by anesthesia, sleep disturbance, sleep problems, insomnia, intermittent sleep, nocturnal myoclonus, interruption of REM sleep, decompensation jet lag syndrome, shift worker sleep disorder, dyssomnia, sleep terror, depression, major depression, sleepwalking, enuresis, sleep disorder, Alzheimer's sundown syndrome, disease associated with the circadian rhythm, fibromyalgia , condition resulting from decreased sleep quality, bulimia, obsessive eating disorder, obesity-related diseases, hypertension, diabetes, elevated plasma insulin level / insulin resistance, hyperlipidemia, hyperlipidemia, endometrial cancer, cancer breast, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart rhythm, arrhythmia, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disease, sudden death, polycystic ovary, craniopharyngioma, Prader-Willi syndrome, Froehlich syndrome, growth hormone deficiency, variant short stature, Turner syndrome, children suffering from acute lymphoblastic leukemia, syndrome reproductive hormone abnormality, decreased fertility, infertility, hypogonadism in men, dysfunction of sexual / reproductive function such as hirsutism in women, fetal defect associated with obesity in motherhood, gastrointestinal motility disorder such as gastroesophageal reflux related to obesity, obesity hypoventilation syndrome (Pickwickian syndrome), respiratory disease such as respiratory distress, inflammation such as vascular systemic inflammation, arteriosclerosis, hypercholesterolemia, hyperuricemia, lower back pain, gallbladder disease, gout, renal cancer, secondary risk of obesity such as risk of left ventricular hypertrophy, migraine, headache, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweats, disease in the genital / urinary system, disease associated with sexual function or fertility, persistent depressive disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder , separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorder such as brain deficiency developed after cardiac bypass surgery or heart transplant, stroke, ischemic stroke, cerebral ischemia, spinal column trauma, head injury, periparturient hypoxia, cardiac arrest, hypoglycemic nerve injury, Huntington's disease,amyotrophic lateral sclerosis, multiple sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorder associated with muscle spasm, delirium, amnestic disorder, age-related cognitive decline, schizoaffective disorder, paranoia, drug addiction, movement disorder, chronic fatigue syndrome, fatigue, drug-induced parkinsonian syndrome, Giles de la Tourette syndrome, chorea, myoclonus, tic, restless leg syndrome, dystonia, dyskinesia, attention deficit hyperactivity disorder (ADHD), behavioral disorder, urinary incontinence, withdrawal syndrome, trigeminal neuralgia, hearing loss, ringing in the ears, nerve injury, retinopathy, macular degeneration, vomiting, cerebral edema, pain, bone pain, arthralgia, dental pain, cataplexy, or traumatic brain injury, comprising the compound of any of Items 1 to 25 or a pharmaceutically acceptable salt thereof. ζζίταηη / ζζηζ / Ε / γίΛΐ (Point 28) A medication for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy body, comprising the compound of any of Items 1 to 25 or a pharmaceutically acceptable salt thereof. (Point 29) A method for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy body, comprising administering a therapeutically effective of the compound of any of Items 1 to 25 or a pharmaceutically acceptable salt thereof to a patient in need thereof. (Point 30) The use of the compound of any of Items 1 to 25 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicine for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving type symptoms narcolepsy, hypersomnia associated with Parkinson's disease, or hypersomnia associated with dementia with Lewy body. DETAILED DESCRIPTION OF THE INVENTION Hereinafter, the present invention is explained in more detail. In the description, the number of carbon atoms in the definition of substituents may indicate, for example, Ci-e. The specific definition alkyl of Ci-e means alkyl group having 1 to 6 carbon atoms. In the present description, a substituent group that is not accompanied by optionally substituted or substituted means an unsubstituted substituent group. For example, Ci6 alkyl means unsubstituted Ci-6 alkyl. Substituent groups herein may sometimes be expressed without the term group. In case optionally substituted is used in the definition of substituent groups, the number of the substituting groups is not limited as long as substitutions are available, i.e., it is one or more. It means that the possible number of substitution groups is the number available for substitution on the carbon atoms or carbon / nitrogen atoms in a substituent group that are acceptable for substitution. Unless otherwise specified, the definition of each substituent group also extends to the case where the substituent group is partially included in another substituent group or the case where the substituent group is attached to another substituent group. Unless otherwise specified, the site of attachment of substituent groups is not limited as long as the site is available for attachment. Halogen includes, for example, fluorine, chlorine, bromine, iodine, and the like. It is preferably fluorine or chlorine. C1-4 alkyl means straight or branched chain saturated hydrocarbon group having 1 to 4 carbon atoms, and Ci-e alkyl means straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms. C1-4 alkyl includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl, and C1-alkyl includes, for example, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, and a structural isomer thereof, in addition to the C1-4 alkyl above. Preferred examples of Ci-e alkyl or C1-4 alkyl include methyl, ethyl, propyl, and isopropyl; more preferably methyl and isopropyl. Cí e alkylene means straight or branched chain divalent saturated hydrocarbon group having 1 to 6 carbon atoms. Cie alkylene preferably includes C1-4 alkylene, more preferably C1-3 alkylene. C1-3 alkylene includes, for example, methylene, ethylene, propylene, trimethylene and the like. C1-4 alkylene includes, for example, butylene, 1,1-dimethylethylene, 1,2-dimethylethylene, l-methyltrimethylene, 2-methyltrimethylene and the like, in addition to the examples listed in said C1-3 alkylene. Ci-e alkylene includes, for example, pentylene, 1,1-dimethyltrimethylene, 1,2-dimethyltrimethylene, 1-methylbutylene, 2-methylbutylene, 1-methylpentylene, 2-methylpentylene, 3-methylpentylene, hexylene and the like, in addition to the examples listed in said C1-4 alkylene. C3-7 cycloalkyl means a non-aromatic cyclic hydrocarbon group (i.e., saturated hydrocarbon group and partially unsaturated hydrocarbon group) having 3 to 7 carbon atoms, preferably including C3-6 cycloalkyl. The C3-7 cycloalkyl also includes a bridged one. C3-10 cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, and cycloheptyl. C3-7 cycloalkyl also includes a bicyclic fused ring in which the C3-7 cycloalkyl is fused with benzene or a 5- or 6-membered ring having a heteroatom selected from nitrogen, sulfur, or oxygen atom, or the same or different and two or more (e.g., 2 to 4) heteroatoms thereof (e.g., 5- or 6-membered monocyclic heteroaryl mentioned later, and 5- or 6-membered ring in saturated 4- to 10-membered heterocyclyl mentioned later). ζζίταηη / ζζηζ / Ε / γίΛΐ C1-4 alkoxy means oxy group substituted with the above Cm alkyl, and Ci-e alkoxy means oxy group substituted with the above C1-6 alkyl. Cu alkoxy includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy. Preferably, C1-4 alkoxy includes methoxy, ethoxy, and isopropoxy. C3-7 cycloalkoxy means oxy group substituted with the above C3-7 cycloalkyl, preferably including C3-6 cycloalkoxy. C3-7 cycloalkoxy includes, for example, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, and cyclohexyloxy, and preferably cyclohexyloxy. The aromatic carbocyclyl group of Ce-io means an aromatic hydrocarbon group having 6 to 10 carbon atoms, which is also referred to as aryl of Co-io. More preferably, it is phenyl. The aromatic carbocyclyl group of Ce-ium includes, for example, phenyl, 1-naphthyl, and 2-naphthyl. The aromatic carbocyclyl group of Ce-ium also includes a fused ring in which the phenyl is fused with a 5- or 6-membered ring having one heteroatom selected from nitrogen, sulfur, or oxygen atom, or the same or different and two or more (e.g., 2 to 4) heteroatoms thereof (e.g., 5- or 6-membered monocyclic aromatic heterocyclic group mentioned below, and 5- or 6-membered ring in 4- to 10-membered saturated heterocyclyl group mentioned below), or one 5- to 7-membered cycloalkyl ring (e.g., cyclopentane, cyclohexane, and cycloheptane). The 5- to 10-membered aromatic heterocyclyl group means a 5- to 10-membered mono- or multiple-cyclic aromatic group having one heteroatom selected from nitrogen, sulfur, or oxygen atom, or the same or different and two or more (e.g. 2 to 4) heteroatoms thereof, in addition to carbon atoms as the ring atoms, preferably, 5- or 6-membered monocyclic aromatic heterocyclyl group. The 5- or 6-membered monocyclic aromatic heterocyclyl group means a 5- or 6-membered monocyclic aromatic group within the 5- to 10-membered aromatic heterocyclyl group. The cyclic multiple aromatic heterocyclyl group in the 5- to 10-membered aromatic heterocyclyl group includes, for example, a fused ring in which the same or different two monocyclic aromatic heterorings are fused, or a monocyclic aromatic heteroring and an aromatic ring (e.g. benzene) or a non-aromatic ring (e.g. cyclohexane) are fused. The 5- to 10-membered aromatic heterocyclyl group includes, for example, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, and pyridazinyl. Another embodiment preferably includes benzofuranyl in which the binding site is on the heteroaryl (furan) ring, pyridyl, pyrimidinyl, pyrazinyl, and pyridazinyl. C3-6 saturated carbon ring means a saturated ζζίταηη / ζζηζ / Ε / γίΛΐ or partially unsaturated monocyclic hydrocarbon having 3 to 6 carbon atoms. The C3δ saturated carbon ring includes, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, and cyclohexadiene, and preferably cyclopropane and cyclobutane. The saturated 4 to 10 membered heteroring means a monocyclic or bicyclic saturated heteroring composed of 4 to 10 atoms, having the same or different and one or more (for example, 2 to 4, preferably 2 to 3, more preferably 2) heteroatoms selected from oxygen atom, nitrogen atom, and sulfur atom, in addition to carbon atoms as the ring atoms. The heteroring may include a partially unsaturated one, a partially gated one, and a partially spiro ring. Preferred of these is a saturated 5- or 6-membered heteroring. Bicyclic saturated heteroring also includes a ring fused from a monocyclic saturated heteroring, and benzene or a 5- or 6-membered monocyclic aromatic heteroring. And, the saturated heteroring may further comprise one or two carbonite, thiocarbonyl, sulfinyl, or sulfonyl, that is, the saturated heteroring includes, for example, a cyclic group such as lactam, thiolactam, lactone, thiolactone, cyclic amide, cyclic carbamate , and cyclic thiocarbamate, where the number of atoms composing the 4- to 10-membered ring (i.e., ring size) or the number of heteroatoms composing the heteroring does not count the oxygen atom in carbonite, sulfinyl, and sulfonyl, nor the sulfur atom in thiocarbonyl. The 4- to 10-membered saturated heteroring preferably includes monocyclic or bicyclic 4- to 8-membered saturated heteroring, more preferably monocyclic 4- to 6-membered saturated heteroring, and even more preferably monocyclic 5- or 6-membered saturated heteroring. The 4- to 10-membered saturated heteroring includes, for example, piperazine, oxetanyl, azetidinyl, pyranyl, tetrahydrofuryl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, morpholinyl, homopiperidinyl, oxetanyl, thiomorpholinyl, dioxothiomorpholinyl, hexamethyleneiminyl, oxazolidinyl, thiazolidinyl, imidazole idinyl, oxoimidazolidinyl , dioxoimidazolidinyl, oxooxazolidinyl, dioxooxazolidinyl, dioxothiazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, and tetrahydropyridinyl, and preferably pyranyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl. The bicyclic saturated heteroring includes, for example, dihydroindolyl, dihydroisoindolyl, dihydropurinyl, dihydrothiazolopyrimidinyl, dihydrobenzodioxanyl, isoindolinyl, indazolyl, pyrrolopyridinyl, tetrahydroquinolinyl, decahydroquinolinyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, tetrahydronaphthyridinyl, and tetrahydropyridinyl. -azepinyl. The 4- to 6-membered saturated heterocyclyl group means a monovalent substituent derived from 4- to 6-membered saturated heteroring belonging to the above 4- to 10-membered saturated heteroring. Preferably it includes azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl. The saturated 3- to 7-membered nitrogen-containing heterocycle that is formed by taking Rb8 and Rb9 together with the nitrogen atom to which they are attached corresponds to the previous ζζίταηη / ζζηζ / Ε / γίΛΐ 4- to 10-membered saturated heteroring where the number of atoms The number that makes up the ring is 3 to 7, and a nitrogen atom is included as a compound ring atom in addition to the carbon atoms. The compound of the present invention includes various hydrates, solvates, and crystalline polymorphs thereof. The compound of the present invention may include one or more isotope atoms such as D,3H,nC,13C,14C,13N,15N,15O,35S,18F, and125I by substitution, and such isotope substituted compound is also included in the compound of the present invention. The pharmaceutically acceptable salt used herein means a pharmaceutically usable acid addition salt and a pharmaceutically usable basic addition salt. The pharmaceutically acceptable salt includes, but is not limited to, for example, an acid addition salt such as acetate, propionate, butyrate, formate, trifluoroacetate, maleate, fumarate, tartrate, citrate, stearate, succinate, ethylsuccinate, malonate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, benzenesulfonate, p-toluenesulfonate (tosylate), laurylsulfate, malate, ascorbate, mandelate, sacharin, xinafoate, pamoate, cinnamate, adipate, cysteine, N-acetylcysteine, hydrochloride, bromhydrate, phosphate, sulfate , hydroiodide, nicotinate, oxalate, picrate, thiocyanate, undecanoate, polyacrylate, and carboxy vinyl polymer; an inorganic base addition salt such as lithium salt, sodium salt, potassium salt, and calcium salt; an organic base addition salt such as morpholine and piperidine; and amino acid addition salt such as aspartate and glutamate. The present compounds may be administered orally or parenterally directly or as a suitable formulation such as pharmaceutical product, medicament, and pharmaceutical composition. The formulation thereof may include, for example, tablet, capsule, powder, granule, liquid, suspension, injection, patch, gel patch, and the like, but is not limited thereto. The formulation can be prepared with pharmaceutically acceptable additive agents in known means. The additive agents can be chosen for any purpose, including an excipient, a disintegrant, a binder, a fluidizer, a lubricant, a coating agent, a solubilizer, a solubilizing agent, a thickener, dispersant, a stabilizing agent, a sweetening agent, a flavor, and the like. Specifically, they include, for example, lactose, mannitol, microcrystalline cellulose, lower substituted hydroxypropyl cellulose, corn starch, partially pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate , polyethylene glycol, propylene glycol, titanium oxide, talc, and the like. The dose of the present compound should be conveniently determined depending on the animal subject for administration, route of administration, target disease, and age, body weight, and condition of the patients. For example, in the case of oral administration, about 0.01 mg at least to 10000 mg at most can be administered per day for an adult in one to several servings. The compound of the present invention has agonist activity for the orexin receptor. Thus, the compound may be a medicament for the prevention of or treatment of a disease related to the orexin receptor. The disease includes, for example, narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, hypersomnia associated with dementia with Lewy body, hypersomnia syndrome involving daytime hypersomnia (e.g. Kleine-Levin syndrome, major depression accompanied by hypersomnia, dementia with Lewy body, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, Niemann's disease -Pick type C, cerebral contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, Rasmussen encephalitis, Wernicke encephalopathy, limbic encephalitis, Hashimoto encephalopathy), coma, loss of consciousness, obesity (e.g. malignant mast cells, extrinsic obesity, hyperinsulin obesity, hyperplasmic obesity, pituitary obesity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, childhood obesity, upper body obesity, alimentary obesity, gonadal obesity, systemic mastocytosis, primary obesity, central obesity), insulin resistance syndrome, Alzheimer's, impaired consciousness such as coma, side effect or complication caused by anesthesia, sleep disturbance, sleep problems, insomnia, intermittent sleep, nocturnal myoclonus, disruption of REM sleep , jet lag, jet lag syndrome, shift worker sleep disorder, dyssomnia, sleep terror, depression, major depression, sleepwalking, enuresis, sleep disorder, Alzheimer's sundown syndrome, disease associated with the circadian rhythm , fibromyalgia, condition resulting from decreased sleep quality, bulimia, obsessive eating disorder, obesity-related diseases, hypertension, diabetes, elevated plasma insulin level / insulin resistance, hyperlipemia, hyperlipidemia, endometrial cancer , breast cancer, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart rhythm, arrhythmia, myocardial infarction, congestive heart failure, heart failure, heart disease coronary heart disease, cardiovascular disease, sudden death, polycystic ovary, craniopharyngioma, Prader-Willi syndrome, Froehlich syndrome, growth hormone deficiency, variant short stature, Turner syndrome, children suffering from acute lymphoblastic leukemia, syndrome X, abnormality of reproductive hormone, decreased fertility, infertility, hypogonadism in men, dysfunction of ζζίταηη / ζζηζ / ε / γίλΐ sexual / reproductive function such as hirsutism in women, fetal defect associated with obesity in motherhood, disorder of gastrointestinal motility such as obesity-related gastroesophageal reflux, hypoventilation syndrome of obesity (Pickwickian syndrome), respiratory disease such as respiratory distress, inflammation such as systemic vascular inflammation, arteriosclerosis, hypercholesterolemia, hyperuricemia, lower back pain, gallbladder, gout, kidney cancer, secondary risk of obesity such as risk of left ventricular hypertrophy, migraine, headache, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweats, disease in the genital system / urinary, illness associated with sexual function or fertility, persistent depressive disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack , panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorder such as brain deficiency developed after cardiac bypass surgery or heart transplant,stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head injury, periparturient hypoxia, cardiac arrest, hypoglycemic nerve injury, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, eye damage , retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorder associated with muscle spasm, delirium, amnestic disorder, age-related cognitive decline, schizoaffective disorder, paranoia, drug addiction, movement disorder, chronic fatigue syndrome, fatigue , drug-induced parkinsonian syndrome, Giles de la Tourette syndrome, chorea, myoclonus, tic, restless leg syndrome, dystonia, dyskinesia, attention deficit hyperactivity disorder (ADHD), conduct disorder, urinary incontinence, withdrawal syndrome , trigeminal neuralgia, hearing loss, ringing in the ears, nerve injury, retinopathy, macular degeneration, vomiting, cerebral edema, pain, bone pain, arthralgia, dental pain, cataplexy, and traumatic brain injury; and preferably narcolepsy, idiopathic hypersominus, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, and hypersomnia associated with dementia with Lewy body. Hereinafter, the processes for preparing the compound of the present invention of the formula (1) are exemplified together with examples, but the processes of the present invention should not be limited to the examples. Preparation process The compound of the present invention can be synthesized according to each Preparation Process shown below or its combination with a known ζζίταηη / ζζηζ / Ε / γίΛΐ synthesis process. Each compound in the following schemes may exist as a salt thereof, wherein the salt includes, for example, the pharmaceutically acceptable salt mentioned above. The following schemes are disclosed only as examples, therefore, it is also possible to optionally prepare the present compound by a different process based on the knowledge of a person skilled in the field of synthetic organic chemistry. In each Preparation Process described below, protecting groups may be used as necessary, even if the use of protecting groups is not explicitly stated. And, protecting groups can be deprotected after a reaction is completed or a series of reactions has been carried out to obtain the desired compound. As such protecting groups, for example, the general protecting groups described in T. W. Greene, andP. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wuey & Sons, Inc, New York (1999), and the like. Examples of amino protecting groups include, for example, tert-butoxycarbonyl, benzyloxycarbonyl, p-toluenesulfonyl, onitrobenzenesulfonyl, tetrahydropyranyl, and the like; Examples of hydroxy protecting groups include, for example, trialkylsilyl, acetyl, benzyl, tetrahydropyranyl, methoxymethyl, and the like; Examples of aldehyde protecting groups include, for example, dialkylacetal, cyclic alkylacetal, and the like; and examples of carboxyl protecting groups include, for example, tert-butyl ester, orthoester, amide, and the like. The introduction and removal of protective groups can be carried out by a method commonly used in the chemistry of organic synthesis (for example, see T. W. Greene, and P. G. M. Wuts, Protective Groups ¡n Organic Synthesis, 3rd Ed., John Wiiey & Sons, Inc, New York (1999)}, or a similar method. Preparation Process 1: In the compounds according to the formula (1) or a pharmaceutically acceptable salt thereof, the compound of the formula (s-1-1) or a pharmaceutically acceptable salt thereof which is a compound of the formula (1) wherein A3es nitrogen atom can be prepared, for example, by the following process. ζζίταηη / ζζηζ / Ε / γίΛΐ where R1- R4, L1, L2, n, ring G, A1, and the link accompanied by a dashed line are as defined in Point 1. Step (1-1): Compound (s-1-1) can be prepared by reacting compound (s-12) and compound (s-1-3) in a suitable inert solvent under a urea-binding formulation reaction condition. The present reaction condition includes, for example, using triphosgene, 4-nitrophenyl chloroformate, Ι,Γ-carbonyldiimidazole, or thiophosgene. A base is used in the present reaction, and the base used herein includes triethylamine and diisopropylethylamine. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. In Step (1-1), the intermediate such as an isocyanate can be isolated, followed by transformation of the intermediate. Preparation Process 2: In compounds according to the formula (s-1-3), the compound of the formula (s2-1) which is a compound of the formula (s-1-3) having no unsaturated bond in the ring can be prepared, for example, by the following process, provided that L2 is oxygen atom or NR10-, or L2 is single bond and the ring G is connected to the cycloalkyl via the nitrogen atom therein, where R10 is H or alkyl of Ci-4, that definition is used below unless otherwise indicated. ζζίταηη / ζζηζ / Ε / γίΛΐ where R3, R4, L2, n, and ring G are as defined in Point 1; P1 is a suitable protecting group; and LG is a suitable leaving group, such definitions are used below unless otherwise indicated. Compound (s-2-1) can be prepared from compound (s-2-2) via Step (2-1) and Step (2-2). Step (2-1): The compound (s-2-4) can be prepared by reacting the compound (s-22) and the compound (s-2-3) in a suitable inert solvent without additives or in the presence of an acid or a base. The acid used herein includes, for example, a protonic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, and ptoluenesulfonic acid; and a Lewis acid such as zinc(II) chloride, scandium(III) triflate, copper(I) chloride, boron trifluoride, boronic acid, and boronate ester. The base used herein includes, for example, an organic base such as triethylamine, diisopropylethylamine, and DBU; an inorganic base such as sodium hydrogen carbonate, sodium carbonate, and potassium carbonate; a metal alkoxide such as potassium tert-butoxide; an organometallic reagent such as n-butyl lithium and isopropylmagnesium chloride; and a metal amide reagent such as LDA and LHMDS. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (2-2): The compound (s-2-1) can be prepared by reacting the compound (s-24) in a suitable inert solvent or under a hydrogen atmosphere as necessary, under a conventional nitro reduction condition. The present reaction condition includes, for example, using iron, zinc, tin(II) chloride, Raney nickel, palladium on carbon, or palladium(II) hydroxide. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; an ester solvent such as ethyl acetate and methyl acetate; and an alcohol solvent such as methanol and ethanol. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Compound (s-2-1) can also be prepared from compound (s-2-5) via Step (2-3) and Step (2-4). Step (2-3): The compound (s-2-6) can be prepared by reacting the compound (s-25) and the compound (s-2-3) in a suitable inert solvent without additives or in the presence of a low acid or base. a conventional aziridine ring opening reaction condition. The acid used herein includes, for example, a protonic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid; and a Lewis acid such as zinc(II) chloride, scandium(III) triflate, copper(I) chloride, boron trifluoride, boronic acid, and boronate ester. The base used herein includes, for example, an organic base such as triethylamine, diisopropylethylamine, and DBU; an inorganic base such as sodium hydrogen carbonate, sodium carbonate, and potassium carbonate; a metal alkoxide such as potassium tert-butoxide; an organometallic reagent such as n-butyl lithium and isopropylmagnesium chloride; and a metal amide reagent such as LDA and LHMDS. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and a ζζίταηη / ζζηζ / Ε / γίΛΐ ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (2-4): The compound (s-2-1) can be prepared by deprotection of the compound (s-2-6) in a known manner (for example, a manner described in Protective Groups in Organic Synthesis 3rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, edited by R. C. Larock, VCH publisher Inc., 1989, etc.) or a manner similar thereto. Compound (s-2-1) can also be prepared from compound (s-2-7) via Step (2-5) - Step (2-7), and Step (2-4). Step (2-5): The compound (s-2-8) can be prepared by reacting the compound (s-27) and the compound (s-2-3) in a suitable inert solvent without additives or in the presence of a low acid or base. a conventional epoxy ring opening reaction condition. The acid used herein includes, for example, a protonic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid; and a Lewis acid such as boron trifluoride, zinc(II) chloride, scandium(III) triflate, copper(I) chloride, boronic acid, and boronate ester. The base used herein includes, for example, an organic base such as triethylamine, diisopropylethylamine, and DBU; an inorganic base such as sodium hydrogen carbonate, sodium carbonate, and potassium carbonate; a metal alkoxide such as potassium tert-butoxide; an organometallic reagent such as n-butyl lithium and isopropylmagnesium chloride; and a metal amide reagent such as LDA and LHMDS. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (2-6): The compound (s-2-9) can be prepared by reacting the compound (s-28) in a suitable inert solvent under a conventional transformation reaction condition of the hydroxy group to a leaving group. The present reaction condition includes, for example, using methanesulfonyl chloride, p-toluenesulfonyl chloride, or trifluoromethanesulfonyl chloride. A ζζίταηη / ζζηζ / Ε / γίΛΐ base is used in the present reaction, and the base used herein includes, for example, an organic base such as triethylamine, diisopropylethylamine, and DBU; an inorganic base such as sodium hydrogen carbonate, sodium carbonate, and potassium carbonate; a metal alkoxide such as potassium tert-butoxide; an organometallic reagent such as n-butyl lithium and isopropylmagnesium chloride; and a metal amide reagent such as LDA and LHMDS. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (2-7): The compound (s-2-6) can be prepared in a general nucleophilic substitution with the compound (s-2-9), P^H?, and a base. The base used herein includes, for example, an organic base such as triethylamine, diisopropylethylamine, and DBU; an inorganic base such as sodium hydrogen carbonate, sodium carbonate, and potassium carbonate; a metal alkoxide such as potassium tert-butoxide; an organometallic reagent such as n-butyl lithium and isopropylmagnesium chloride; and a metal amide reagent such as LDA and LHMDS. The solvent used herein includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (2-6) and Step (2-7) can be carried out as one step without isolating the intermediary. And, Step (2-6) and Step (2-7) can also be carried out as one step under the Mitsunobu reaction condition. Preparation Process 3-1: In compounds according to the formula (s-2-1), the compound of the formula (s3-1) which is a compound of the formula (s-2-1) where L2 is single bond and the ring G is binds to cycloalkyl via a nitrogen atom therein can also be prepared, for example, by the following process. ζζίταηη / ζζηζ / Ε / γίΛΐ ζζίταηη / ζζηζ / Ε / γίΛΐ (s-2-2) (s-3-2) where R3, R4, n, and ring G are as defined in Point 1. Compound (s-3-1) can be prepared from compound (s-2-2) via Step (3-1) Step (3-3). Step (3-1): The compound (s-3-2) can be prepared in a manner similar to Step (2-1) with the compound (s-2-2) and ammonia or a reagent equal to ammonia that includes a protected amine reagent that is deprotects after amination and an azide inducer that is reduced after azidation. Step (3-2): The compound (s-3-3) can be prepared in a nitrogen-containing heteroring formulation with the compound (s-3-2). For example, the compound (s-3-3) where the G ring is piperazine can be prepared by reacting the compound (s-3-2) with N-benzyl-bis(2chloroethyl) amine, followed by deprotection and alkylation. . Step (3-3): Compound (s-3-1) can be prepared in a manner similar to Step (2-2) with compound (s-3-3). Compound (s-3-1) can also be prepared from compound (s-2-5) via Step (3-4) - Step (3-6). Step (3-4): The compound (s-3-4) can be prepared in a manner similar to Step (2-3) with the compound (s-2-5) and ammonia or a reagent equal to ammonia that includes a protected amine reagent that is deprotects after amination and an azide inducer that is reduced after azidation. ζζίταηη / ζζηζ / Ε / γίΛΐ Step (3-5): The compound (s-3-5) can be prepared in a manner similar to Step (3-2) with the compound (s-3-4). Step (3-6): Compound (s-3-1) can be prepared in a deprotection similar to Step (2-4) with compound (s-3-5). Preparation Process 3-2: The compound according to the formula (s-3-1) can also be prepared, for example, by the following process. (s-3-6) where R3, R4, n, and ring G are as defined in Point 1. Compound (s-3-1) can be prepared from compound (s-3-6) via step (3-7) and step (3-8). Step (3-7): The compound (s-3-6) is the compound (s-2-9) in Preparation Process 2, where L2 is single bonded and the G ring is connected to the cycloalkyl via a nitrogen atom therein. The compound (s-3-7) can be prepared in a general nucleophilic substitution reaction as Step (2-7) with the compound (s-3-6) and a conventional base as an intramolecular reaction. The compound (s-3-7) can be used in the next step without insulation. Step (3-8): The compound (s-3-1) can be prepared in a general ring opening reaction with the compound (s-3-7) and ammonia or a reagent equal to ammonia that includes a protected amine reagent that is deprotected after amination and an azide inducer that is reduced after azidation. ζζίταηη / ζζηζ / Ε / γίΛΐ Preparation Process 4: In the compounds according to the formula (s-2-1), the compound of the formula (s4-1) which is a compound of the formula (s-2-1) where L2 is O or NR10 can also be prepared, for example, by the following process. (s-2-5) (s-4-4) (s-4-5) where R3, R4, n, and ring G are as defined in Point 1; and Y is O or NR10, such definitions are used below unless otherwise indicated. Compound (s-4-1) can be prepared from compound (s-2-2) via Step (4-1) or Step (4-3). Step (4-1): Compound (s-4-2) can be prepared by reacting compound (s-22) in a manner similar to Step (2-1) with YH2 or a reagent equal to YH2 that includes a P2YH protected reagent that is deprotected. after the addition reaction, where P2 is a suitable protecting group, said definition is used below unless otherwise indicated. Step (4-2): The compound (s-4-3) can be prepared in a general nucleophilic substitution reaction or aromatic nucleophilic substitution reaction with the compound (s-4-2), Ring G accompanied with a leaving group, and a base. The base used herein includes, for example, an organic base such as triethylamine, diisopropylethylamine, and DBU; an inorganic base such as sodium hydrogen carbonate, sodium carbonate, and potassium carbonate; a metal alkoxide such as potassium tert-butoxide; an organometallic reagent such as n-butyl lithium and isopropylmagnesium chloride; and a metal amide reagent such as LDA and LHMDS. The solvent used herein includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is 20°C at the boiling point of a solvent used herein. Step (4-3): Compound (s-4-1) can be prepared in a manner similar to Step (2-2) with compound (s-4-3). Compound (s-4-1) can also be prepared from compound (s-2-5) via step (4-4) - step (4-6). Step (4-4): Compound (s-4-4) can be prepared by reacting compound (s-25) in a manner similar to Step (2-3) with YHz or a reagent equal to YH2 that includes a P2YH protected reagent that is deprotected. after the addition reaction. Step (4-5): The compound (s-4-5) can be prepared in a manner similar to Step (4-2) with the compound (s-4-4). Step (4-6): Compound (s-4-1) can be prepared in a deprotection similar to Step (2-4) with compound (s-4-5). Preparation Process 5: The compound of the formula (s-2-5) can also be prepared, for example, by the following process. ζζίταηη / ζζηζ / Ε / γίΛΐ ζζίταηη / ζζηζ / Ε / γίΛΐ where R3, R4, and n are as defined in Point 1. Compound (s-2-5) can be prepared from compound (s-5-1) via Step (5-1) and Step (5-4). Step (5-1): The compound (s-2-7) can be prepared by reacting the compound (s-51) in a suitable inert solvent under a conventional epoxide formulation condition. The present reaction condition includes, for example, using an oxidizing agent such as hydrogen peroxide solution, mCPBA, tert-butyl hydroperoxide, and Oxone. In the present reaction, a metal catalyst such as V, Mo, Al, Ti, Fe, Ta, Zr, Nb, W, and Re can be used, as appropriate. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (5-2): The compound (s-5-2) can be prepared in a manner similar to Step (2-5) with the compound (s-2-7) and Ρ^Ης in a suitable inert solvent. Step (5-2) can be carried out in a process comprising reacting the compound (s-2-7) and ammonia or a reagent equal to ammonia that includes a protected amine reagent that is deprotected after amination. and an azide inducer that is reduced after azidation, and then protect the product with a P1 protecting group. Step (5-3): The compound (s-5-3) can be prepared in a manner similar to Step (2-6) with the compound (s-5-2) in a suitable inert solvent. Step (5-4): The compound (s-2-5) can be prepared by the reaction of the compound (s-53) in the presence of a base in a suitable inert solvent under a conventional intramolecular cyclization reaction condition. The base used herein includes, for example, an organic base such as triethylamine, diisopropylethylamine, and DBU; an inorganic base such as sodium hydrogen carbonate, sodium carbonate, and potassium carbonate; a metal alkoxide such as potassium tert-butoxide; an organometallic reagent such as n-butyl lithium and isopropylmagnesium chloride; and a metal amide reagent such as LDA and LHMDS. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (5-3) and Step (5-4) can be carried out as one step without isolating the intermediary, and, (5-3) and Step (5-4) can also be carried out as one step under the Mitsunobu reaction condition. Compound (s-2-5) can also be prepared from compound (s-5-1) via Step (5-5). Step (5-5): The compound (s-2-5) can be prepared by reacting the compound (s-51) in a suitable inert solvent under a conventional aziridine ring formulation reaction condition. The present reaction condition includes, for example, using P1NH2 and an oxidizing agent such as iodosylbenzene in the presence of a metal catalyst, and using a hydroxylamine derivative P^HjO-LG and a metal catalyst. Preparation Process 6: In compounds according to the formula (s-1-1), the compound of the formula (s6-1) having an unsaturated bond in the ring can be prepared, for example, by the process ζζίταηη / ζζηζ / Ε / γίΛΐ next. Step (6-4) Step (6-3) LG _3J- — R4R'-Pin Step (6-5) “TR4R'-Pin (s-6-7) (s-6-8) (s-6-1) zzfronn / zznz / E / YiAi where R3, R4, L2, n, and ring G are as defined in Point 1; Z is boronic acid, boronate ester, BF3K, BFsNa, trialkyl tin, zinc halide, or hydrogen atom; and X 5 is halogen. Compound (s-6-1) can be prepared from compound (s-6-6) via Step (6-7). And, compound (s-6-6) can be prepared from compound (s-6-2) via Step (6-1) - Step (6-3), or via Step (6-4) - the Step (6-6). Step (6-1): The compound (s-6-4) where L2 is single bond or methylene which may be optionally substituted with the same or different one or more Ci-4 alkyl can be prepared by reacting the compound (s-6-2) with the compound (s-6-3) wherein Z is boronic acid, boronate ester, BF3K, BFsNa, trialkyl tin, or zinc halide, in the presence of palladium catalyst and phosphine ligand, and optionally in the presence of a base, in a suitable inert solvent. The compound (s-6-3) is commercially available, or can be prepared according to a known method or a method similar thereto. The palladium catalyst used herein includes, for example, tetrakis(triphenylphosphine)palladium (0), bis(dibenzyldenacetone)palladium (0), tris(dibenzyldenacetone)palladium (0), bis(tri-tert-butylphosphine)palladium(0), palladium(O) acetate, [l,l-bis(diphenylphosphine)ferrocene]palladium(II) dichloride, and bis (di-tert-but¡l(4dimet¡lam¡nophen¡l)phosphina)dichloropalladium(II). The phosphine ligand used herein includes, for example, o-tolylphosphine, 2-di¡clohex¡lphosphino-2',6'-dimethoxy¡biphenyl (S-Phos), 2-dicyclohex¡ lphosphino-2l,4l,6'-triisopropylbiphenyl (XPhos), l,l'-bis(diphenylphosphino)ferrocene (DPPF), l,2-bis(diphenylphosphino)ethane (DPPE), 1,3bis(diphen lphosphino)propane (DPPP), l,4-bis(diphenylphosphino)butane (DPPB), 2,2'-bis(diphenylphosphino)-l,rbinaphthyl (BINAP), 4,5-bis( diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), and bis((2-diphenylphosphino)phenyl) ether (DPE-Phos). The base used herein includes, for example, sodium carbonate, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydroxide, and potassium hydroxide. The inert solvent includes, for example, 1,4-dioxane, THF, 1,2-dimethoxyethane, acetonitrile, water, and a mixture thereof. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Furthermore, the compound (s-6-4) where L2 is O or NR10 can also be prepared by reacting the compound (s-6-2) with the compound (s-6-3) where Z is hydrogen atom in the presence of palladium catalyst, phosphine ligand, and a base in a suitable inert solvent. Step (6-2): The compound (s-6-5) can be prepared in a manner similar to Step (2-6) with the compound (s-6-4). Step (6-3): The compound (s-6-6) can be prepared in a manner similar to Step (2-7) with the compound (s-6-5) and Ρ^Ης. Step (6-3) may be carried out in a process comprising reacting ζζίταηη / ζζηζ / Ε / γίΛΐ the compound (s-6-5) and ammonia or a reagent equal to ammonia including a protected amine reagent. which is deprotected after amination and an azide inducer which is reduced after azidation, and then protect the product with a P1 protecting group. Step (6-2) and Step (6-3) can be carried out as one step without isolating the intermediary. And, Step (6-2) and Step (6-3) can also be carried out as one step under the Mitsunobu reaction condition. Step (6-4): The compound (s-6-7) can be prepared in a manner similar to Step (6-2) with the compound (s-6-2). Step (6-5): The compound (s-6-8) can be prepared in a manner similar to Step (6-3) with the compound (s-6-7). Step (6-5) can be carried out in a process comprising reacting the compound (s-6-7) and ammonia or a reagent equal to ammonia that includes a protected amine reagent that is deprotected after amination. and an azide inducer that is reduced after azidation, and then protect the product with a P1 protecting group. Step (6-4) and Step (6-5) can be carried out as one step without isolating the intermediary. And, Step (6-4) and Step (6-5) can also be carried out as one step under the Mitsunobu reaction condition. Step (6-6): The compound (s-6-6) can be prepared in a manner similar to Step (6-1) with the compound (s-6-8). Step (6-7): Compound (s-6-1) can be prepared in a deprotection similar to Step (2-4) with compound (s-6-6). Preparation Process 7: In compounds according to the formula (s-1-1), the compound of the formula (s7-1) which does not have an unsaturated bond in the ring can be prepared, for example, by the following process. ζζίταηη / ζζηζ / Ε / γίΛΐ ζζίταηη / ζζηζ / Ε / γίΛΐ Step (7-3) (s-7-1) where R1- R4, L1, L2, n, the ring G, and A1 are as defined in Point 1. Compound (s-7-1) can be prepared from compound (s-7-4) via Step (7-6). And, compound (s-7-4) can be prepared from compound (s-5-3) via Step (7-1) - Step (7-3), or from compound (s-2-5) via Step (7-4) and Step (7-5). Step (7-1): Compound (s-7-2) can be prepared in a deprotection similar to Step (2-4) with compound (s-5-3). Step (7-2): Compound (s-7-3) can be prepared in a ureation similar to Step (1-1) with compound (s-7-2) and compound (s-1-2). In this step, the hydroxy group can be protected and deprotected, if necessary. Step (7-3): The compound (s-7-4) can be prepared in a manner similar to Step (5-3) and Step (5-4) with the compound (s-7-3). Step (7-4): Compound (s-7-5) can be prepared in a deprotection similar to Step (2-4) with compound (s-2-5). Step (7-5): Compound (s-7-4) can be prepared in a urea formation similar to Step (1-1) with compound (s-7-5) and compound (s-1-2). Step (7-6): Compound (s-7-1) can be prepared in an aziridine ring opening reaction similar to Step (2-3) with compound (s-7-4) and compound (s-2-3). Preparation Process 8: The compound of formula (s-1-1) can also be prepared from compound (s-81) via Step (8-1) - Step (8-3). zzfronn / zznz / E / YiAi (s-1-1) where R1- R4, L1, L2, n, ring G, A1, and the bond accompanied by a dashed line are as defined in Point 1. Step (8-1): The compound (s-8-2) can be prepared by reacting the compound (s-8-1) in a suitable inert solvent under a conventional acyl azide formulation condition. The present reaction condition includes, for example, using diphenylphosphoryl azide, or converting the carboxylic acid to its acid halide and then aziding the acid halide with a metal azide. The inert solvent includes an ether solvent such as diethyl ether, diisopropyl ether, tetrahydrofuran, and 1,4dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; an ester solvent such as ethyl acetate and methyl acetate; a polar aprotic solvent such as N,Ndimethylformamide, Ν,Ν-dimethylacetamide, N-methyl-2-pyrrolidinone, l,3-dimethyl-2-midazolidinone, and dimethyl sulfoxide. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (8-2): The compound (s-8-3) can be prepared by reacting the compound (s-8-2) in a suitable inert solvent under a Curtius rearrangement reaction condition. The compound (s-8-2) used herein may be the non-isolated product of the previous step. Step (8-3): The compound (s-1-1) can be prepared by reacting the compound (s-8-3) and the compound (s-1-2) in a suitable inert solvent under a conventional addition reaction condition. The compound (s-8-3) used herein may be the non-isolated product of the previous step. ζζίταηη / ζζηζ / Ε / γίΛΐ Preparation Process 9: In compounds according to the formula (s-8-1), the compound of the formula (s9-1) which does not have an unsaturated bond in the ring can be prepared, for example, by the following process. (s-9-2) (s-2-3) Step (9-1) Step (9-3) where R3, R4, L2, n, and ring G are as defined in Point 1; and P3 is a suitable protecting group or C1-3 alkyl, such definitions are used below unless otherwise indicated. Compound (s-9-1) can be prepared from compound (s-9-2) via step (9-1) and step (9-2). Step (9-1): Compound (s-9-3) can be prepared in a manner similar to Step (2-1) with compound (s-9-2) and compound (s-2-3). Step (9-2): The compound (s-9-1) can be prepared by subjecting the compound (s-9-3) to a general hydrolysis or deprotection condition. Compound (s-9-1) can be prepared from compound (s-2-9) via Step (9-3) and Step (9-4). Step (9-3): The compound (s-9-4) can be prepared in a manner similar to Step (2-7) with the compound (s-2-9) and a metal cyanide. Step (9-4): The compound (s-9-1) can be prepared by reacting the compound (s-9-4) in a suitable inert solvent under a general hydrolysis condition. Preparation Process 10: In compounds according to the formula (s-8-1), the compound of the formula (s10-1) having an unsaturated bond in the ring can be prepared, for example, by the following process. where R3, R4, L2, n, and ring G are as defined in Point 1; Z is boronic acid, boronate ester, BF3K, BFsNa, trialkyl tin, zinc halide, or hydrogen atom; and X is halogen. Compound (s-10-1) can be prepared from compound (s-10-2) via Step (1090 2) . And, compound (s-10-2) can be prepared from compound (s-6-5) via Step (10-1), or from compound (s-6-7) via Step (10-3). and the Step (10-4). Step (10-1): The compound (s-10-2) can be prepared in a manner similar to Step (2-7) with the compound (s-6-5) and a metal cyanide. Step (10-2): The compound (s-10-1) can be prepared by reacting the compound (s-102) in a suitable inert solvent under a general hydrolysis condition. Step (10-3): The compound (s-10-3) can be prepared in a manner similar to Step (10-1) with the compound (s-6-7) and a metal cyanide. Step (10-4): Compound (s-10-2) can be prepared in a manner similar to Step (6-1) with compound (s-10-3) and compound (s-6-3). Preparation Process 11: In the compounds according to the formula (1) or a pharmaceutically acceptable salt thereof, the compound of the formula (s-11-1) which is a compound of the formula (1) wherein A3 is a carbon atom or a salt pharmaceutically acceptable thereof may be prepared, for example, by the following process. ζζίταηη / ζζηζ / Ε / γίΛΐ ζζίταηη / ζζηζ / Ε / γίΛΐ where R1- R4, L1, L2, n, the G ring, and the bond accompanied by a dashed line are as defined in Point 1. Step (11-1): The compound (s-11-1) can be prepared by reacting the compound (s-112) and the compound (s-1-3) in a suitable inert solvent under a conventional amide bond formulation reaction condition. The present reaction condition includes, for example, using a condensing agent and a base, and the condensing agent used herein includes, for example, a carbodiimide such as dicyclohexylcarbodiimide, Ι,Ι'-carbonyldiimidazole, diphenylphosphoryl azide (DPPA ), diethylphosphoryl cyanide (DEPC), dicyclohexylcarbodiimide (DCC), carbonyldiimidazole (CDI), l-ethyl-3-(3-dimethylaminopropyl)carbodimide hydrochloride (EDCHCI), O-tetraborohydrate (1Hbenzotrázole-l-¡l)-l,l,3,3-tetramethyl-uron¡o (TBTU), O-(benzotnazol-l-¡l)-N,N,N',N' -tetramethyluronium hexafluorophosphate (HBTU), and O-(7-azabenzotnazol-l-¡l)-N,N,N',N',-tetramethyluronium hexafluorophosphate (HATU). The base used herein includes an organic base such as triethylamine, diisopropylethylamine, tributylamine, DBU, pyridine, and dimethylaminopyridine. The inert solvent includes a halogenated hydrocarbon solvent such as dichloromethane and chloroform; an ether solvent such as diethyl ether, diisopropyl ether, tetrahydrofuran, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; an ester solvent such as ethyl acetate and methyl acetate; a polar aprotic solvent such as N,N-dimethylformamide, Ν,Ν-dimethylacetamide, N-methyl92 2-pyrrolidinone, l,3-dimethyl-2-imidazolidinone, and dimethyl sulfoxide. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Compound (s-11-1) can also be prepared from compound (s-11-2) via Step (11-2) and Step (11-3). Step (11-2): The compound (s-11-3) can be prepared by reacting the compound (s-112) in a suitable inert solvent under a conventional acid halide formulation reaction condition. The present reaction condition includes, for example, using a halogenating agent, and the halogenating agent used herein includes, for example, thionyl chloride, oxalyl chloride, phosphoryl chloride, sulfuryl chloride, phosphorus trichloride, phosphorus tribromide, and phosphorus pentachloride. The inert solvent includes a halogenated hydrocarbon solvent such as dichloromethane and chloroform; an ether solvent such as diethyl ether, diisopropyl ether, tetrahydrofuran, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (11-3): The compound (s-11-1) can be prepared by reacting the compound (s-113) and the compound (s-1-3) in a suitable inert solvent in the presence of a base. The base used herein includes an organic base such as triethylamine, diisopropylethylamine, tributylamine, DBU, pyridine, and dimethylaminopyridine; and an inorganic base such as sodium hydrogen carbonate, sodium carbonate, and potassium carbonate. The inert solvent includes a halogenated hydrocarbon solvent such as dichloromethane and chloroform; an ether solvent such as diethyl ether, diisopropyl ether, tetrahydrofuran, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Preparation Process 12: In the compounds according to the formula (1) or a pharmaceutically acceptable salt thereof, the compound of the formula (s-12-1) which is a compound of the formula (1) wherein A2 is an oxygen atom or a pharmaceutically acceptable salt thereof may be prepared, for example, by the following process. (s-12-1) ζζίταηη / ζζηζ / Ε / γίΛΐ where R1- R4, L1, L2, n, ring G, A1, and the bond accompanied by a dashed line are as defined in Point 1. Step (12-1): The compound (s-12-1) can be prepared by reacting the compound (s-1-2) and the compound (s-12-2) in a suitable inert solvent under a conventional carbamate formulation reaction condition. The present reaction condition includes, for example, using triphosgene, 4-nitrophenyl chloroformate, or thiophosgene. A base is used in the present reaction, and the base used herein includes triethylamine and diisopropylethylamine. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. The compound (s-12-2) that does not have an unsaturated bond in the ring is prepared in the Compound Preparation Process (s-2-8). And, the compound (s-12-2) that has an unsaturated bond in the ring is prepared in the Preparation Process of the compound (s-6-4). Preparation Process 13: In compounds according to the formula (s-1-2), the compound of the formula (s13-1) can be prepared, for example, by the following process. ζζίταηη / ζζηζ / Ε / γίΛΐ where R2 is as defined in Point 1, Raly Q2 are as defined in Point 4; and P4 is a suitable protecting group, such definitions are used below unless otherwise indicated. Step (13-1): The compound (s-13-4) can be prepared by reacting the compound (s-132) and the compound (s-13-3) in a suitable inert solvent under a conventional addition reaction condition. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; an alcohol solvent such as methanol and ethanol; and water. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (13-2): The compound (s-13-6) can be prepared by reacting the compound (s-134) and the compound (s-13-5) in a suitable inert solvent under a conventional condensation reaction condition. The present reaction condition includes, for example, using HATU, DCC, or GDI. A base is used in the present reaction, and the base used herein includes triethylamine and diisopropylethylamine. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (13-3): The compound (s-13-7) can be prepared by reacting the compound (s-136) in a suitable inert solvent under a conventional dehydration reaction condition. In the present reaction, a base such as triethylamine and DBU can be used as appropriate. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is 20°C at the boiling point of a solvent used herein. ζζίταηη / ζζηζ / Ε / γίΛΐ Step (13-4): The compound (s-13-1) can be prepared by deprotection of the compound (s-13- 7) in a known manner (for example, a manner described in Protective Groups in Organic Synthesis 3rd Edition (John Wiley & Sons, Inc.), Comprehensive Organic Transformation, edited by R. C. Larock, VCH publisher Inc., 1989, etc.) or a similar way to it. Preparation Process 14: In compounds according to the formula (s-1-2), the compound of the formula (s14-1) which is a compound of the formula (s-1-2) wherein L1 is a single bond and R1 is an aromatic heterocyclyl group Optionally substituted 5-membered can also be prepared, for example, by the following process. (s-14-4) Step (14-2) Ra1-=X4 where R2 is as defined in Point 1, X4 and Ralson as defined in Point 4. Compound (s-14-1) can be prepared from compound (s-14-2) via Step (ΜΙ) - Step (14-3). Step (14-1): The compound (s-14-3) can be prepared by reacting the compound (s-142) in a suitable inert solvent under a conventional chlorination reaction condition. The present reaction condition includes, for example, using chlorine, N-succinimide, and trimethylbenzylammonium tetrachloroiodate. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; a polar aprotic solvent such as Ν,Ν-dimethylformamide, N,N-dimethylacetam¡de, N-methyl-2-pyrrolidinone, l,3-dimethyl-2-im¡dazol¡dinone and dimethyl sulfoxide; water; and a mixture thereof. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (14-2): The compound (s-14-5) can be prepared by reacting the compound (s-143) and the compound (s-14-4) in a suitable inert solvent under a conventional 1,3-dipolar cycloaddition reaction condition. The present reaction condition includes, for example, using a base, and the base used herein includes an inorganic base such as potassium carbonate, cesium carbonate, sodium carbonate, sodium hydrogen carbonate, sodium methoxide, t- sodium butoxide, sodium hydroxide, potassium hydroxide, and potassium fluoride; and an organic base such as triethylamine, diisopropylethylamine, tributylamine, DBN, DABCO, DBU, pyridine, dimethylaminopyridine, picoline, and NMM. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (14-3): Compound (s-14-1) can be prepared in a manner similar to Step (13-4) with compound (s-14-5). ζζίταηη / ζζηζ / Ε / γίΛΐ Preparation Process 15: In compounds according to the formula (s-1-2), the compound of the formula (s15-1) can be prepared, for example, by the following process. Step (15-1) (s-15-3) ζζίταηη / ζζηζ / Ε / γίΛΐ (s-15-4) (s-15-5) (s-15-1) where R2 is as defined in Point 1, X1- X3, Q1 and Ra6 are as defined in Point 4. Step (15-1): Compound (s-15-4) can be prepared by reacting compound (s-152) and compound (s-15-3) in a suitable inert solvent under a condensation reaction as Step (13-2). Step (15-2): The compound (s-15-5) can be prepared by reacting the compound (s-154) in a suitable inert solvent under a conventional dehydration reaction condition, or a cyclization condition after treatment with Lawesson reagent or the like. . Step (15-3): Compound (s-15-1) can be prepared in a manner similar to Step (13-4) with compound (s-15-5). Preparation Process 16: In compounds according to the formula (s-1-2), the compound of the formula (s16-5) or the compound of the formula (s-16-8) which is a compound of the formula (s-1 -2) where L1 is single bond and R1 is optionally substituted Ce-ium aromatic carbocyclyl group or optionally substituted 5- to 10-membered aromatic heterocyclyl group can be prepared, for example, by the following process. ζζίταηη / ζζηζ / Ε / γίΛΐ ^p4 Step (16-3) (s-16-4) (s-16-5) (s-16-6) (s-16-7) (s-16-8) where R1 and R2 are as defined in Point 1; Z is exemplified in the following Step (16-1); and X is halogen. Compound (s-16-5) can be prepared from compound (s-16-1) via Step (161) - Step (16-3). Step (16-1): The compound (s-16-3) can be prepared by coupling the compound (s-16-1) with an organic boron compound (for example, Z is B(OH)2 and the like), organic zinc compound ( for example, Z is ZnCl and the like), alkenyl compound, alkynyl compound, hydroxy compound (for example, Z is OH and the like), amine compound (for example, Z is NH2 and the like), or metal cyanide (for example example, Z is CuCN and the like), in the presence of a metal base and catalyst. The base used herein includes an inorganic base such as potassium carbonate, cesium carbonate, sodium carbonate, sodium hydrogen carbonate, sodium methoxide, sodium t-butoxide, sodium hydroxide, potassium hydroxide, and fluoride. potassium; and an organic base such as triethylamine, diisopropylethylamine, tributylamine, DBN, DABCO, DBU, pyridine, dimethylaminopyridine, picoline, and NMM. Sometimes, a base is not used depending on the type of coupling. The metal catalyst used herein includes, for example, bis(tri-tert-butylphosphine)palladium, bis(tri-otolylphosphine)dichloropalladium, bis(tri-o-tolylphosphine)palladium, tetrakis(triphen, lphosphine)palladium, dichlorob¡s(acetonitrile)palladium, bis(tri-o-tol¡lphosphine)dichloropalladium, [1,1'bis(diphen¡lphosphino)ferrocene] dichloropalladium, and PEPPSITM'IPr^l^-bis^ó-diisopropylphenyljimidazolidene) (3-chloropyrid¡l)palladium(II) dichloride). Palladium acetate or palladium chloride may be used herein, and a ligand described in Plladium reagents and catalysts, John Wiley & Sons Inc. (2004) or a similar ligand may also be used in place of the acetate in palladium acetate. or the chloride in palladium chloride. The solvent used herein includes, for example, an ether solvent such as diethyl ether, diisopropyl ether, tetrahydrofuran, methyl cyclopentyl ether, anisole, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, chlorobenzene, and xylene; an ester solvent such as ethyl acetate and methyl acetate; a polar aprotic solvent such as N,Ndimethylformamide, Ν,Ν-dimethylacetamide, N-methyl-2-pyrrolidinone, l,3-dimethyl-2-¡m¡dazol¡dinone, and dimethyl sulfoxide; water; and a mixture thereof. The reaction temperature should be determined depending on the starting compound to be used, which is generally about 0°C to about 250°C, preferably about 20°C to about 200°C. The reaction time is generally 30 minutes to 48 hours, preferably 1 to 24 hours. Step (16-2): The compound (s-16-4) can be prepared by reacting the compound (s-163) in a suitable inert solvent under a conventional alkene reduction reaction condition, and under a hydrogen atmosphere if necessary. The present reaction condition includes, for example, using a reducing agent such as palladium on carbon, palladium(II) hydroxide, platinum on carbon, platinum(IV) oxide, Raney nickel, ruthenium on carbon, and tris chloride. (triphenylphosphine)rhodium(I). The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene, and xylene; an alcohol solvent such as methanol and ethanol; and an ester solvent such as ethyl acetate and methyl acetate. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (16-3): The compound (s-16-5) can be prepared in a manner similar to Step (13-4) with the compound (s-16-4). Compound (s-16-8) can be prepared from compound (s-16-1) via Step (161), and Step (16-4) - Step (16-6). Step (16-4): The compound (s-16-6) can be prepared by reacting the compound (s-163), an alkylating agent R2-X, and a base in a suitable inert solvent under an alkylation reaction condition. The base used herein includes LDA, LHMDS, and n-butyllithium. The solvent ζζίταηη / ζζηζ / Ε / γίΛΐ 100 inert includes an ether solvent such as diethyl ether, THF, and 1,4-dioxane; and an aromatic hydrocarbon solvent such as benzene, toluene, and xylene. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (16-5): The compound (s-16-7) can be prepared by reacting the compound (s-166) in a suitable inert solvent in a manner similar to Step (16-2) where the reducing agent may include sodium borohydride, cyanoborohydride sodium, and sodium triacetoxyborohydride. ζζίταηη / ζζηζ / Ε / γίΛΐ Step (16-6): The compound (s-16-8) can be prepared in a manner similar to Step (13-4) with the compound (s-16-7). Preparation Process 17: In compounds according to the formula (s-1-2), the compound of the formula (s17-1) can be prepared, for example, by the following process. (s-17-2) (s-17-3) (s-17-4) (s-17-5) (s-17-1) where R1 is as defined in Point 1, and R8 is C1-3 alkyl. Step (17-1): The compound (s-17-3) can be prepared by reacting the compound (s-17101 2) and an alkylation agent R^X where X is halogen in a suitable inert solvent under an alkylation reaction condition as Step (16-4). Step (17-2): The compound (s-17-4) can be prepared by reacting the compound (s-173) in a suitable inert solvent under a conventional reduction reaction condition. The present reaction condition includes, for example, using LAH or DIBAL. The inert solvent includes a hydrogenated carbon solvent such as chloroform and dichloromethane; an ether solvent such as diethyl ether, THF, and 1,4-dioxane; and an aromatic hydrocarbon solvent such as benzene, toluene, and xylene. The reaction time is generally about 1 hour to 24 hours, and the reaction temperature is -20°C to the boiling point of a solvent used herein. Step (17-3): The compound (s-17-5) can be prepared by reacting the compound (s-174) in a suitable inert solvent under a Barton-McCombie deoxygenation condition. Step (17-4): Compound (s-17-1) can be prepared in a manner similar to Step (13-4) with compound (s-17-5). EXAMPLES The present invention is explained in more detail below with reference to Reference Examples, Examples and Tests; However, the technical scope of the present invention should not be limited to them. It should be understood that the names of the compounds used in the following Reference Examples and Examples do not necessarily follow IUPAC nomenclature. In this specification, the abbreviations shown below may be used. CDCh: deuterochloroform DMSO-de: deuterodimethyl sulfoxide Rt: retention time min: minute HATU: O-(7-aza-lH-benzotráazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate zzfronn / zznz / E / YiAi 102 DCC: Ν,Ν'-dicyclohexylcarbodiimide CDI: carbonyldiimidazole THF: tetrahydrofuran TFA: trifluoroacetic acid DMF: Ν,Ν-dimethylformamide DMSO: dimethyl sulfoxide CPME: cyclopentyl methyl ether Boc: tert-butoxycarbonyl Ns: 2-nitrobenzenesulfonyl Tf: trifluoromethanesulfonyl DBU: diazabicycloundecene DBN: l,5-diazabicyclo[4.3.0]non-5-ene LDA: lithium diisopropylamide LHMDS: lithium bis(trimethyls¡l)amide mCPBA: meta-chloroperbenzoic acid DABCO: l,4-diazabicyclo[2.2.2]octane NMM: N-methylmorpholine LAH: lithium aluminum hydride DIBAL: diisobutylaluminum hydride Abs: Absolute Configuration; Each chemical structure of the described compounds along with the Abs label surrounded with a square flame is shown in the absolute configuration with a discontinuous wedge bond. However, not all compounds without the Abs label are shown in the non-absolute configuration, that is, the configuration must be appropriately judged based on the description about the compound of interest in the present description and its context, and a knowledge technician from an expert person, with or without the Abs brand. In the column chromatography and amino chromatography used in the Reference Examples and Examples, a silica gel column and amino column manufactured by YAMAZEN CORPORATION were used. The TLC (silica gel plate) used in the TLC purification was Silica gel 60F254 (Merck), and the TLC (silica gel plate NH) used in the same was NH TLC plate (FujiSilysia). In the Reference Examples and Examples, the reactors shown below were used. The physicochemical data described in the Reference Examples and Examples were obtained with the following apparatus. Microwave reactor: Biotage AB Initiator ^-NMR: JEOL JNM-AL400 Spectrometer; JEOL JNM-ECS400; Brucker AVANCE 400 ζζίταηη / ζζηζ / Ε / γίΛΐ 103 The symbols used in NMR are defined as follows, s: singlet, d: doublet, dd: doublet of doublet, ddd: doublet of doublet of doublet, dddd: doublet of doublet of doublet of doublet, t: triplet, td: triplet doublet, q: quartet, m: multiplet, br: singlet or wide multiplet, and J: coupling constant. LC / MS data for each compound in the Examples and Reference Examples were obtained with any of the following apparatus. Method A Detection device: ACQUITY™ SQ Detector (Waters Corporation) HPLC: ACQUITY™ UPLC SYSTEM Column: Waters ACQUITY™ UPLC BEH C18 (1.7 pm, 2.1 mm x 30 mm) Method B Detection apparatus: Shimadzu LCMS-2020 Column: Phenomenex Kinetex (C18, 1.7 pm, 2.1 mm x 50 mm) Method C Detection device: ACQUITY™ SQ Detector (Waters Corporation) HPLC: ACQUITY™ UPLC SYSTEM Column: Waters ACQUITY™ UPLC BEH C18 (1.7 pm, 2.1 mm x 30 mm) high-performance liquid chromatograph-mass spectrometer; The LC / MS measurement conditions are as follows, where the observed [MS (m / z)] is denoted by [M+H]+ and the retention time is denoted by Rt (min). Each MS measured value shown in the working examples is accompanied by any of A - D which were measurement methods used in the actual measurements. Method A Solvent: A; 0.06% formic acid / Η2θ, B; 0.06% formic acid / acetonitrile Gradient condition: 0.0-1.3 min (linear gradient from B 2% to B 96%) Flow rate: 0.8 mL / min; Detection UV: 220nm and 254nm; Temperature: 40°C Hereafter, LC-MS data shown below were measured by Method A, unless otherwise indicated. Method B Solvent: A; 0.05% TFA / Η2θ, B; acetonitrile Gradient condition: 0.0-1.7 min (linear gradient from B 10% to B 99%) Flow rate: 0.5 mL / min; Detection UV: 220nm; Temperature: 40°C Method C zzfronn / zznz / E / YiAi 104 Solvent: A; 0.05% formic acid / Η2θ, B; acetonitrile Gradient condition: 0.0-1.3 min (linear gradient from B 10% to B 95%) 1.3-1.5 min (B 10%) Flow rate: 0.8 mL / min; Detection UV: 220nm and 254nm; Temperature: 40°C ζζίταηη / ζζηζ / Ε / γίΛΐ EXAMPLE 1 / -<^c-4-(4-Methylphenyl)-N-{(lS,2S)-2-[4-(propan-2-¡l)piperazin-l-yl]cyclohexyl}p¡per¡ dna-lcarboxamide To a mixture of Reference Example 1 (211 mg) (Material A), triethylamine (0.391 mL), and chloroform (3 mL) was added 4-nitrophenyl chloroformate (208 mg) at 0°C, and the mixture was stirred. at the same temperature for 40 minutes. 4-(4methylphenyl)piperidine hydrochloride (238 mg) (Material B) was added to the reaction mixture at 0°C, and the mixture was stirred at room temperature for one hour. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound (346 mg). ^-NMR (CDCh) δ: 1.02 (6H, d, J = 6.7 Hz), 1.04-1.11 (1H, m), 1.12-1.40 (3H, m), 1.58-1.71 (3H, m), 1.76-1.93 (4H, m), 2.27 (1H, dd, J = 10.4, 3.6 Hz), 2.32 (3H, s), 2.35-2.54 (6H, m), 2.54-2.65 (3H, m), 2.65-2.75 (2H , m), 2.78-2.91 (2H, m), 3.25-3.33 (1H, m), 4.08-4.19 (2H, m), 5.76 (1H, s), 7.09 (2H, d, J = 8.8 Hz), 7.12 (2H, d, J = 8.8 Hz). EXAMPLES 2 TO 16 The compounds of Examples 2 to 16 shown in the table below were prepared in the same manner as Example 1, using commercial compounds or Reference Example compounds corresponding to Material A and Material B described in Example 1. 105 Example Structure Material A Material B Spectral data 2 ^Me Me.^ N Λ 0 Reference Example 3 Commercial Product ^Me 0 N h2n^A^ \ / nh HCI ^-NMR (CDCh) δ: 1.07 (3H, t, J = 7.3 Hz), 1.12-1.35 (6H, m), 1.36-1.45 (2H, m), 1.56-1.69 (2H, m), 1.80-1.88 (2H, m), 1.89-1.96 (1H, m), 2.12-2.20 (1H, m), 2.302.58 (11H, m), 2.59-2.70 (2H, m), 2.80-2.91 (2H, m), 3.98-4.04 (1H, m), 4.07-4.15 (2H , m), 5.16 (1H, s), 7.10 (2H, d, J = 8.5 Hz), 7.13 (2H, d, J = 8.5 Hz). 3 Me^^Me P'N < > Me—4- jl Μθ L J H γ LTÓ Reference Example 1 Commercial Product Me^^Me N PN Me—4 1M® L^NH HCl ^-NMR (CDCh) δ: 1.03 ( 6H, d, J = 6.1 Hz), 1.14-1.28 (3H, m), 1.32 (3H, s), 1.581.68 (3H, m), 1.76-1.82 (1H, m), 1.83-1.91 (1H, m), 2.19-2.30 (3H, m), 2.34-2.53 (6H, m), 2.53-2.62 (6H, m), 2.62-2.71 (2H, m), 3.07 (2H, ddd, J = 13.2, 10.4 , 2.8 Hz), 3.20-3.31 (1H, m), 3.63-3.74 (2H, m), 5.70 (1H, s). 4 Me^Me Μθ.^. N .v MeO Reference Example 4 Commercial Product Mex,Me | 3HCI N h2n,„Yi MeO'' \ / NH HCI ^-NMR (CDCh) δ: 1.01 (6H, d, J = 6.1 Hz), 1.15-1.35 (4H, m), 1.42-1.58 (2H, m) , 1.58-1.71 (2H, m), 1.81-1.90 (2H, m), 1.91-2.01 (1H, m), 2.32 (3H, s), 2.38-2.63 (8H, m), 2.63-2.71 (3H, m), 2.72-2.95 (3H, m), 3.35 (3H, s), 3.50-3.57 (1H, m), 4.014.06 (1H, m), 4.06-4.23 (2H, m), 5.53 (1H, d, J = 3.7 Hz), 7.09 (2H, d, J = 8.2 Hz), 7.12 (2H, d, J = 8.2 Hz). 5 Reference Example 5 Commercial Product ζζίταηη / ζζηζ / Ε / γίΛΐ 106 ^-NMR (CDCh) δ: 1.06 (6H, d, J = 6.1 Hz), 1.35-1.48 (1H, m), 1.48-1.73 (5H, m), 1.78-1.91 (2H, m), 2.12-2.25 (1H, m), 2.32 (3H, s), 2.39-2.79 (12H, m), 2.79-2.93 (2H, m), 3.96-4.12 (3H, m), 4.63 (1H, s), 7.09 (2H , d, J = 7.9 Hz), 7.12 (2H, d, J = 7.9 Hz)·____________ ζζίταηη / ζζηζ / Ε / γίΛΐ íH-NMR (CDCh) δ: 0.92-0.99 (2H, m), 0.99-1.09 (8H, m), 1.26 (3H, s), 1.35-1.45 (1H, m), 1.46 -1.76 (6H, m), 1.80-1.90 (1H, m), 1.94-2.10 (3H, m), 2.10-2.21 (1H, m), 2.37-2.84 (9H, m), 3.08-3.17 (2H, m), 3.52-3.64 (2H, m), 3.98-4.08 (1H, m), 4.61 (1H, S), 5.77 (1H, s). Example of Reference 7 Reference Example 8 ^-NMR (CDCh) δ: 0.80-0.91 (1H, m), 1.02 (3H, d, J = 6.0 Hz), 1.03 (3H, d, J = 6.0 Hz), 1.18-1.23 (4H, m), 1.24-1.28 (2H, m), 1.31 (3H, s), 1.53-1.70 (2H, m), 1.922.28 (5H, m), 2.28-2.69 (7H, m), 2.73-2.81 (2H, m ), 3.02-3.14 (4H, m), 3.52-3.63 (1H, m), 3.63-3.75 (2H, m), 5.52 (1H s). Reference Example 14 Commercial Product F F 107 ^-NMR (CDCh) δ: 0.96-1.52 (11H, m), 1.70-1.93 (3H, m), 1.94-2.08 (2H, m), 2.132.26 (1H, m), 2.32 (3H, s ), 2.42-3.27 (12H, m), 4.02-4.26 (3H, m), 4.61 (1H, d, J = 6.7 Hz), 7.08 (2H, d, J = 8.5 Hz), 7.12 (2H, d, J = 8.5 Hz). Example of Reference 6 Reference Example 8 HCI ζζίταηη / ζζηζ / Ε / γίΛΐ ^-NMR (CDCh) δ: 1.46-1.63 (6H, m), 1.12-1.24 (4H, m), 1.24-1.39 (5H, m), 1.391.50 (1H, m ), 1.51-1.71 (3H, m), 1.86-1.96 (1H, m), 2.07-2.29 (4H, m), 2.31-2.59 (6H, m), 2.59-2.74 (2H, m), 2.74-2.89 (2H, m), 2.93-3.17 (1H, m), 3.18-3.41 (1H, m), 3.62-3.83 (1H, m), 3.83-4.00 (1H I, m), 4.82-5.00 (1H Reference Example 6 mi__________ Comercial product ^-NMR (CDCh) δ: 0.88-1.10 (6H, m), 1.23-1.39 (1H, m), 1.33 (3H, s), 1.40-1.51 (1H, m), 1.53-2.99 (2H, m) , 1.73-1.83 (1H, m), 1.83-1.96 (1H, m), 2.06-2.31 (3H, m), 2.31-2.60 (9H, m), 2.60-2.86 (3H, m), 2.90-3.16 ( 1H, m), 3.16-3.42 (1H, m), 3.63-3.86 (1H, m), 3.86-4.03 (1H, m), 4.83-5.00 (1H, m) Example of Reference 6 Reference Example 20 ^-NMR (CDCh) δ: 0.90-1.10 (10H, m), 1.15-1.37 (5H, m), 1.37-1.50 (1H, m), 1.531.81 (4H, m), 1.83-1.95 (1H, m), 1.95-2.24 (4H, m), 2.24-2.71 (7H, m), 2.71-2.87 (2H, m), 3.01-3.49 (2H, m), 3.60-3.81 (1H, m), 3.81- 3.97 (1H, m), 4.83-5.00 (1H, m), 5·77 (1H, s). Example of Reference 6 Reference Example 10 108 F. O'N Jv F Me^,Me A 1® II F ^-NMR (CDCh) δ: 0.82-1.12 (6H, m) 1.97 (1H, m), 2.10-2.33 (3H, m), 2.3 ( 1H, m), 3.21-3.48 (1H, m), 3.65-3.8 m), 6.79 (1H, t, J = 52.3 Hz). 13 / ^N Γ>—N J I' L J --Λό F iH-NMR (CDCh) δ: 0.83-1.15 (10H, n (1H, m), 1.52-1.72 (3H, m), 1.72-1.8 m), 2.21-2.60 (8H, m), 2.60-2.73 (2 3.14-3.37 (1H, m), 3.42-3.59 (1H, m; 5.02 (1H, m), 8.00 (1H, s). 14 P'N Me ^^Me B N L J F ^-NMR (CDCh) δ: 1.46-1.63 (6H, m) 1.50 (1H, m), 1.51-1.71 (3H, m), 1.8 (6H, m), 2.59-2.74 (2H, m ), 2.74-2.8 m), 3.62-3.83 (1H, m), 3.83-4.00 (1H 15 Me^^Me Λ F F. O-N F HC le ^NH 1 ), 1.23-1.50 (5H, m), 1.56-1.83 (4H, m), 1.8533-2.73 (8H, m), 2.73-2.88 (2H, m), 2.95-3.22 34 (1H, m), 3.86-4.04 (1H, m), 4.85-5.00 (1H, Reference Example 6 Reference Example 27 Me^,Me 0 Ή F / =N f>—N Λ H Me , H, m), 2.73-2.89 (2H, m), 2.91-3.11 (1H, m), ), 3.59-3.83 (1H, m), 3.83-4.03 (1H, m), 4.79- Reference Example 42 Reference Example 8 Me^^Me |Abs] < > ΗΟ,, ,Ρ F-k^J F ΞΓ / í~> ------- le ;i ), 1.12-1.24 (4H, m), 1.24-1.39 (5H, m), 1.3936-1.96 (1H, m), 2.07-2.29 (4H, m), 2.31-2.59 39 (2H, m), 2.93-3.17 (1H, m), 3.18-3.41 (1H, , m), 4.82-5.00 (1H, m). Reference Example 44 Reference Example 20 ζζίταηη / ζζηζ / Ε / γίΛΐ 109 ^-NMR (CDCh) δ: 0.89-0.98 (2H, m), 0.98-1.06 (2H, m), 1.18 (3H, s), 1.28 (6H, d, J = 7.3 Hz), 1.32-1.41 (1H , m), 1.41-1.54 (1H, m), 1.54-1.79 (2H, m), 1.79-2.05 (5H, m), 2.12-2.32 (2H, m), 2.91-3.09 (3H, m), 3.35 -3.44 (1H, m), 3.50-3.59 (1H, m), 4.37 (1H, d, J = 7.9 Hz), 4.90-4.97 (1H, m), 5.72 (1H, s), 6.26 (1H, dd , J = 3.7, 3.7 Hz), 7.10 (1H, d, J = 8.3 Hz), 7.61 (1H, dd, J = 8.3, 2.0 Hz), 8.55 (1H, d, J = 2.0 HzL Example of Reference 44 Reference Example 8 ^-NMR (CDCh) δ: 1.15-1.20 (4H, m), 1.23 (3H, s), 1.24-1.32 (1H, m), 1.28 (6H, d, J = 6.7 Hz), 1.37 (1H, ddd , J = 14.1, 10.3, 3.6 Hz), 1.50 (1H, ddd, J = 14.1, 10.3, 3.8 Hz), 1.69-1.79 (1H, m), 1.79-1.97 (2H, m), 2.02-2.18 (3H , m), 2.18-2.34 (2H, m), 2.84-3.09 (3H, m), 3.39-3.48 (1H, m), 3.53-3.61 (1H, m), 4.36 (1H, d, J = 7.9 Hz ), 4.91-4.98 (1H, m), 6.27 (1H, dd, J = 4.0, 4.0 Hz), 7.10 (1H, d, J = 8.2 Hz), 7.61 (1H, dd, J = 8.2, 2.1 Hz) , 8·56 (1H, d, J = 2.1 Hz)· The chemical names from Example 2 to Example 16 are listed below. Example 2: rac-N-[(lR,2S)-2-(4-eth¡lp¡peraz¡n-l-yl)cyclohex¡l]-4-(4-met¡lfen¡l)p¡per dna1-carboxamide Example 3: r<?c-4-methyl¡l-4-(5-methyl¡l-l,2,4-oxad¡azol-3-¡l)-N-{(lS,2S)-2-[4 -(propan-2yl)piperaz¡n-l-¡l]cyclohexyl}piperdine-l-carboxamide Example 4: rac-N-{(lR,2S,6S)-2-methoxy¡-6-[4-(propan-2-yl)piperaz¡n-l-yl]cyclohexyl}-4(4-met¡ lfen¡l)p¡perid¡na-l-carboxamide Example 5: / ac-4-(4-met¡lfen¡l)-N-{(lS,2S)-2-[4-(propan-2-¡l)p¡perazin-l10 ¡l]c¡ clopentyl}piperidine-l-carboxamide Example 6: / ac-4-(5-dcloprop¡l-l,2-oxazol-3-¡l)-4-methyl-N-{(lS,2S)-2-[4-(propan-2¡l) p¡perazin-l-¡l]cyclopentyl}p¡peridine-l-carboxamide Example 7: rac-4-(5-dcloprop¡l-l,2,4-oxad¡azol-3-¡l)-N-{(lR,2S)-3,3-difluoro-2-[4( propan-2-¡l)p¡perazin-l-¡l]cyclohex¡l}-4-met¡lp¡per¡dina-l-carboxam¡da Example 8: / ac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}- 4110 (4-methylphenyl)peridine-l-carboxamide Example 9: r5C-(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-yl]cyclohexyl 4-(5c¡cloprop¡l-l,2,4-oxad azole-3-l)-4-methylpiperidine-l-carboxylate Example 10: cac-(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)piperazin-l-yl]cyclohex¡l 4methyl-4-(5- met¡l-l,2,4-oxad¡azol-3-¡l)p¡perina-l-carboxylate Example 11: rac-(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperaz¡n-l-yl]cyclohexyl 4-(5c¡cloprop¡l·l,2-oxazole -3-¡l)-4-met¡lp¡perídina-l-carbox¡late Example 12: zac-(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)p¡perazin-l-¡l]cyclohexyl 4-[5(difluoromethyl)-l ,2,4-oxad¡azol-3-yl]-4-methylpiper¡dina-l-carboxylate Example 13: rac-(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)piperaz¡n-l-yl]cyclohexyl 4-(lc¡cloprop¡l-lH-l, 2,4-tr¡azol-3-yl)-4-methyl¡lp¡per¡na-l-carboxylate Example 14: (1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-yl]cyclohexyl 4-(5dclopropíl-1,2,4-oxadíazol-3 -¡l)-4-met¡lp¡perídina-l-carbox¡late Example 15: rac-4-(5-cycloprop¡l-l,2-oxazol-3-¡l)-4-methyl-N-{2-[6-(propan-2-¡l)pyr¡din3- ¡l]cyclohex-2-en-l-¡l}piper¡dina-l-carboxamide Example 16: r<3c-4-(5-cyclopropíl-l,2,4-oxadíazol-3-íl)-4-methyl-N-{2-[6-(propan-2yl)pyridin -3-¡l]cyclohex-2-en-l-iI}piperidine-l-carboxamide EXAMPLE 17 / ac-N-[(lS,2S)-2-(4-ethylpiperazin-l-yl)cyclohexyl]-4-(4-methylphenyl)piperidine-lcarboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ To a mixture of Reference Example 2 (73.7 mg), sodium acetate (18.9 mg), acetaldehyde (0.054 ml), and dichloromethane (2 mL) was added sodium triacetoxyborohydride (122 mg) at 0°C, and the mixture It was warmed to room temperature and stirred for 1.5 hours. Water was added to the reaction mixture at 0°C, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound (24 mg). 111 ^-NMR (CDCh) δ: 1.02-1.12 (1H, m), 1.07 (3H, t, J = 7.3 Hz), 1.14-1.41 (3H, m), 1.57-1.71 (3H, m), 1.75- 1.96 (5H, m), 2.16-2.78 (15H, m), 2.78-2.90 (2H, m), 3.24-3.39 (1H, m), 4.05-4.18 (2H, m), 5.72 (1H, s), 7.09 (2H, d, J = 7.9 Hz), 7.12 (2H, d, J = 7.9 Hz). EXAMPLE 18 zac-4-(5-cyclopropyl-l,2,4-oxadíazol-3-íl)-4-methyl-N-{2-[l-(propan-2-íl)- l,2,3,6tetrahydro¡r¡din-4-¡l]cyclohex-2-en-l-¡l}p¡peridine-l-carboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ To a solution of Reference Example 13 (13.5 mg) in chloroform (2 mL) was added hydrogen chloride / acetic acid solution (4 M, 0.198 mL), and the mixture was stirred at room temperature. After the reaction was completed judging by the consumption of the starting material, the reaction mixture was concentrated in vacuo. Sodium acetate (8.66 mg), acetone (0.058 mL), and chloroform (2 mL) were added to the residue obtained. Sodium triacetoxyborohydride (33.6 mg) was added to the mixture at 0°C, and the mixture was warmed to room temperature and stirred. After the reaction was completed, water was added to the reaction mixture under ice temperature, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, concentrated in vacuo, and then the obtained residue was purified by silica amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound (10 mg ). 1H-NMR (CDCh) δ: 1.07 (6H, d, J = 6.1 Hz), 1.17-1.22 (4H, m), 1.23-1.32 (2H, m), 1.29 (3H, s), 1.43-1.66 (3H , m), 1.91-1.98 (1H, m), 2.08-2.26 (6H, m), 2.26-2.41 (1H, m), 2.50 (1H, ddd, J = 11.2, 7.2, 4.8 Hz), 2.63-2.76 (2H, m), 2.97-3.13 (3H, m), 3.13-3.23 (1H, m), 3.52-3.63 (2H, m), 4.43 (1H, d, J = 7.3 Hz), 4.63-4.69 (1H , m), 5.78-5.84 (1H, m), 5.85-5.91 (1H, m). 112 EXAMPLE 19 [4-(propan-2yl)piperazin-l-yl]cyclohexyl}-4-methylpiperina-l-carboxamide To a mixture of Reference Example 14 (84.6 mg) (Material A), triethylamine (0.318 mL), and chloroform (2 mL) was added triphosgene (27.1 mg) at 0°C, and the mixture was stirred at the same temperature. for 40 minutes. Reference Example 8 (66.7 mg) (Material B) was added to the reaction mixture at 0°C, and the mixture was stirred at room temperature for one hour. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: chloroform / methanol) to give the title compound (99.1 mg). ^-NMR (CDCh) δ: 1.00 (3H, d, J = 6.0 Hz), 1.01 (3H, d, J = 6.0 Hz), 1.17-1.22 (4H, m), 1.23-1.30 (1H, m), 1.30-1.48 (2H, m), 1.31 (3H, s), 1.57-1.70 (2H, m), 1.75-1.84 (1H, m), 1.891.97 (1H, m), 2.10-2.27 (4H, m ), 2.32-2.53 (7H, m), 2.53-2.64 (1H, m), 2.68-2.78 (2H, m), 3.08 (1H, ddd, J = 13.6, 10.7, 3.1 Hz), 3.16 (1H, ddd , J = 13.6, 10.7, 3.1 Hz), 3.66 (1H, ddd, J = 13.6, 4.7, 4.1 Hz), 3.77 (1H, ddd, J = 13.6, 4.7, 4.1 Hz), 4.10-4.21 (1H, m ), 4.54 (1H, d, J = 7.3 Hz). EXAMPLES 20 TO 76 The compounds of Examples 20 to 76 shown in the table below were prepared in the same manner as Example 19, using commercial compounds or Reference Example compounds corresponding to Material A and Material B described in Example 19. 113 Example Structure Material A Material B Spectral data Me^^Me Me 1 1 F Reference Example 14 Reference Example 20 Me^Me 3HCI Γ Ί 'Ó F ^4—' o / T / \ ^-NMR (CDCh) δ: 0.92-1.19 (10H, m), 1.27 (3H, s), 1.30-1.74 (3H, m), 1.75-1.88 (3H, m), 1.89-1.97 (1H, m) , 1.97-2.04 (1H, m), 2.05-2.27 (3H, m), 2.32-2.67 (8H, m), 2.69-2.81 (2H, m), 3.12-3.29 (2H, m), 3.57-3.68 ( 1H, m), 3.68-3.80 (1H, m), 4.08-4.25 (1H, m), 4.54 (1H, d, J = 7.3 Hz), 5.77 (1H, s). Example Reference 14 Reference Example 21 ^-NMR (CDCh) δ: 0.93 (6H, d, J = 6.1 Hz), 1.22-1.43 (2H, m), 1.45 (3H, s), 1.631.86 (4H, m), 1.89-1.97 (1H , m), 2.11-2.22 (1H, m), 2.28-2.54 (10H, m), 2.68-2.78 (2H, m), 3.11-3.26 (2H, m), 3.76 (1H, ddd, J = 13.5, 4.1, 4.0 Hz), 3.84 (1H, ddd, J = 13.5, 4.1, 4.0 Hz), 4.09-4.22 (1H, m), 4.56 (1H, d, J = 7.3 Hz), 7.29-7.35 (2H, m ), 7.47-7.53 (1H, m), 7.67-7.72 (1H, m). Reference Example Example Reference 15' 20 XH-RMN (CDCH) δ: 0.92-0.98 (2h, m), 1.00-1.08 (2h, m), 1.13 (6h, d, j = 6.0 Hz), 1.28 (3h, s), 1.28-1.47 (3h , m), 1.47-1.88 (5H, m), 1.90-2.25 (5H, m), 2.25-3.07 (8H, m), 3.13-3.03 (2H, m), 3.58-3.74 (2H, m), 4.07 -4.23 (1H, m), 4.54 (1H, d, J = 8.0 Hz), 5.78 (1H, s). 114 23 Me^^Me n t 1 Ρ'Ν [Abs] < > Γ>—4 lí Μθ II ν^Ψ^ί 1 Η Z ^ΝγΝνΛ 0 F ^-NMR (CDCb) δ: 0.97-1.16 (6H, n ( 3H, s), 1.47-1.75 (5H, m), 1.75-l.í m), 2.28-3.01 (6H, m), 3.01-3.26 G 4.54 (1H, d, J = 8.0 Hz). 24 Me^^Me P-N (Abs) <n>Γ>—4 Me --- 1 1 h .<ώ F ^-NMR (CDCI3) δ: 1.00 (3H, d, J = (4H, m), 1.23-1.30 (1H, m), 1.30-1 1.75 -1.84 (1H, m), 1.89-1.97 (1H, ir 2.64 (1H, m), 2.68-2.78 (2H, m), 3. ddd, J = 13.6, 10.7, 3.1 Hz), 3.66 ( J = 13.6 , 4.7, 4.1 Hz), 4.10-4.21 (11 25 Me^^Me r> í-------1 P'N [Abs] < > L J F !H-NMR (CDCI3) δ: 0.92-1.19 ( 10H, (3H, m), 1.89-1.97 (1H, m), 1.97-2. m), 2.69-2.81 (2H, m), 3.12-3.29 G 4.08-4.25 (1H, m), 4.54 (1H, d, J = 26 Reference Example 15' Reference Example 8 ¡AbJ Me^^Me 3HCI Γ Ί ^iy H2NkY\ F F P'N r>-^ o HC / le \^NH 31 n), 1.16-1.26 (4H, m), 1.26-1.44 (3H, m), 1.31 88 (2H, m), 1.88-2.03 (1H, m), 2.09-2.28 (4H, 2H, m), 3.58-3.84 (2H, m), 4.06-4.26 ( 1H, m), Reference Example 15 Reference Example 8 [Abs] Me^^Me 3HCI Γ Ί Ρϋ F P'N r>-^ i h HC / le \ / NH 31 = 6.0 Hz), 1.01 (3H, d , J = 6.0 Hz), 1.17-1.22 L.48 (2H, m), 1.31 (3H, s), 1.57-1.70 (2H, m), n), 2.10-2.27 (4H, m), 2.32-2.53 (7H, m), 2.5308 (1H, ddd, J = 13.6, 10.7, 3.1 Hz), 3.16 (1H, 1H, ddd, J = 13.6, 4.7, 4.1 Hz), 3.77 (1H, ddd, H, m) , 4.54 (1H, d, J = 7.3 Hz). Reference Example 15 Reference Example 20 (Abs) Me^.Me 3HCI Γ Ί PÓ F P'N HC / le \ / NH 31 m), 1.27 (3H, s), 1.3 04 (1H, m), 2.05- 2.2 2H, m), 3.57-3.68 (1 7.3 Hz), 5.77 (1H, s) 0-1.74 (3H, m), 1.75-1.88 7 (3H, m), 2.32-2.67 (8H, H, m) , 3.68-3.80 (1H, m), Reference Example 14 Reference Example 22 115 ^-NMR (CDCh) δ: 0.84-0.91 (4H, m), 1.02 (6H, d, J = 6.7 Hz), 1.20-1.31 (3H, m), 1.31-1.41 (2H, m), 1.45 (3H , s), 1.46-1.59 (3H, m), 1.66-1.85 (3H, m), 1.89-1.97 (1H, m), 2.10-2.22 (1H, m), 2.35-2.55 (7H, m), 2.55 -2.66 (1H, m), 2.67-2.79 (2H, m), 2.98-3.13 (2H, m), 3.18 (1H, ddd, J = 13.8, 10.5, 3.6 Hz), 3.59 (1H, ddd, J = 13.8, 4.6, 3.6 Hz), 3·63-3·79 (2H, m), 4.10-4.22 (1H, m), 4.53 (1H, d, J = 7.9 Hz). Example Reference Example Reference 14 19 ^-NMR (CDCh) δ: 1.00 (6H, d, J = 6.8 Hz), 1.28-1.46 (2H, m), 1.32 (3H, s), 1.571.66 (2H, m), 1.74-1.88 (6H , m), 1.89-1.97 (1H, m), 2.10-2.21 (1H, m), 2.22-2.31 (2H, m), 2.35-2.54 (9H, m), 2.54-2.63 (3H, m), 2.69 -2.78 (2H, m), 3.09 (1H, ddd, J = 13.8, 10.5, 2.9 Hz), 3.17 (1H, ddd, J = 13.8, 10.5, 2.9 Hz), 3.65 (1H, ddd, J = 13.8, 4.1, 4.1 Hz), 3.79 (1H, ddd, J = 13.8, 4.1, 4.1 Hz), 4.08-4.22 (1H, m), 4.53 (1H, d, J = 7.9 Hz). Example of Reference 14 Reference Example 9 XH-NMR (CDCh) δ: 1.00 (3H, d, J = 6.0 Hz), 1.00 (3H, d, J = 6.0 Hz), 1.20-1.43 (3H, m), 1.33 (3H, s), 1.39 ( 3H, t, J = 7.7 Hz), 1.61-1.74 (2H, m), 1.75-1.86 (1H, m), 1.89-1.98 (1H, m), 2.10-2.21 (1H, m), 2.21-2.30 ( 2H, m), 2.34-2.54 (7H, m), 2.54-2.64 (1H, m), 2.70-2.78 (2H, m), 2.89 (2H, q, J = 7.7 Hz), 3.09 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.17 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.66 (1H, ddd, J = 13.6, 4.4, 4.4 Hz), 3.79 (1H, ddd, J = 13.6, 4.4, 4.4 Hz), 4.08-4.22 (1H, m), 4.53 (1H, d, J = 7.9 Hz)._______________________________________________________ Example Reference Example Reference 14 27 116 1H-NMR (CDCh) δ: 0.94-1.15 (10H, m), 1.16-1.47 (3H, m), 1.29 (3H, s), 1.52-1.87 (5H, m), 1.87-1.99 (1H, m) , 2.10-2.22 (1H, m), 2.23-2.36 (2H, m), 2.37-2.92 (8H, m), 2.97-3.08 (1H, m), 3.08-3.19 (1H, m), 3.43-3.65 ( 2H, m), 3.72-3.84 (1H, m), 4.07-4.23 (1H, m), 4.52 (1H, d, J = 7.9 Hz), 8.00 (1H, s). Reference Example Example Reference 14 23 !H-NMR (CDCh) δ: 1.03 (6H, d, J = 6.1 Hz), 1.10-1.21 (1H, m), 1.22-1.51 (9H, m), 1.54-1.86 (5H, m), 1.61 ( 3H, s), 1.89-1.98 (1H, m), 2.08-2.23 (3H, m), 2.32-2.55 (7H, m), 2.55-2.65 (1H, m), 2.68-2.79 (2H, m), 3.01-3.19 (2H, m), 3.66 (1H, ddd, J = 13.6, 4.4, 3.2 Hz), 3.78 (1H, ddd, J = 13.6, 4.4, 3.2 Hz), 4.09-4.23 (1H, m), 4.52 (1H, d, J = 7.3 Hz).__________________________________________________________ Example Reference Example Reference 14 28 XH-RMN (CDCH) δ: 1.00 (3h, D, J = 6.1 Hz), 1.01 (3h, D, J = 6.1 Hz), 1.11-1.18 (2h, m), 1.22-1.35 (4h, m), 1.30 (3H, s), 1.35-1.47 (1H, m), 1.62-1.75 (2H, m), 1.75-1.85 (1H, m), 1.88-1.97 (1H, m), 2.10-2.22 (1H, m ), 2.31-2.62 (11H, m), 2.67 2.78 (2H, m), 3.01 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.10 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.65 (1H, ddd, J = 14.0, 4.3 , 4.3 Hz), 3.79 (1H, ddd, J = 14.0, 4.3, 4.3 Hz), 4.08-4.22 (1H, m), 4.53 (1H, d J = 7.3 Hz). Example of Reference 14 Comercial product 117 ^Nz Me^Me v, 0 1 Η I 0 F Y / 1 F Me^Me 3HCI Γ F \^NH 2HCI 1H-NMR (CDCh) δ: 1.01 (6H, d, J = 6.8 Hz), 1.21-1.49 ( 2H, m), 1.62-1.88 (4H, m), 1.89-2.06 (3H, m), 2.10-2.23 (1H, m), 2.34-2.66 (8H, m), 2.70-2.83 (2H, m), 2.853.07 (3H, m), 4.05-4.30 (3H, m), 4.60 (1H, d, J = 8.0 Hz), 7.10-7.18 (2H, m), 7.62 (1Η, ddd, J = 8.0, 8.0 , 1.6 Hz), 8.52 (1H, dd, J = 4.8, 1.6 Hz). Reference Example 14 Commercial Product 33 or H | Y [ 1 0 F Me Me 3HCI Γ h2n,,z JL f F \^NH 1.66 (4H, m), 1.66-1.86 (3H, m), 1.88-1.98 (1H, m), 2.08-2.24 (1H, m), 2.26-2.56 (6H, m), 2.562.69 (1H, m ), 2.69-2.82 (2H, m), 3.20-3.51 (4H, m), 4.06-4.25 (1H, m), 4.52 (1H, d, J = 8.0 Hz). Reference Example 14 Reference Example 24 34 Me^^Me 3·γΊ η V .......TQÓ F Me^^Me 3HCI Γ Ί ^Y τώ F n~n Γ>~Υ n Me \^NH XH-NMR (CDCh) δ: 1.01-1.23 (10H, m), 1.23-1.46 (4H, m), 1.43 (3H, s), 1.60-1.74 (1H, m), 1.74-1.87 (3H, m) , 1.92-2.03 (1H, m), 2.11-2.29 (3H, m), 2.31-2.40 (1H, m), 2.40-3.14 (8H, m), 3.26-3.38 (2H, m), 3.58-3.71 ( 2H, m), 4.08-4.23 (1H, m), 4.52 (1H, d, J = 7.9 Hz). 35 Reference Example 14 Commercial Product ζζίταηη / ζζηζ / Ε / γίΛΐ 118 Me^Me Η Ϊ ^VrS o F F 3HCI Γ Ί h2n% .Λ F F HCI ^-NMR (CDCh) δ: 0.82-1.07 (3H, m), 1.03 (6H, d, J = 6.8 Hz), 1.07-1.49 (11H, m), 1.49-1.86 (6H, m), 1.89-1.99 (1H, m), 2.09-2.25 (1H, m), 2.34-2.56 (7H, m), 2,562.67 (1H, m) , 2.67-2.87 (4H, m), 3.89-3.99 (1H, m), 4.05-4.27 (2H, m), 4.49 (1H, d, J = 8.0 Hz). 36 Me^^Me % ú F Reference Example 14 Commercial Product Me^^Me 3HCI Γ Ú F r^N L if L NH HCI ^-NMR (CDCh) δ: 0.99 (6H, d, J = 6.4 Hz), 1.21 -1.49 (2H, m), 1.61-2.00 (5H, m), 2.01-2.12 (2H, m), 2.12-2.24 (1H, m), 2.29-2.64 (8H, m), 2.68-2.81 (2H, m), 2.873.00 (1H, m), 3.00-3.14 (2H, m), 3.97-4.09 (1H, m), 4.09-4.29 (2H, m), 4.58 (1H, d, J = 8.0 Hz) , 7.13 (1H, t, J = 4.8 Hz), 8.67 (2H, d, J = 4.8 Hz). 37 Me^Me N Η ϊ O F— F Reference Example 14 Commercial Product Me-^Me 3HCI Γ Ί YOU F L 1.22-1.51 (2H, m), 1.59-1.90 (4H, m), 1.90-2.07 (3H, m), 2.10-2.24 (1H, m), 2.34-2.65 (8H, m), 2.69-2.82 (2H , m), 3.333.50 (2H, m), 3.92-4.10 (2H, m), 4.13-4.28 (1H, m), 4.64 (1H, d, J = 8.0 Hz), 5.30 (1H, bs), 7.23 (1H, ddd, J = 8.0, 8.0, 1.6 Hz), 7.32 (1H, dd, J = 8.0, 1.6 Hz), 7.71 (1H, ddd, J = 8.0, 8.0, 1.6 Hz), 8.51-8.55 ( 1H, m). 38 Reference Example 14 Commercial Product ζζίταηη / ζζηζ / Ε / γίΛΐ 119 ^-NMR (CDCh) δ: 1.02 (6H, d, J = 6.4 Hz), 1.22-1.50 (2H, m), 1.61-1.77 (3H, m), 1.77-2.00 (4H, m), 2.11-2.24 (1H, m), 2.31-2.64 (8H, m), 2.65-2.82 (3H, m), 2.833.04 (2H, m), 4.02-4.13 (1H, m), 4.13-4.33 (2H, m) , 4.60 (1H, d, J - 8.0 Hz), 7.177·24 (3H, m), 7.27-7.34 (2H, m). ζζίταηη / ζζηζ / Ε / γίΛΐ F XH-NMR (CDCh) δ: 0.95 (6H, d, J = 6.4 Hz), 1.18-1.48 (4H, m), 1.60-1.86 (5H, m), 1.87-1.98 (1H, m), 2.07-2.23 (3H, m), 2.25-2.55 (8H, m), 2.66-2.78 (2H, m), 3.28 3.62 (4H, m), 4.07-4.24 (1H, m), 4.54 (1H, d, J = 8.0 Hz), 7.16-7.24 (1H, m), 7.287.38 (4H, m). Example den, . _ „ . . „ . ... Comercial product Reference 14 XH-RMN (CDCH) δ: 0.99 (6h, D, J = 6.4 Hz), 1.22-1.49 (2h, m), 1.56-1.88 (5h, m), 1.89-2.00 (1H, m), 2.01-2.24 (3H, m), 2.29-2.61 (8H, m), 2.68-2.81 (2H, m), 3.303.47 (2H, m), 3.85-4.05 (2H , m), 4.11-4.27 (1H, m), 4.62 (1H, d, J = 8.0 Hz), 7.25 7.31 (1H, m), 7.36 (2H, t, J = 8.0 Hz), 7.48 (2H, d, J = 8.0 Hz). Example of Reference 14 Comercial product 120 Me^^Me ñ 0 F Me-^Me 3HCI Γ Ί h2n% F F Cl\^\ L^jY )H ^NH 1H-NMR (CDCh) δ: 0.99 (6H, d, J = 6.0 Hz), 1.21- 1.49 (2H, m), 1.60-1.88 (5H, m), 1.88-1.97 (1H, m), 1.97-2.09 (2H, m), 2.10-2.23 (1H, m), 2.27-2.61 (8H, m ), 2.662.80 (2H, m), 3.25-3.43 (2H, m), 3.84-4.03 (2H, m), 4.07-4.24 (1H, m), 4.61 (1H, d, J = 8.0 Hz), 7.31 (2H, d, J = 8.8 HZ), 7.41 (2H, d, J = 8.8 Hz). Reference Example 14 Example 31 Reference 42 M U l Me^Me s Λ ^1 η V Y II O F—YY F Me Me 3HCI Γ Ί F O b ^NH HCI ^-NMR (CDCh) δ: 1.01 (6H, d, J = 6.1 Hz), 1.19-1.47 (3H, m), 1.65 (3H, s), 1.671.84 (3H, m), 1.90-1.97 (1H, m), 2.09-2.21 (1H, m), 2.36- 2.53 (9H, m), 2.55-2.66 (1H, m), 2.70-2.80 (2H, m), 3.19-3.36 (2H, m), 3.66 (1H, ddd, J = 13.0, 4.1, 3.5 Hz), 3.76 (1H, ddd, J = 13.0, 4.1, 3.5 Hz), 4.11-4.26 (1H, m), 4.52 (1H, d, J = 7.3 Hz), 6.68 (1H, d, J = 8.3 Hz), 6.81 (1H, dd, J = 6.7, 5.5 Hz), 7.49-7.54 (1H, m), 8.10 (1H, dd, J = 5.5, 1.7 Hz). Reference Example 15 Example 28 Reference 43 ,S~N —4 lí ÍAbs] Me Γ j h y F Me^^Me 3HCI Γ Ί Ύ 'ib F P'N II 1 / \ / le ^NH iH-NMR (CDCh) δ: 1.00 (3H, d, J = 6.1 Hz), 1.01 (3H, d, J = 6.1 Hz), 1.11-1.18 (2H, m), 1.22-1.35 (4H, m), 1.30 (3H, s) , 1.35-1.47 (1H, m), 1.62-1.75 (2H, m), 1.75-1.85 (1H, m), 1.88-1.97 (1H, m), 2.10-2.22 (1H, m), 2.31-2.62 ( 11H, m), 2.672.78 (2H, m), 3.01 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.10 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.65 (1H, ddd, J = 14.0, 4.3, 4.3 Hz), 3.79 (1H, ddd, J = 14.0, 4.3, 4.3 Hz), 4.08-4.22 (1H, m), 4.53 (1H, d, J = 7.3 Hz). 44 Reference Example 15 Example 24 Reference ζζίταηη / ζζηζ / Ε / γίΛΐ 121 N-N r>—n Me^^Me ÍAbs] , 2.40-3.14 (8H, m), 3.26-3.38 G 4.52 (1H, d, J = 7.9 Hz). 45 P-N MeO—X U N^ Me^^Me ix O 2. m), 2.74-3.03 (3H, m), 3.05-3.22 G 4.14 (3H, s), 4.53 (1H, s). 46 Me^^Me Qx 0 Ν Ί Η Ϊ 0 F F 1H-NMR (CDCh) δ: 1.02 (6H, d, J = 1.88-2.01 (3H, m), 2.10-2.23 (1H, m 3.43 (2H, m ), 3.89-4.01 (1H, m), 4. (1H, ddd, J = 8.0, 4.8, 1.2 Hz), 7.5 8.0, 8.0, 1.2 Hz), 8.51 (1H, d, J = 4 47 Me^^Me 3HCI Γ Ί F N~N -2.29 (3H, m), 2.31-2.40 (1H, 2H, m), 3.58-3.71 (2H, m), 4.08-4.23 (1H, m), Reference Example 14 Reference Example 29 Me^,Me 3HCI Γ Ί qó F ,S'N MeO^ JL N^' Me (2H, m), 2.40-2.74 (7H, 2H, m), 3.58-3.77 (2H, m), 4.05-4.22 (1H, m), Reference Example 14 Commercial Product Me^^Me 3HCI Γ Ί ^ΙΨ h2n„z F F or NH 6.4 Hz), 1.22-1.49 (2H, m), 1.62-1.88 (2H, m), 1), 2.23-2.66 (10H, m), 2.70-2.83 (2H, m), 3.2006 -4.27 (2H, m), 4.62 (1H, d, J = 8.0 Hz), 7.20 5 (1H, dd, J = 8.0, 1.2 Hz), 7.72 (1H, ddd, J = .8 Hz). Reference Example 14 Reference Example 26 ζζίταηη / ζζηζ / Ε / γίΛΐ 122 ^-NMR (CDCh) δ: 0.96-1.02 (2H, m), 0.99 (6H, d, J = 6.0 Hz), 1.05-1.16 (2H, m), 1.18-1.48 (3H, m), 1.28 (3H , s), 1.62-1.76 (3H, m), 1.89-1.99 (1H, m), 2.08-2.23 (3H, m), 2.24-2.32 (1H, m), 2.32-2.63 (8H, m), 2.68 -2.80 (2H, m), 3.24 (1H, ddd, J = 13.1, 9.2, 3.7 Hz), 3.34 (1H, ddd, J = 13.1, 9.2, 3.7 Hz), 3.43-3.52 (1H, m), 3 ·57-3·67 (1H, m), 4·07-4·22 (1H, m), 4.54 (1H, d, J = 7.3 Hz), 6·63 (1H, s). Example Reference Example Reference 14 25 !H-NMR (CDCh) δ: 0.68-0.78 (2H, m), 0.95-1.16 (8H, m), 1.22-1.50 (3H, m), 1.35 (3H, s), 1.62-1.86 (3H, m ), 1.88-1.97 (1H, m), 1.97-2.08 (1H, m), 2.10-2.30 (3H, m), 2.32-2.66 (8H, m), 2.68-2.86 (2H, m), 3.23 (1H , ddd, J = 13.6, 9.6, 3.2 Hz), 3.32 (1H, ddd, J = 13.6, 9.6, 3.2 Hz), 3.55-3.66 (1H, m), 3.66-3.76 (1H, m), 4.084.23 (1H, m), 4.54 (1H, d, J = 7.3 Hz), 7.32 (1H, s). ^-NMR (CDCh) δ: 0.95 (6H, d, J = 6.4 Hz), 1.19-1.47 (3H, m), 1.25 (3H, s), 1.611.85 (3H, m), 1.88-1.97 (1H , m), 2.06-2.22 (3H, m), 2.28-2.53 (8H, m), 2.32 (3H, s), 2.67-2.76 (2H, m), 3.32 (1H, ddd, J = 11.6, 8.0, 3.6 Hz), 3.40-3.49 (2H, m), 3.56 (1H, ddd, J = 11.6, 8.0, 3.6 Hz), 4.09-4.22 (1H, m), 4.53 (1H, d, J = 7.8 Hz), 7.14 (2H, d, J = 8.2 Hz), 7.22 (2H, d, J = 8.2 Hz). Example Reference 14 Comercial product 123 ζζίταηη / ζζηζ / Ε / γίΛΐ ^-NMR (CDCh) δ: 0.99 (6H, d, J = 6.0 Hz), 1.21-1.49 (2H, m), 1.62-1.89 (4H, m), 1.89-2.06 (3H , m), 2.09-2.23 (1H, m), 2.30 (3H, s), 2.34-2.63 (8H, m), 2.67-2.80 (2H, m), 2.80-3.06 (3H, m), 4.03-4.29 (3H, m), 4.59 (1H, d, J = 8.0 Hz), 7.04 (1H, d, J = 8.0 Hz), 7.42 (1H, dd, J = 8.0, 2.4 Hz), 8·34 (1H, d, J = 2.4 Hz)·____________ Example Reference Example Reference 14 41 XH-NMR (CDCh) δ: 1.01 (6H, d, J=6.8 Hz), 1.21-1.48 (2H, m), 1.61-1.88 (4H, m), 1.88-2.04 (3H, m), 2.09-2.24 (1H, m), 2.31 (3H, s), 2.35-2.66 (8H, m), 2.69-2.81 (2H, m), 2.85-3.09 (2H, m ), 3.10-3.23 (1H, m), 4.00-4.10 (1H, m), 4.10-4.33 (2H, m), 4.58 (1H, d, J = 8.0 Hz), 7.14 (1H, d, J = 11.2 Hz), 8.14 (1H, s). Example of Reference 14 Comercial product XH-NMR (CDCh) δ: 1.00 (6H, d, J=6.4 Hz), 1.22-1.50 (2H, m), 1.62-1.87 (4H, m), 1.90-2.06 (3H, m), 2.10-2.23 (1H, m), 2.33-2.65 (8H, m), 2.69-2.81 (2H, m), 2.853.06 (3H, m), 4.04-4.30 (3H , m), 4.59 (1H, d, J = 8.0 Hz), 7.15 (1H, dd, J = 8.4, 4.4 Hz), 7.33 (1H, ddd, J = 8.4, 8.4 2.8 Hz), 8·38 (1H, d, J = 2.8 Hz)· Example of Reference 14 Comercial product 124 Me^^Me Vr 0 F ^-NMR (CDCh) δ: 1.00 (6H, d, J = 1.88-2.03 (3H, m), 2.09-2.23 (1H, n 3.06 (3H, m), 3.84 (3H, s), 4.03-4.2 d, J = 8.4 Hz), 7.14 (1H, dd, J = 8? 54 Me^^Me Me. _N. Χγ. Y 'τΥ F JH-NMR (CDCh) δ: 0.99 (6H , d, J = 1.99-2.10 (2H, m), 2.10-2.22 (1H, (2H, m), 2.85-3.11 (2H, m), 3.95-4 = 8.0 Hz), 8.48 (2H, s). 55 Me^^Me n. or -4.32 (3H, m), 4.( 7.86 (1H, d, J = 8.4, 2.4 Hz), 8.79 i 56 Me^Me 3HCI Γ Ί ^ΙΨ h2n,,z Λ. F "XX F MeO.^. χ1 \^NH 6.4 Hz), 1.21-1.49 (2H, m), 1.63-1.87 (4H, m), n), 2.34-2.64 (8H, m), 2.68-2.80 ( Reference Example 14 Commercial Product Me^^Me 3HCI Γ h2n„z F—XX F Φ s), 2.30-2.63 (8H, m), 2.67-2.81 .08 (1H, m), 4.09-4.26 (3H, m), 4.58 (1H, d, J Reference Example 14 Commercial Product Me^Me 3HCI Γ Ί Ύ F F3C.^. 2H, m), 2.8960 (1H, d, J = 8.0 Hz), 7.29 (1H, d, J = 8.4 Hz), 1H, s). ζζίταηη / ζζηζ / Ε / γίΛΐ 125 ^-NMR (CDCh) δ: 0.94 (6H, d, J = 6.1 Hz), 1.23-1.47 (3H, m), 1.34 (3H, s), 1.671.86 (3H, m), 1.88-1.97 (1H , m), 2.10-2.23 (3H, m), 2.31 (3H, s), 2.31-2.52 (8H, m), 2.67-2.76 (2H, m), 3.36 (1H, ddd, J = 11.6, 8.0, 3.6 Hz), 3.40-3.52 (2H, m), 3.53-3.59 (1H, m), 4.07-4.23 (1H, m), 4.54 (1H, d, J = 7.9 Hz), 6.81-6.91 (2H, m ), 7.11 (1H, dd, J = 7.6, 7.6 Hz)· ______________________________________ Example Reference Example Reference 15 30 ^-NMR (CDCh) δ: 0.86-0.93 (2H, m), 0.94-1.07 (2H, m), 1.00 (3H, d, J = 6.4 Hz), 1.01 (3H, d, J = 6.4 Hz), 1.20-1.48 (3H, m), 1.30 (3H, s), 1.54-1.85 (3H, m), 1.891.97 (1H, m), 2.09-2.22 (1H, m), 2.31-2.54 (9H, m ), 2.54-2.64 (1H, m), 2.68-2.79 (2H, m), 3.06 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.16 (1H, ddd, J = 13.8, 10.7, 3.1 Hz ), 3.58-3.68 (1H, m), 3.74-3.84 (1H, m), 4.09-4.23 (2H, m), 4.53 (1H, d, J = 7.9 _ iH-NMR (CDCh) δ: 0.95 (6H, d, J = 6.4 Hz), 1.19-1.47 (3H, m), 1.25 (3H, s), 1.611.85 (3H, m), 1.88-1.97 (1H , m), 2.06-2.22 (3H, m), 2.28-2.53 (8H, m), 2.32 (3H, s), 2.67-2.76 (2H, m), 3.32 (1H, ddd, J = 11.6, 8.0, 3.6 Hz), 3.40-3.49 (2H, m), 3.56 (1H, ddd, J = 11.6, 8.0, 3.6 Hz), 4.09-4.22 (1H, m), 4.53 (1H, d, J = 7.8 Hz), 7.14 (2H, d, J = 8.2 Hz), 7.22 (2H, d, J = 8.2 Hz). __________________________ Example Reference Example Reference 14 33 126 ^-NMR (CDCh) δ: 0.92 (3H, d, J = 6.7 Hz), 0.93 (3H, d, J = 6.7 Hz), 1.22-1.46 (3H, m), 1.29 (3H, s), 1.64- 1.85 (3H, m), 1.88-1.96 (1H, m), 2.06-2.22 (3H, m), 2.25-2.54 (8H, m), 2.66-2.76 (2H, m), 3.36 (1H, ddd, J = 11.2, 7.6, 3.6 Hz), 3.413.59 (3H, m), 4.08-4.22 (1H, m), 4.54 (1H, d, J = 7.9 Hz), 6.63 (1H, t, J = 56.5 Hz), 7·42 (2H, d, J = 8.5 Hz), 7.48 2H, d, J = 7.9 Hz) Example of Reference 15 Reference Example 34 ζζίταηη / ζζηζ / Ε / γίΛΐXH-NMR (CDCh) δ: 0.95 (6H, d, J = 6.7 Hz), 1.23-1.48 (2H, m), 1.52 (3H, s), 1.591.74 (1H, m) , 1.74-1.84 (1H, m), 1.89-1.98 (1H, m), 2.00-2.10 (2H, m), 2.10-2.20 (1H, m), 2.21-2.32 (2H, m), 2.32-2.58 ( 8H, m), 2.35 (3H, s), 2.69-2.80 (2H, m), 3.43 (1H, ddd, J = 13.1, 9.2, 3.7 Hz), 3.48-3.61 (3H, m), 4.09-4.23 ( 1H, m), 4.52 (1H, d, J = 7.3 Hz), 7.29-7.36 (2H, m), 7.51 (1H, s). Example of Reference 16 Comercial product XH-NMR (CDCh) δ: 0.95-1.14 (6H, m), 1.17-1.31 (2H, m), 1.24 (3H, s), 1.33-1.80 (5H, m), 1.80-1.88 (1H, m) , 2.05-2.25 (3H, m), 2.32 (3H, s), 2.53-2.63 (1H, m), 2.63-2.73 (1H, m), 2.78-2.88 (1H, m), 2.89-3.14 (2H, m), 3.20-3.34 (3H, m), 3.343.54 (3H, m), 3.84-3.98 (2H, m), 4.22-4.37 (1H, m), 4.61 (1H, d, J = 8.5 Hz) , 7.15 (2H, d, J = 8.5 Hz), 7.20 (2H, d, J = 8.5 Hz). Example Reference 17 Reference Example 8 127 Ρ'Ν γ>-4 ji i---) Me^ ,Me [AbsJ - A A Η Ϊ Ajó F 1H-NMR (CDCh) δ: 0.89 (3H, d, J = (4H, m), 1.22-1.35 (1H, m), 1.29 ( 1.61-1.70 (3H, m), 1.70-1.85 (5H, π 2.57 (4H, m), 3.03-3.19 (3H, m), 3. (1H, m), 4.72 ( 1H, d, J = 7.3 Hz). 63 0 Φ <---1 Me. ^Me [Abs] A Η y A F NMR (CDCh) δ: 0.84 (3H, d, J = (1H, m), 1.24 (3H, s), 1.35-1.43 (1 2.02-2.18 (4H, m), 2.21-2.27 (1H, (1H, m), 3.18-3.25 (1H, m), 3.34-3. m), 4.73 ( 1H, d, J = 7.3 Hz), 7.13 ( 64 P~N —Z \l Me rm Me lAbs] y_Me rN Ί H -TÓ F HRMN (CDCh) δ: 1.06 (6H, d, J = 1.48 (2H, m), 1.56-1.68 (2H, m), 1. (2H, m), 2.46-2.58 (1H, m), 2.63-2. m), 4.08-4.28 (2H, m), 4.51-4.60 (1 65 Me-^Me N 3HCI D—J H2N,, A. F / AA F P~N H( \ / le \ / NH 31 = 6.0 Hz), 0.90 (3H, d, J = 6.0 Hz), 1.15-1.22 :3H , s), 1.35-1.44 (1H, m), 1.44-1.53 ​​(1H, m), Π), 2.04-2.19 (3H, m), 2.20-2.29 (3H, m), 2.41.19-3.24 (1H , m), 3.68-3.83 (2H, m), 3.94-4.07 Reference Example 17 Commercial Product Me^^Me 3HCI AA Ά F T ¡1 M e HCI = 6.8 Hz), 0.85 (3H, d, J = 6.8 Hz ), 1.19-1.35 1H, m), 1.43-1.53 ​​(1H, m), 1.59-1.85 (7H, m), m), 2.32 (3H, s), 2.34-2.59 (5H, m), 3.03-3.09 .45 (2H, m), 3.46-3.59 (2H, m), 3.94-4.08 (1H, 2H, d, J = 7.9 Hz), 7.21 (2H, d, J = 7.9 Hz). Reference Example 38 Reference Example 8 Me —Me (Abs) n qA / T¿) F P-N II H( \ / le \ / NH DI 6.0 Hz), 1.18-1.24 (4H, m), 1.30 (3H, s ), 1.35.68-1.78 (3H, m), 1.93-2.27 (6H, m), 2.31-2.41 .72 (1H, m), 2.92-3.24 (4H, m), 3.63-3.75 (2H, H, m). Reference Example 17 Reference Example 20 ζζίταηη / ζζηζ / Ε / γίΛΐ 128 ^-NMR (CDCh) δ: 0.88 (3H, d, J = 6.4 Hz), 0.89 (3H, d, J = 6.4 Hz), 0.91-0.99 (2H, m), 0.99-1.07 (2H, m), 1.20-1.35 (1H, m), 1.25 (3H, s), 1.35-1.42 (1H, m), 1.42-1.53 ​​(1H, m), 1.58-1.84 (8H, m), 1.95-2.03 (1H, m ), 2.03-2.16 (4H, m), 2.242.29 (1H, m), 2.41-2.57 (4H, m), 3.04-3.10 (1H, m), 3.10-3.30 (3H, m), 3.67 (1H , ddd, J = 13.6, 4.5, 4.5 Hz), 3.75 (1H, ddd, J = 13.6, 4.5, 4.5 Hz), 3.93-4.07 (1H, m), 4.72 (1H, d, J = 7.3 Hz), 5.75 (1H, s). _______________________________________ Example Reference Example Reference 15 11 ^-NMR (DMSO-d6) δ: 0.87 (6H, d, J = 6.4 Hz), 1.18-1.36 (2H, m), 1.26 (3H, s), 1.47-1.66 (3H, m), 1.66-1.88 (4H, m), 1.95-2.11 (3H, m), 2.17-2.40 (6H, m), 2.432.63 (5H, m), 2.95-3.19 (2H, m), 3.55-3.77 (2H, m) , 3.98-4.18 (1H, m), 5.16 (1H, dddd, J = 65.0, 6.0, 6.0, 3.2 Hz), 5.88 (1H, d, J = 8.0 Hz).________________________ Reference Example 38 Commercial Product im Me lAbsJ Me r-N Γ || Me 1 \ h F Me —Me |Abs] n F T j] Me \^NH HCl 1.25 (3H, s), 1.35- 1.48 (2H, m), 1.65-1.84 (3H, m), 1.98-2.19 (6H, m), 2.25-2.36 (2H, m), 2.32 (3H, s), 2.48 (1H, dd, J = 16.4, 8.0 Hz), 2.59-2.69 (1H, m), 2.94 (1H, dd, J = 10.1, 6.4 Hz), 3.14-3.23 (1H, m), 3.27 -3.42 (2H, m), 3.42-3.56 (2H, m), 4.07-4.28 (2H, m), 4.56 (1H, d, J = 9.2 Hz), 7.14 (2H, d, J = 8.2 Hz), 7.21 (2H, d, J = 8.2 Hz). Example Reference Example Reference 15 12' 129 ζζίταηη / ζζηζ / Ε / γίΛΐ1H-NMR (CDCh) δ: 0.95-1.06 (8H, m), 1.13 (3H, d, J = 6.0 Hz), 1.21-1.57 (7H, m), 1.58-1.73 (2H, m), 1.73-1.87 (1H, m), 1.87-1.98 (1H, m), 2.08-2.30 (4H, m), 2.31 2.66 (8H, m), 2.66-2.83 (2H, m), 3.01-3.19 (2H, m), 3.61-3.72 (1H, m), 3.74-3.85 (1H, m), 4.03-4.24 (1H, m ), 4·53 (1H, d, J = 8.0 Hz)· Example of Reference 15 Reference Example 12 XH-NMR (CDCh) δ: 0.97-1.06 (8H, m), 1.13 (3H, d, J = 6.4 Hz), 1.22-1.58 (7H, m), 1.58-1.73 (2H, m), 1.73-1.87 (1H, m), 1.89-1.99 (1H, m), 2.08-2.30 (4H, m), 2.312.66 (8H, m), 2.66-2.84 (2H, m), 3.00-3.22 (2H, m) , 3.61-3.72 (1H, m), 3.74-3.85 (1H, m), 4.03-4.23 (1H, m), 4.53 (1H, d, J = 8.0 Hz). __________________________ Example den. . _ . . n r„ Commercial Product 1H-NMR (CDCh) δ: 0.97-1.04 (6H, m), 1.20-1.48 (7H, m), 1.62-1.87 (3H, m), 1.891.98 (1H, m), 2.10-2.21 (1H, m), 2.21-2.31 (2H, m) 2.31-2.54 (6H, m) 2.58 (1H, sept, J = 6.4 Hz), 2.68-2.80 (2H, m), 3.10 (1H, ddd, J = 12.8, 10.0, 2.4 Hz), 3.17 (1H, ddd, J = 13.2, 10.4, 2.8 Hz), 3.63-3.73 (1H, m) 3.73-3.83 (3H, m), 4.08-4.23 (1H, m), 4· 54 (1H, d, J = 8.0 Hz) Example of Reference 37 Reference Example 8 íH-NMR (CDCh) δ: 1.05 (3H, d, J = 6.4 Hz), 1.06 (3H, d, J = 6.4 Hz), 1.17-1.23 (4H, m), 1.30 (3H, s), 1.36- 1.47 (2H, m), 1.56-1.81 (5H, m), 1 98 (1H, ddd, J = 130 16.0, 13.6, 8.0 Hz), 2.03-2.26 (5H, m), 2.31-2.42 (2H, m), 2.51 (1H, dd, J = 16.0, 8.0 Hz), 2.60-2.67 (1H, m), 2.97 (1H, dd, J = 10.1, 6.4 Hz), 3.04-3.23 (3H, m), 3·63-3·75 (2H, m), 4.07-4.27 (2H, m), 4.55 (1H, d, J = 9.2 Hz). Reference Example Example Reference 37 11 ^-NMR (CDCh) δ: 1.04 (3H, d, J = 6.0 Hz), 1.05 (3H, d, J = 6.0 Hz), 1.33 (3H, s), 1.35-1.53 ​​(3H, m), 1.57- 1.82 (5H, m), 1.90-2.03 (2H, m), 2.03-2.20 (2H, m), 2.212.30 (2H, m), 2.30-2.41 (3H, m), 2.50 (1H, dd, J = 18.4, 8.4 Hz), 2.64 (1H, ddd, J = 8.5, 8.4, 4.6 Hz), 2.98 (1H, dd, J = 10.1, 6.4 Hz), 3.03-3.25 (3H, m), 3.65-3.75 ( 2H, m), 4.06-4.27 (2H, m), 4.55 (1H, d, J = 9.1 Hz), 4.91 (1H, dddd, J = 63.7, 6.4, 6.4, 4.0 Hz).___________________________________________________________________ Example Reference Example Reference 38 11 íH-NMR (CDCh) δ: 1.61 (6H, d, J = 6.4 Hz), 1.89 (3H, s), 1.92-2.10 (3H, m), 2.152.41 (5H, m), 2.47-2.77 (4H , m), 2.78-2.86 (2H, m), 2.86-2.97 (3H, m), 3.01-3.13 (1H, m), 3.17-3.27 (1H, m), 3.53 (1H, ddd, J = 19.8, 9.9, 6.5 Hz), 3.59-3.81 (3H, m), 4.20-4.34 (2H, m), 4.64-4.86 (2H, m), 5.07-5.17 (1H, m), 5.48 (1H, dddd, J = 63.7, 6.0, 6.0, 3.6 Hz)______________________________________________________________ Example Reference Example Reference 37 12 XH-NMR (CDCh) δ: 1.06-1.12 (1H, m), 1.13 (3H, d, J = 6.1 Hz), 1.24-1.38 (11H, m), 1.39-1.55 (3H, m), 1.56-1.66 (2H, m), 1.67-1.79 (1H, m), 1.93-2.02 (1H, m), 2.042.19 (3H, m), 2.19-2.28 (3H, m), 2.78-2.84 (1H, m) , 2.88 (1H, ddd, J = 10.4, 10.4, 6.8 Hz), 3.02-3.19 (3H, m), 3.20-3.36 (2H, m), 3.56-3.73 (3H, m), 4.12-4.28 (2H, m), 4.74 (1H, d, J = 9.2 Hz). Example of Reference 39 Reference Example 8 131 ζζίταηη / ζζηζ / Ε / γίΛΐ1H-NMR (CDCh) δ: 1.01-1.09 (6H, m), 1.17-1.23 (4H, m), 1.30 (3H, s), 1.37-1.50 (2H, m), 1.55- 1.67 (2H, m), 1.67-1.81 (2H, m), 2.05-2.27 (6H, m), 2.32-2.42 (1H, m), 2.54-2.69 (1H, m), 2.93-3.36 (5H, m ), 3.63-3.76 (2H, m), 4.06-4.31 (2H, m), 4·59-4·68 (1H, m), 4.76-4.96 (1H, m). Example of Reference 40 Reference Example 8 1H-NMR (CDCh) δ: 1.02 (3H, d, J = 6.1 Hz), 1.04 (3H, d, J = 6.7 Hz), 1.17-1.23 (4H, m), 1.30 (3H, s), 1.32- 1.51 (2H, m), 1.58-1.70 (2H, m), 1.71-1.87 (2H, m), 2.11-2.26 (5H, m), 2.35-2.50 (2H, m), 2.61-2.74 (1H, m ), 3.04-3.27 (4H, m), 3.413.50 (1H, m), 3.62-3.75 (2H, m), 4.00-4.10 (1H, m), 4.19-4.32 (1H, m), 4.64 (1H , d, J = 8.5 Hz). The chemical names from Example 20 to Example 76 are listed below. Example 20: ζ3Γ-4-(5-αοΙορΓθρίΙ-1,2-οχ3ζοΙ-3-ϋ)-Ν-{(1Ρ,65)-2,2-όίίΙυοΓθ-6-[4(propan-2-¡l) p¡perazin-l-¡l]cyclohex¡l}-4-met¡lp¡per¡dina-l-carboxamide Example 21: / ^-4-(1,3-benzoxazol-2-yl)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2yl)piperaz¡n-l-¡ l]cyclohexyl}-4-methylp¡perina-l-carboxamide Example 22: 4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2yl)piperaz n-l-yl]cyclohexyl}-4-methylpiperidine-l-carboxamide Example 23: 4-(5-cyclopropyl-l,2,4-oxadíazol-3-íl)-N-{(lS,6R)-2,2-difluoro-6-[410 (propan- 2-¡l)p¡peraz¡n-l-yl]cyclohex¡l}-4-met¡lp¡perídine-l-carboxamide Example 24: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-l)-N-{(lR,6S)-2,2-difluoro-6-[4( propan-2-yl)p¡peraz¡n-l-yl]cyclohex¡l}-4-met¡lpiper¡dina-l-carboxam¡de Example 25: 4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2¡l) piperaz¡n-l-¡l]cyclohex¡l}-4-methylp¡perina-l-carboxamide Example 26: / ^c-4-cyclopent¡l-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡perazin-lyl]cyclohexyl}- 4-methylpiperdine-l-carboxamide Example 27: zac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohexyl}-4met ¡l-4-(4,5,6,7-tetrahydro-l,3-benzoxazol-2-yl)p¡perina-l-carboxamide 132 Example 28: / ac-N-{(lR,6S)-2,2-d¡fluorO-6-[4-(propan-2-¡l)piperazin-l-yl]cyclohex¡l}-4 (5-ethyl-l,2,4-oxadiazol-3-l)-4-methylpiperidine-l-carboxamide Example 29: rac-4-(l-cyclopropyl-lH-l,2,4-triazole-3-l)-N-{(lR,6S)-2,2-difluoro-6 -[4(propan-2-¡l)piperazin-l-yl]cyclohex¡l}-4-methylpi¡perina-l-carboxamide Example 30: rac-4-(4,4-difluorocyclohex¡l)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2¡l)p¡perazin- l-yl]cyclohex¡l}-4-methylpiperidina-l-carboxamide Example 31: rac-4-(5-cyclopropyl-l,2,4-thiadilazole-3-l)-N-{(lR,6S)-2,2-difluoro-6 -[4(propan-2-¡l)p¡perazin-l-¡l]c¡clohex¡l}-4-met¡lp¡perídina-l-carboxamide Example 32: A3c-N-{(lR,6S)-2,2-difluorO-6-[4-(propan-2-yl)piperaz¡n-l-yl]cyclohexyl}-4(p¡r¡d ¡n-2-¡l)piperidine-l-carboxamide Example 33: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-8azaspiro[4.5 ]decane-8-carboxamide Example 34: rac-4-(5-cyclopropyl-1,3 / 4-t¡ad¡azol-2-yl)-N-{(lR,6S)-2,2-difluoro-6-[4 (propan-2-¡l)p¡perazin-l-¡l]cyclohex¡l}-4-met¡lp¡per¡dina-l-carboxam¡da Example 35: rac-4-cyclohex¡l-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l¡l]cyclohexyl}piperidine-l- carboxamide Example 36: rac-N-{(lR,65)-2,2-difluoro-6-[4-(propan-2-¡l)piperaz¡n-l-yl]cyclohex¡l}-4(pir¡ m¡d¡n-2-yl)p¡peridine-l-carboxamide Example 37: rac-N-{(lR,6S)-2,2-difluorO-6-[4-(propan-2-¡l)p¡peraz¡n-l-yl]cyclohexyl}-4h¡drox¡-4 -(p¡r¡d¡n-2-¡l)p¡perídine-l-carboxamide Example 38: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-yl]cyclohexíl}-4phenylpiperidine-l-carboxamide Example 39: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4methyl-4 -phenylpiperidine-l-carboxamide Example 40: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4hyd roxi- 4-pheniI p¡ perid i na -1 -ca rboxamide Example 41: zac-4-(4-chlorophen¡l)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)p¡peraz¡nl- il]cyclohexyl}-4-hydroxypiperdine-l-carboxamide Example 42: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4met ¡l-4-[(pyr¡din-2-¡l)oxy]p¡peridina-l-carboxamide Example 43: 4-(5-cyclopropíl-1,2,4-thiadiazol-3-íl)-N-{(lR,6S)-2,2-difluoro-6-[4(propan-2-íl )p¡perazin-l-¡l]cyclohex¡l}-4-met¡lp¡per¡dina-l-carboxamide Example 44: 4-(5-cyclopropyl-l,3,4-thiadiazol-2-íl)-N-{(lR,6S)-2,2-difluoro-6-[4(propan-2-íl )piperaz¡n-l-¡l]cyclohex¡l}-4-met¡lp¡per¡dine-l-carboxamide Example 45: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]c¡clohex¡l}-4ζζίταηη / ζζηζ / Ε / γίΛΐ 133 (5-methoxy-l,2,4-t¡ad¡azol-3-yl)-4-methyl¡lp¡perína-l-carboxamide Example 46: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)p¡peraz¡n-l-¡l]cyclohexyl}-4fluoro-4- (pyridin-2-yl)pyridine-l-carboxamide Example 47: r5c-4-(2-cyclopropyl-1,3-thiazol-4-¡l)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan2-¡ l)p¡peraz¡n-l-¡l]cyclohex¡l}-4-met¡lpiper¡na-l-carboxamide Example 48: rac-4-(5-cyclopropyl-1,3-thiazol-2-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan2- ¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4-met¡lp¡perídine-l-carboxamide Example 49: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-¡l]cyclohexyl}-4methyl-4-(4 -methylphenyl)piperdina-l-carboxamide Example 50: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-yl]cyclohex¡l}-4(5- methylpyridin-2-l)pyridine-l-carboxamide Example 51: r3C-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperaz¡n-l-yl]cyclohexyl}-4(3-fluoro-5-met lp¡rid¡n-2-¡l)p¡perídina-l-carboxamide Example 52: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-¡l]cyclohexyl}-4(5-fluoropyridin- 2-yl)piperdina-l-carboxamide Example 53: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-yl]cyclohex¡l}-4(5- methoxypyridin-2-l)pyrdina-l-carboxamide Example 54: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-yl]cyclohexyl}-4(5-methyllp¡r m¡din-2-yl)p¡peridana-l-carboxamide Example 55: rac-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-yl]cyclohexyl}-4[5-(tr¡ fluoromet¡l)pyridin-2-¡l]piperidine-l-carboxamide Example 56: N-{(lR,6S)-2,2-difluoro-6-[4-(prOpan-2-yl)p¡peraz¡n-l-yl]cyclohex¡l}-4-(2fluoro- 4-methylphenyl)-4-methylpiperidane-l-carboxamide Example 57: 4-[5-(cyclopropyloxy)-l,2,4-thiadiazol-3-yl]-N-{(lR,6S)-2,2-difluoro-6-[4(propan-2-¡ l)piperazin-l-yl]cyclohex¡l}-4-methylp¡perdina-l-carboxamide Example 58: rac-N-{(lR,6S)-2,2-difluorO-6-[4-(propan-2-yl)piperazin-l-¡l]cyclohex¡l}-4methyl- 4-(4-methylphenyl)pyridine-l-carboxamide Example 59: rac-4-[4-(difluoromethyl)phenyl]-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2¡l)piperaz¡n-l-¡ l]cyclohex¡l}-4-methylp¡perina-l-carboxamide Example 60: 4-(2-cyano-4-methylphenyl)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2l)piperazn-l- il]cyclohex¡l}-4-methylpiperid¡na-l-carboxamide Example 61: N-{(lR,6S)-2,2-difluoro-6-[6-(propan-2-yl)-3,6-diazabicyclo[3.1.1]heptan3-¡l]c¡ clohex¡l}-4-methyl¡l-4-(4-met¡lfen¡l)p¡perídine-l-carboxamide Example 62: 4-(5-cyclopropyl-l,2,4-oxadíazol-3-íl)-N-{(lR,6S)-2,2-difluoro-6-[3( propan-2-¡l)-3,8-d¡azabic¡clo[3.2.1]octan-8-¡l]cyclohex¡l}-4-methylpiperid¡na-l-carboxam¡da ζζίταηη / ζζηζ / Ε / γίΛΐ 134 Example 63: N-{(lR,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazab¡cyclo[3.2.1]octan8-¡l] cyclohex¡l}-4-methyl¡l-4-(4-methylphenyl)piper¡dina-l-carboxamide Example 64: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-l)-N-[(lR,6S)-2,2-difluoro-6-{[( 3R)-l(propan-2-¡l)pyrrolidin-3-yl]ox¡}cyclohexyl]-4-met¡lp¡peridína-l-carboxamide Example 65: 4-(5-cyclopropyl-l,2-oxazol-3-l)-N-{(lR,6S)-2,2-difluoro-6-[3-(propan-211 )-3,8-diazabicyclo[3.2. l]octan-8-yl]cyclohexyl}-4-methyl¡lp¡peridine-l-carboxamide Example 66: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡perazin-l-yl]cyclohex¡l}-4-{5 [(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡perídina-l-carboxamide Example 67: N-[(lR,6S)-2,2-difluoro-6-{[(3R)-l-(propan-2-yl)pyrrolidin-3¡l]oxy¡}c¡clohexyl]-4 -methyl-4-(4-methylphenyl)pyridine-l-carboxamide Example 68: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4methyl-4 -{5-[(lS,2R)-2-methylcyclopropyl]-l,2,4-oxadilazole-3-yl}piperidine-l-carboxamide Example 69: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)p¡perazin-l-yl]cyclohexyl}-4methyl-4-{5-[(lR,2S)-2-met¡lc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}p¡perid¡na-l-carboxamide Example 70: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-yl]cyclohexyl}-4methyl-4-[5- (2,2,2-trifluoroethyl)-l,2,4-oxadiazol-3-l]piperdina-l-carboxamide Example 71: 4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l (propan-2-¡l)pyrrolidin-3-yl]ox¡}c¡clohexyl]-4-met¡lp¡perídina-l-carboxamide Example 72: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-yl)pyrrolidin-3¡l]ox¡}c¡clohex¡l] -4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxadiazol-3-¡l}-4-methylpi¡perina-lcarboxamide Example 73: N-[(lR,6S)-2,2-difluoro-6-{[(3R)-l-(propan-2-yl)pyrrolidin-3yl]oxy}cyclohexyl]- 4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 74: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-yl)pyrrolídin-3yl]oxy}cyclohexyl]-4- methyl-4—{5-[(lR,2S)-2-methylcyclopropyl]-l,2,4-oxadiazol-3-yl}piperidine-lcarboxamide Example 75: 4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-2,2-difluoro-6-{[( 3S,4S)4-fluoro-l-(propan-2-¡l)pyrrolidin-3-¡l]ox¡}cyclohexyl]-4-met¡lpiper¡na-l -carboxamide Example 76: 4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-6-{[(3R)-4,4-d ¡fluoro-l(propan-2-yl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-methylpiperidine-l-carboxamide EXAMPLE 77 -4'-metal 135 l,2,3,6-tetrahydro[l,r-biphen¡l]-4-carboxam¡da ζζίταηη / ζζηζ / Ε / γίΛΐ To a solution of 4-(4-methylphenyl)-cyclohex-l-ene-carboxylic acid (64.3 mg) in chloroform (2 mL), oxalyl chloride (0.036 mL) and DMF (5 pL) were added. and the mixture was stirred at room temperature for 3 hours. Next, the reaction solution was concentrated in vacuo, and chloroform (2 mL), triethylamine (0.120 mL), and Reference Example 14 (53.3 mg) were added to the reaction residue. The mixture was stirred. After the reaction was completed, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound ( 55.6 mg). 1H-NMR (CDCh) δ: 1.02 (6H, d, J = 6.7 Hz), 1.23-1.50 (2H, m), 1.71-1.91 (4H, m), 1.93-2.11 (2H, m), 2.13-2.68 (14H, m), 2.69-2.89 (4H, m), 4.27-4.44 (1H, m), 5.68-5.77 (1H, m), 6.67-6.77 (1H, m), 7.09-7.20 (4H, m) . EXAMPLE 78 / ac-(lR,6S)-2,2-Difluoro-6-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohexyl 4'-methyl-l, 2.3 ,6tetra hydro[ 1,Γ-bifeni I]-4-ca rboxylate The compound of Example 78 shown in the table below was prepared in the same manner as Example 77, using Reference Example 6 instead of Reference Example 14 in Example 77. 136 Example Structure Instrumental analytical data 78 Me^^Me o.r and F^-NMR (CDCh) δ: 1.02 (3H, d, J = 6.0 Hz), 1.03 (3H, d, J = 6.0 Hz), 1.29-1.53 ​​(2H , m), 1.58-1.85 (4H, m), 1.88-1.97 (1H, m), 1.98-2.08 (1H, m), 2.14-2.25 (1H, m), 2.25-2.53 (11H, m), 2.532 .66 (2H, m), 2.67-2.83 (4H, m), 5.04-5.16 (1H, m), 7.09-7.16 (5H, m). ζζίταηη / ζζηζ / Ε / γίΛΐ EXAMPLE 79 rac-4-(5-cyclopropyl-l,2,4-oxadíazol-3-íl)-N-{(lR,6S)-2,2-difluoiO-6-[4-( propan-2¡l)p¡peraz¡n-l-¡l]cyclohex¡l}-4-methylp¡peradina-l-carbothioamide To a mixture of Reference Example 14 (10.0 mg) (Material A), N,Ndiisopropylamine (0.034 mL), and chloroform (0.2 mL) was added thiophosgene (4.40 mg) at 0°C, and the mixture was stirred at same temperature for 40 minutes. Reference Example 8 (66.7 mg) (Material B) was added to the reaction mixture at 0°C, and the mixture was stirred at room temperature for one hour. The mixture was purified directly by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound (9.6 mg). ^-NMR (CDCh) δ: 1.02 (6H, d, J = 5.6 Hz), 1.14-1.27 (4H, m), 1.27-1.50 (2H, m), 1.50-1.91 (8H, m), 1.91-2.04 (1H, m), 2.08-2.24 (2H, m), 2.24-2.35 (2H, m), 2.35-2.55 (5H, m), 2,552.70 (2H, m), 2.79-3.00 (2H, m) , 3.33 (1H, t, J = 11.2 Hz), 3.49 (1H, t, J = 11.2 Hz), 4.16 (1H, d, J = 12.8 Hz), 4.49 (1H, d, J = 12.8 Hz), 5.02 -5.26 (1H, m), 5.42 (1H, d, J = 8.0 Hz). EXAMPLE 80 4-(5-cycloprop¡l-l,2,4-oxadiazol-3-¡l)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2¡l) piperazin-l-¡l]c¡clohex¡l}-4-methylpiper¡dina-l-carbot¡oamide The compound of Example 80 shown in the following table was prepared in the same manner as Example 79, using Reference Example 15 corresponding to the Material 137 A in Example 79 and Reference Example 8 corresponding to Material B in Example 79. Example Structure Material A Material B Spectral data 80 Me^^Me n [Abs] N. P~N < > Me II H Y F Reference Example 15 Reference Example 8 [Abs] Me^^Me 3HCI Γ Ί Ió F P'N ϊ\—ά Me \ / NH HCI ^-NMR (CDCh) δ: 1.02 (6H, d, J = 5.6 Hz), 1.14-1.27 (4H, m), 1.27-1.50 (2H, m), 1.50-1.91 (8H, m), 1.91-2.04 (1H, m), 2.08-2.24 (2H, m), 2.24-2.35 (2H, m), 2.352.55 (5H, m), 2.55-2.70 (2H, m) , 2.79-3.00 (2H, m), 3.33 (1H, t, J = 11.2 Hz), 3.49 (1H, t, J = 11.2 Hz), 4.16 (1H, d, J = 12.8 Hz), 4.49 (1H, d, J = 12.8 Hz), 5.02-5.26 (1H, m), 5.42 (1H, d, J = 8.0 Hz). ζζίταηη / ζζηζ / Ε / γίΛΐ EXAMPLE 81 / -ac-4-(4-Methylphen¡l)-N-[(lS,4R)-3-{[4-(propan-2-yl)piperazin-l¡l]methyl}bic¡ clo[2.2. l]heptan-2-¡l]piper¡dina-l-carboxamide To a solution of Reference Example 40 (20 mg) in chloroform (0.5 mL) was added TFA (0.057 ml) at room temperature, and the mixture was stirred at the same temperature for one hour. The reaction solution was concentrated in vacuo, and the residue obtained was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate). The residue obtained was dissolved in chloroform (0.284 mL). Ν,Ν-diisopropylethylamine (36.8 mg) and triphosgene (8.4 mg) were added to the solution at 0°C, and the mixture was stirred at the same temperature for one hour. Next, 4-(4methylphenyl)piperidine (0.057 mL) was added to the reaction mixture, which was stirred at room temperature for one hour. The reaction mixture was purified directly by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound (8 mg). 138 ^-NMR (CDCh) δ: 1.24 (6H, d, J = 7.3 Hz), 1.31-1.49 (7H, m), 1.54-1.67 (4H, m), 1.84 (2H, m), 2.24 (1H, m), 2.32 (3H, s), 2.63 (2H, m), 2.80-2.99 (4H, m), 3.06-3.49 (8H, m), 4.054.14 (3H, m), 7.07-7.13 (4H, m). EXAMPLES 82 - 156 The compounds of Examples 82 to 156 shown in the table below were prepared in the same manner as Example 19, using commercial compounds or Reference Example compounds corresponding to Material A and Material B described in Example 19. Example Structure Material A Material B Spectral data 82 Me^Me F< O~N ÍÁbs) V ^ / . u Me II h 0 F / X / F Reference Example 58 Reference Example 116 Me^^Me |Abs| H2N^zk F-k^l F lAbsl V / °'N K -Z 1¡ Me L^NH 1H-NMR (DMSO-d6) δ: 0.87 (6H, d, J = 6.4 Hz), 1.18-1.36 (2H, m ), 1.26 (3H, s), 1.47-1.66 (3H, m), 1.66-1.88 (4H, m), 1.95-2.11 (3H, m), 2.17-2.40 (6H, m), 2.432.63 (5H , m), 2.95-3.19 (2H, m), 3.55-3.77 (2H, m), 3.98-4.18 (1H, m), 5.16 (1H, dddd, J - 65.0, 6.0, 6.0, 3.2 Hz), 5.88 (1H, d, J = 8.0 Hz). 83 Me \ O-N £b¡) Γ>·Η,ν Ve i J χ'ώ F Reference Example 96 Reference Example 115 Me lAbsl ί^Ν^Μβ H2N,. F lAbsl fa O'N nA|| \xNH 1.90-2.30 (8H, m), 2.32-2.41 (1H, m), 2.60-2.74 (4H, m), 3.033.15 (2H, m), 3.17-3.28 (1H, m), 3.33-3.44 (1H , m), 3.65- 3.76 (2H, m), 4.13-4.30 (1H, m), 4.51 (1H, d, J = 9.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz ). 84 Reference Example 96 Reference Example 8 139 ^-NMR (CDCh) δ: 1.00 (6H, dd, J = 6.8, 1.2 Hz), 1.17-1.25 (4H, m), 1.30 (3H, s), 1.38-1.46 (2H, m), 1.50-1.69 (4H, m), 1.69-1.85 (4H, m), 2.00-2.30 (7H, m), 2.602.74 (3H, m), 3.03-3.15 (2H, m), 3.17-3.28 (1H, m) , 3.33-3.42 (1H, m), 3.64- 3.74 (2H, m), 4.13-4.30 (1H, m), 4·50 (1H, d, J = 9·2 Hz)· _______________________ Example of Example of Reference 91 Reference 8 ^-NMR (CDCh) δ: 1.16-1.23 (4H, m), 1.27 (3H, s), 1.36 (6H, d, J = 6.8 Hz), 1.441.58 (2H, m), 1.58-1.75 (1H , m), 1.80-2.06 (4H, m), 2.09-2.23 (3H, m), 2.23-2.35 (1H, m), 2.88-3.08 (3H, m), 3.11-3.25 (1H, m), 3.48 -3.67 (2H, m), 4.41-4.57 (1H, m), 4.57-4.67 (1H, m). Example of Reference 91 Example Reference 115 JH-NMR (CDCh) δ: 1.30 (3H, s), 1.35 (6H, d, J = 6.4 Hz), 1.42-1.62 (3H, m), 1.621.75 (1H, m), 1.80-2.07 (5H , m), 2.11-2.22 (2H, m), 2.22-2.41 (2H, m), 2.89-3.08 (3H, m), 3.11-3.24 (1H, m), 3.50-3.66 (2H, m), 4.41 -4.56 (1H, m), 4.58-4.67 (1H, m), 4·93 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Example Example Reference 97 Reference 115 F ζζίταηη / ζζηζ / Ε / γίΛΐXH-NMR (CDCh) δ: 1.25 (3H, s), 1.26-1.37 (1H, m), 1.30 (3H, d, J = 6.4 Hz), 1.31 (3H, d, J = 6.4 Hz), 1.39-1.74 (4H, m), 1.74-2.01 (3H, m), 2.10-2.19 (2H, m), 2.192.30 (1H, m), 2.30-2.39 (2H, m), 2.86 (1H, ddd, J = 14.0, 11.0, 3.1 Hz), 2.96-3.08 (2H, m), 3.41-3.50 (1H, m), 3.63-3.72 (1H, m), 4.46-4.60 (1H, m) , 4.78-4.86 (1H, 140 m), 4.41 (1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz), 5.06-5.15 (1H, m). 88 ___ Me C^bs) and_Me F<. P'N r-N lí Me p z n 1 1 H f O F-Psz^ F Reference Example 98 Reference Example 115 Me Me II ,N 0^ Ή F _ lAbsl \ P'N 1 ¥e L^nh ^-NMR ( CDCh) δ: 1.30 (3H, s), 1.41-1.89 (14H, m), 1.90-2.02 (1H, m), 2.13-2.30 (4H, m), 2.31-2.41 (1H, m), 2.99-3.13 (2H, m), 3.60-3.78 (2H, m), 4.32-4.50 (2H, m), 4.63 (1H, d, J = 9.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 7.17 (1H, s), 7.21 (1H, s). 89 / —S Me F< o-N © T Γ>··4 !LMe Λ / Ν Me F Reference Example 99 Reference Example 115 Me (Abs) _ xk Γ*Ν Me F _ lAbsl F< P'N L^ nh ^-NMR (CDCh) δ: 1.13 (6H, d, J = 6.0 Hz), 1.32 (3H, s), 1.42-1.83 (5H, m), 1.872.04 (2H, m), 2.06-2.17 ( 2H, m), 2.18-2.28 (4H, m), 2.31-2.41 (1H, m), 2.60-2.73 (1H, m), 2.88-3.17 (5H, m), 3.30-3.80 (6H, m), 4.80-5.04 (1H, m). 90 Me y- Me O-N II Me I / z*n I 1 H o F-TXx^ F Reference Example 98 Reference Example 8 Me x—X—Me (Abs / / --N JI / n F P'N -Λ η Me Ι^ΝΠ HCI 1H-NMR (CDCh) δ: 1.17-1.23 (4H, m), 1.27 (3H, s), 1.44 (3H, d, J = 6.7 Hz), 1.45 (3H, d, J = 6.7 Hz), 1.46-1.65 (4H, m), 1.69-1.91 (2H, m), 2.12-2.30 (5H, m), 2.993.12 (2H, m), 3.59-3.69 (2H, m) , 3.69-3.77 (1H, m), 4.31-4.50 (2H, m), 4.63 (1H, d, J = 9.2 Hz), 7.16 (1H, s), 7.20 (1H, s). 91 __ Me G\ bs) —Me Fy-. P'N Ph r-N. Γ>.·ι<χ lí Me 112 N Η Π | 1 o Frxx^ F Reference Example 89 Reference Example 115 ® MyMe Ph r-N Tó F lAbsl \ θ'Ν Γ>··ν 1 ϊ® l___,NH 141 1H-NMR (CDCh) δ: 1.09-1.43 (11H, m), 1.43-1.56 (2H, m), 1.56-1.76 (3H, m), 1.762.24 (7H, m), 2.24-2.48 (5H, m), 2.48-2.75 (1H, m), 2.75-3.06 (1H, m), 3.06-3.45 (4H, m), 3.45-3.71 (1H, m), 3.71-3.87 (1H, m), 3.87- 4.13 (1H, m), 4.13-4.50 (1H, m), 4.94 (1H, dddd, J = 64.4, 6.0, 6.0, 4.0 Hz), 7.13-7.44 (5H, m), 11.97 (1H, brs). Reference Example 119 Reference Example 115 x—s. MeK .Me Me..Me 92 F< P'N N^N y® l y T 1 H O F F z o- _ |Absl F<. P'N Γ>··ν ή Me N>T—Ί Y.NH 1H-NMR (CDCh) δ: 1.18-1.29 (1H, m), 1.22 (3H, s), 1.30 (3H, d, J = 6.4 Hz), 1.31 (3H, d, J = 6.4 Hz), 1.40-1.53 ​​(3H, m), 1.58-1.71 (1H, m), 1.78-2.03 (3H, m), 2.052.12 (2H, m ), 2.17-2.28 (1H, m), 2.30-2.40 (2H, m), 2.81 (1H, ddd, J = 13.6, 10.8, 2.9 Hz), 2.93-3.06 (2H, m), 3.37-3.47 (1H , m), 3.54-3.61 (1H, m), 4.41-4.54 (1H, m), 4.74 (1H, d, 1 = 9.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz ), 5.40-5.48 (1H, m), 6.53 (1H, d, J = 5.5 Hz), 8.35 (1H, d, J = 5.5 Hz). Reference Example 92 Reference Example 115 93 __ Me (&b¡) Y—Me P'N N —( ^nyntS z—s Me / —Me N—( n: > N H2N, Λ. lAbsl \ P'N Γ >°ν iLYe l^NH 0 F γΎ F F ^-NMR (CDCh) δ: 1.24-1.30 (9H, m), 1.35-1.53 ​​(3H, m), 1.65-2.04 (6H, m), 2.072.20 ( 2H, m), 2.27-2.40 (2H, m), 2.83 (1H, ddd, J = 14.0, 11.6, 3.2 Hz), 2.95-3.10 (2H, m), 3.40-3.49 (1H, m), 3.57- Reference Example 93 Reference Example 115 Me (Abs) Me— / Me Me— / 94 P'N N—Λ t>-«4 n υ Ν^ΚΊ η Ϊ ® Y N h2n„. |Abs| F< P'N l£ M® L___,NH 0 F F F ^-NMR (CDCh) δ: 0.89 (6H, t, J = 6.8 Hz), 1.27 (3H, s), 1.36-1.53 ​​(3H, m), 1.642.04 (6H, m), 2.07-2.20 ( 2H, m), 2.27-2.40 (3H, m), 2.48-2.63 (2H, m), 2.84 (1H, ddd, J = 14.0, 11.2, 3.2 Hz), 2.98 (1H, ddd, J = 14.0, 11.2 , 3.2 Hz), 3.40-3.50 (1H, m), 3.54-3.65 (1H, m), 4.60-4.76 (3H, m), 4.90 (1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz), 7.43 (1H, s) 95 Reference Example 81 Reference Example 115 ζζίταηη / ζζηζ / Ε / γίΛΐ 142 F ^-NMR (CDCh) δ: 1.00-1.11 (6H, m), 1.15-1.54 (7H, m), 1.54-1.75 (4H, m), 1.752.07 (5H, m), 2.15 (3H, s) , 2.20-2.30 (3H, m), 2.30-2.42 (2H, m), 2.42-2.57 (1H, m), 2.59-2.70 (1H, m), 2.73-2.85 (1H, m), 2.90 (1H, t, J = 8.0 Hz), 3.02-3.18 (2H, m), 3.23 (1H, tt, J = 15.2, 7.2 Hz), 3.63- 3.79 (2H, m), 4.07-4.22 (1H, m), 4.54 (1H, d, J = 7.6 Hz), 4.91 (1H, dddd, J = 63.6, 6.0 6.0, 3.6 Hz)· _______________________ Example of Example of Reference 59 Reference 115 ^-NMR (CDCh) δ: 0.92-1.02 (6H, m), 1.20-1.54 (6H, m), 1.54-2.03 (8H, m), 2.08 (3H, s), 2.10-2.27 (3H, m) , 2.32-2.48 (2H, m), 2.60-2.70 (2H, m), 2.76-3.23 (6H, m), 3.62-3.77 (2H, m), 4.07-4.22 (1H, m), 4.53 (1H, d, J = 8.0 Hz), 4.91 (1H, dddd, J = Example of Reference 18 Example of Reference 117 ^-NMR (CDCh) δ: 1.00 (6H, d, J = 6.4 Hz), 1.22-1.48 (2H, m), 1.34 (3H, s), 1.491.60 (1H, m), 1.61-1.75 (2H , m), 1.75-1.87 (1H, m), 1.87-1.98 (1H, m), 1.98-2.22 (3H, m), 2.22-2.33 (2H, m), 2.33-2.54 (11H, m), 2.54 -2.64 (1H, m), 2.68-2.81 (2H, m), 3.14 (2H, dddd, J = 32.4, 14.0, 10.8, 3.2 Hz), 3.62-3.84 (3H, m), 4.16 (1H, dddd, J = 23.6, 11.2, 8.0, 3.6 Hz), 4.54 (1H, d, J = 8.0 Hz). _______________________ Example of Example of Reference 100 Reference 115 143 100 1H-NMR (CDCh) δ: 1.00-1.11 (6H, m), 1.33 (3H, s), 1.36-1.84 (13H, m), 1.85-2.07 (4H, m), 2.07-2.20 (1H, m) , 2.22-2.31 (2H, m), 2.31-2.41 (1H, m), 2.90 (1H, sep, J = 6.4 Hz), 3.03-3.26 (3H, m), 3.42-3.52 (2H, m), 3.59 - 3.78 (3H, m), 4.10-4.24 (1H, m), 4·50 (1H, d, J = 9.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz)· Example of Example Reference 59 Reference 8 XH-RMN (CDCH) δ: 0.92-1.00 (6h, m), 1.13 (2h, d, J = 6.0 Hz), 1.17-1.24 (4h, m), 1.30 (3h, s), 1.32-1.50 (2h , m), 1.56-1.70 (2H, m), 1.70-1.86 (1H, m), 1.86-1.97 (2H, m), 2.08 (3H, s), 2.11-2.26 (4H, m), 2.44 (1H , t, J = 7.6 Hz), 2.60-2.70 (2H, m), 2.76-2.86 (1H, m), 2.86-2.92 (2H, m), 2.92-3.17 (3H, m), 3.60-3.77 (2H , m), 4.074.23 (1H, m), 4.53 (1H, d, J = 7.6 Hz). ___________________________________________ Reference Example 101 Reference Example 115 (Abs) P'N 4 >-·><\ H "e F Me / —x Me ^bs) T Λ, F _ |Abs] \ O'N r>·^ LL I L___.NH ζζίταηη / ζζηζ / Ε / γίΛΐ 1011H-NMR (CDCh) δ: 0.91-0.97 (6H, m), 1.32 (3H, s), 1.37-1.86 (11H, m), 1.90-2.04 (3H, m), 2.07-2.21 (2H, m) , 2.21-2.41 (5H, m), 2.49 (1H, sep, J = 6.0 Hz), 2.62 (2H, dd, J = 15.6, 10.8 Hz), 3.02-3.16 (2H, m), 3.21-3.32 (1H , m), 3.59 (1H, t, J = 4.4 Hz), 3.63- 3.78 (2H, m), 4.22-4.37 (1H, m), 4.56 (1H, d, J = 8.8 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 4.0 Hz)__________________________________________________ Example of Example of Reference 60 Reference 115 144 I .--. O^Me fa P'N Abs A Γ>·,', v LL Me II n^xI^X T 1 H Α¥Νγ^ o F / xP F Me O^Me [Absl C Ί h2n,,. Λ. F"^P F [Absl F< p-N Γ>-·ι4 11Ύ1® 1___NH ^-NMR (CDCh) δ: 1.11 (6H, d, J = 6.4 Hz), 1.20-1.54 (8H, m), 1.60-1.74 ( 2H, m), 1.74-1.85 (4H, m), 1.85-2.04 (2H, m), 2.09-2.20 (2H, m), 2.21-2.30 (2H, m), 2.322.42 (1H, m), 2.46-2.63 (3H, m), 2.76-2.85 (1H, m), 3.01-3.17 (2H, m), 3.28 (1H, sep, J = 4.4 Hz), 3.61-3.82 (3H, m), 4.08- 4.23 (1H, m), 4.56 (1H, d, J = 7.2 Hz), 4.92 (1H, dddd, J =64.0, 6.0, 6.0, 3.6 Hz). 102 Me p-Me P'N „ Íabs) r-N. ZX -Z i! Me --- 1 \ x< 'n'yS 1 H ^ΝγΝ·|Α 0 F / X / F Reference Example 37 Reference Example 117 Me y~Me |Abs| μ 0''^ F x P~n ZX -Z h Me 6.0 Hz), 1.33 (3H, s), 1.36-1.51 (2H, m), 1.59-1.86 (5H, m), 1.92-2.12 (5H, m), 2.69 (2H, d, J = 13.2 Hz), 2.31-2.40 (2H, m), 2.40-2.55 (5H, m), 2.61-2.73 (1H, m), 2.95-3.27 (4H, m), 3.623.80 (3H, m), 4.06-4.30 (2H , m), 4.54 (1H, d, J = 9.2 Hz). 103 Me y-Me F< O-M tAbs| 0' F Reference Example 37 Reference Example 118 Me y~Me |Abs| n ov<Z F _ (Absl \ P'N k^NH ^-NMR (CDCh) δ: 0.71 (3H, t, J = 7.2 Hz), 1.05 (3H, d, J = 6.0 Hz), 1.06 (3H, d, J = 6.0 Hz), 1.32-1.54 (3H, m), 1.54-1.87 (7H, m), 1.91-2.04 (2H, m), 2.04-2.21 (2H, m), 2.30 (2H, d, J = 18.0 Hz), 2.33-2.42 (3H, m), 2.47 (1H, dd, J = 16.4, 8.0 Hz), 2.60-2.76 (1H, m), 2.88-3.11 (3H, m), 3.14-3.26 (1H, m), 3.79 (2H, d, J = 13.6 Hz), 4.06-4.29 (2H, m), 4.53 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.6, 6.0 , 6.0, 3.6 Hz). 104 Me \ P'N líC'N^Me ΪΧ...ιι<\ 11 Me \ I oX^ F Reference Example 102 Reference Example 115 Me ÉS) rf^N^Me Ή F [Absl F< P'N Γ>·'ν *£ϊβ NxkX l^NH ζζίταηη / ζζηζ / Ε / γίΛΐ 145 105 ^-NMR (CDCh) δ: 0.95 (6H, d, J = 6.1 Hz), 1.29-1.87 (12H, m), 1.33 (3H, s), 1.902.04 (1H, m), 2.04-2.31 ( 8H, m), 2.31-2.43 (1H, m), 2.52-2.67 (2H, m), 3.00-3.31 (3H, m), 3.35-3.43 (1H, m), 3.63-3.79 (2H, m), 4.12-4.29 (1H, m), 4.49 (1H, d, J = 9.2 Hz), 4.80-5.02 (1H, m)._____________________________________________________ __ Me p lAbsl 1 -¾ P~N N' Me 11 Me \ I F Reference Example 103 Reference Example 115 Me r^N^Me Ή F (Abs| \ O-N L___.NH ^-NMR (CDCh) δ: 1.12 ( 6H, br s), 1.29-1.42 (2H, m), 1.33 (3H, s), 1.42-1.53 ​​(2H, 106 m), 1.54-1.85 (8H, m), 1.90-2.21 (6H, m), 2.21-2.30 (2H, m), 2.32-2.41 (1H, m), 2.59-2.71 (1H, m), 3.03- 3.20 (3H, m), 3.25-3.60 (2H, m), 3.61-3.74 (3H, m), 4.174.30 (1H, m), 4.56 (1H, d, J = 9.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 104 Reference Example 115 F, ___ Me [Ábs] L| χχ. χΧχ O-N '--- Me ..•Ú K Me A J Ν'>Χχ'ι o''' = 1 Η » H F Me ÍAbZl H^jN^Me O''' : F [Abs] F< P'N Γ>·ν i X Νγύ \χΝΗ ζζίταηη / ζζηζ / Ε / γίΛΐ ^-NMR (CDCh) δ: 1.01 (6H, d, J = 5.5 Hz), 1.24-1.84 (8H, m), 1.33 (3H, s), 1.902.03 (1H, m ), 2.07-2.30 (5H, m), 2.30-2.47 (4H, m), 2.96-3.17 (4H, m), 3.22-3.30 (1H, m), 3.49-3.57 (1H, m), 3.66-3.75 (2H, m), 4.10-4.24 (1H, m), 4.56 (1H, d, J = 8.5 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz).________________________________ Example of Example of Reference 105 Reference 115 107 108 ^-NMR (CDCh) δ: 0.92 (3H, d, J = 4.3 Hz), 0.94 (3H, d, J = 4.3 Hz), 1.34 (3H, s), 1.36-1.54 (3H, m), 1.58 -1.84 (7H, m), 1.91-2.21 (4H, m), 2.22-2.46 (6H, m), 2.462.58 (1H, m), 2.97-3.24 (4H, m), 3.65-3.74 (2H, m), 4.15-4.25 (2H, m), 4.58 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.6, 6 0, 6.0, 3.6 Hz). _______________________ Example of Example of Reference 106 Reference 115 146 Me Me F< O-N Ν^Π Η k^N^N,, OMe 0 F F Me y-Me [Absl n ΟΜ6 F _ [Abs] F< O~N Γ> · v *£ Ve 1.___,NH 1H -NMR (CDCh) δ: 1.10 (6H, br s), 1.34 (3H, s), 1.39-1.54 (3H, m), 1.54-1.85 (6H, m), 1.91-2.04 (1H, m), 2.04 -2.21 (2H, m), 2.21-2.31 (2H, m), 2.32-2.58 (2H, m), 2.62-2.80 (1H, m), 3.05-3.19 (3H, m), 3.24-3.35 (1H, m), 3.29 (3H, s), 3.61-3.79 (3H, m), 3.92-4.01 (1H, m), 4.15-4.30 (1H, m), 4.65 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 109 Me F<. P~N i^^N^Me 1 H Me F Reference Example 107 Reference Example 115 Me MeJ J cr— F (Absl F< O'N *1 Ύ1® N^S^S 1___.NH ^-NMR ( CDCh) δ: 0.94-1.29 (8H, m), 1.33 (3H, s), 1.38-1.86 (14H, m), 1.89-2.18 (2H, m), 2.18-2.31 (2H, m), 2.31-2.75 (4H, m), 2.98-3.51 (4H, m), 3.57-3.79 (2H, m), 4.08-4.26 (1H, m), 4.51 (1H, d, J = 8.4 Hz), 4.91 (1H, dddd , J = 63.6, 6.4, 6.4, 4.0 Hz). 110 Me^Me F\ P'N lAbsl <Νχ| ^N^'vMe F Reference Example 61 Reference Example 115 Me Me i----i ^N .[Absl < > ^N^Me H2N.X F-JX / I F _ (Absl \ P~N ^•v *£ 'Y1® N^T^| \χΝΗ ^-NMR (CDCh) δ: 0.93-1.04 (9H, m), 1.23-1.53 ​​(6H, m), 1.61-1.75 (2H, m), 1.751.87 (4H, m), 1.90-2.04 (2H, m), 2.10-2.22 (1H, m) , 2.22-2.30 (2H, m), 2.30-2.41 (2H, m), 2.54 (1H, sep, J = 6.4 Hz), 2.62-2.81 (4H, m), 2.88 (1H, t, J = 11.0 Hz ), 3.02-3.12 (1H, m), 3.12-3.22 (1H, m), 3.62-3.72 (1H, m), 3.74-3.84 (1H, m), 4.104.24 (1H, m), 4.48 (1H, m , d, J = 7.4 Hz), 4.91 (1H, dddd, J =63.6, 6.0, 6.0, 3.6 Hz). 111 Me^^Me FP P~N [Abs] Γ>·% ¿ Me 1 1 O F—k / 1 F Reference Example 62 Reference Example 115 Me^^Me i----1 / N. Qm N Me H2N,. Jx F / \ / F [Abs] P'N rk v ¿ Me \ / NH ζζίταηη / ζζηζ / Ε / γίΛΐ 147 1H-NMR (CDCh) δ: 0.92-1.00 (6H, m), 1.09 (3H, d, J = 6.0 Hz), 1.33 (3H, s), 1.421.54 (3H, m), 1.60-1.89 (5H , m), 1.90-2.22 (3H, m), 2.22-2.42 (4H, m), 2.42-2.67 (4H, m), 2.68-2.79 (2H, m), 2.83-2.94 (1H, m), 3.03 -3.18 (2H, m), 3.64-3.77 (2H, m), 4.10-4.27 (1H, m), 4.53 (1H, d, J = 8.4 Hz), 4.91 (1H, dddd, J =64.0, 6.0, 6.0, 3.6Hz). 112 Me Me—ζ r . N—Me F-„ O-N (Abs) Y |l Me / \ NTP h Y 0 F AA F Reference Example 82 Reference Example 115 Me Me—ζ N—Me [Ab?) / —( N H2N,, / L F—j\A F [Abs] P P'N ιί Me N ¡Y \ / nh ^-NMR (CDCh) δ: 0.92-1.02 (6H, m), 1.33 (3H, s), 1.35-1.53 ​​(3H, m), 1.54-1.85 (5H, m), 1.86-2.04 (3H, m), 2.08 (3H, s), 2.10-2.20 (1H, m), 2.20-2.28 (2H, m), 2.312.42 ( 1H, m), 2.56-2.68 (2H, m), 2.70-2.80 (3H, m), 2.85-2.97 (1H, m), 3.02-3.16 (3H, m), 3.66-3.77 (2H, m), 4.05-4.20 (1H, m), 4.59 (1H, d, J = 7.2 Hz), 4.92 (1H, dddd, J =64.0, 6.0, 6.0, 4.0 Hz) 113 Me —Me P O~N (Abs) N Me. A? N γΊ h y ° f / \Y F Reference Example 83 Reference Example 115 Me y-Me ÍAbs) μ Me^ PÓ F [Abs] A O~N Anh ^-NMR (CDCh) δ: 1.02-1.12 ( 6H, m), 1.30-1.54 (6H, m), 1.58-1.89 (6H, m), 1.892.04 (2H, m), 2.09-2.29 (7H, m), 2.29-2.41 (2H, m), 2.42-2.52 (1H, m), 2.52-2.62 (1H, m), 2.72-2.87 (2H, m), 3.03-3.18 (2H, m), 3.23 (1H, quint, J = 7.6 Hz), 3.633. 78 (2H, m), 4.07-4.22 (1H, m), 4.55 (1H, d, J = 7.2 Hz), 4.91 (1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). 114 Me .Me Me N P~N [Abs] fY ϊ>··Λ ϊ [ J YjÓ F Reference Example 84 Reference Example 115 Me A .Me Me N (Abs) pY Η2Ν,, Λ_ F -AA F [Abs ] P P'N i Me L^nh ^-NMR (CDCh) δ: 0.93-1.05 (6H, m), 1.19-1.30 (2H, m), 1.33 (3H, s), 1.37-1.53 ​​(3H, m ), 1.60-1.84 (6H, m), 1.85-2.04 (2H, m), 2.05-2.21 (5H, m), 2.21-2.30 (2H, m), 2.30-2.42 (2H, m), 2.46-2.58 (2H, m), 2.61-2.69 (1H, m), 2.76-2.86 (1H, m), 2.91-3.03 (1H, m), 3.03-3.17 (2H, m), 3.68-3.80 (2H, m) , 4.07-4.22 (1H, m), 4.55 (1H, d, J = 7.2 Hz), 4.91 (1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). ζζίτοηη / ζζηζ / Ε / γίΛΐ 148 115 p (----. _N-Me Λ p-N γ>·Ύ i Y® / \ Ν^Π H Y F Reference Example 85 Reference Example 115 P 1---, N-Me Q H2N,, fy^y F |Abs| P'N νΎ^^ι Υ-ΝΠ 1H-NMR (CDCh) δ: 0.36-0.43 (2H, m), 0.43-0.50 (2H, m), 1.33 (3H, s), 1.34-1.53 (3H, m), 1.55-1.77 (5H, m), 1.77-1.86 (1H, m), 1.86-2.04 (3H, m), 2.10-2.30 (6H, m), 2.31-2.42 (1H, m) , 2.52-2.73 (3H, m), 2.81 (1H, td, J = 8.4, 4.4 Hz), 2.89 (1H, t, J = 7.6 Hz), 2.98-3.17 (3H, m), 3.62-3.77 (2H , m), 4.09-4.23 (1H, m), 4.54 (1H, d, J = 8.0 Hz), 4.91 (1H, dddd, J = 64.0 6.0, 6.0, 4.0 Hz). 116 Me O~N (Abs) / Me r>—4 jl Μθ / ) F Reference Example 105 Reference Example 8 Me ,_____, Μθ [Abs] 1 \ Y F P'N r\__z lí Me ynh HCl iH-MRI (CDCh) δ: 0.89 ( 3H, d, J = 6.8 Hz), 0.90 (3H, d, J = 6.8 Hz), 1.17-1.24 (4H, m), 1.30 (3H, s), 1.35-1.49 (2H, m), 1.56-1.85 (6H, m), 1.93-2.28 (8H, m), 2.28-2.37 (1H, m), 2.40-2.49 (1H, m), 2.56-2.68 (1H, m), 2.89-2.99 (1H, m) , 3.02-3.24 (3H, m), 3.61-3.76 (2H, m), 4.08-4.28 (2H, m), 4.55 (1H, d, J = 9.2 Hz). 117 Me Ω — H ÍAbs) 1' p N Me π Me 1 i Y Y Jk i N J N γΥ h f F Reference Example 95 Reference Example 115 Me SS [^'N^Me h-Y F [Abs] \ p-N γ>·· 4 ií Me Y / nh ^-NMR (CDCh) δ: 1.05 (6H, d, J = 6.7 Hz), 1.33 (3H, s), 1.43-1.54 (2H, m), 1.571.84 (7H, m) , 1.88-2.03 (2H, m), 2.10-2.22 (2H, m), 2.22-2.30 (2H, m), 2.31-2.71 (10H, m), 3.02-3.17 (2H, m), 3.64-3.79 ( 2H, m), 3.88-4.03 (1H, m), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 5.05 (1H, d, J = 7.3 Hz). 118 \ 0~N (Abs) J υύ jl Me L y Y F Reference Example 108 Reference Example 115 (Abs) 0^'ΎΥ F [Abs] \ p-N Γ>4 Me νΎ^\| Y / nh ζζίταηη / ζζηζ / Ε / γίΛΐ 149 Y-NMR (CDCh) δ: 0.13 (2H, d, J = 4.3 Hz), 0.50 (2H, d, J = 7.3 Hz), 0.84-0.95 (1H, m), 1.33 (3H, s), 1.36- 1.54 (3H, m), 1.56-1.87 (7H, m), 1.91-2.21 (4H, m), 2.21-2.30 (2H, m), 2.31-2.46 (3H, m), 2.47-2.60 (1H, m ), 2.95-3.27 (4H, m), 3.64-3.74 (2H, m), 4.10-4.25 (2H, m), 4.56 (1H, d, J = 8.5 Hz), 4.92 (1H, dddd, J = 63.6 , 6.0, 6.0, 3.6 Hz)·________________________________________________________________________________ Example of Example of Reference 109 Reference 8 119 HCI ^-NMR (CDCh) δ: 0.86 (9H, s), 1.18-1.24 (4H, m), 1.30 (s, 3H), 1.35-1.50 (2H, m), 1.55-1.72 (3H, m), 1.72-1.86 (2H, m), 1.86-2.00 (1H, m), 2.00-2.29 (7H, m), 2.46 (1H, dd, J = 10.0, 4.0 Hz), 2.53-2.62 (1H, m), 2.62-2.71 (1H, m), 2.98 (1H, dd, J = 10.0, 6.4 Hz), 3.03-3.27 (3H, m), 3.61-3.78 (2H, m), 4.03-4.12 (1H, m), 4.13-4.29 (1H, m), 4.53 (1H, d, J = 9.2 Hz). ___________________________________________ Example of Example of Reference 109 Reference 115 120 Y-NMR (CDCh) δ: 0.87 (9H, s), 1.33 (3H, s), 1.33-1.54 (3H, m), 1.56-1.85 (6H, m), 1.86-2.31 (7H, m), 2.32 -2.42 (1H, m), 2.43-2.52 (1H, m), 2.54-2.75 (2H, m), 2.893.26 (4H, m), 3.63-3.80 (2H, m), 4.02-4.12 (1H, m), m), 4.13-4.29 (1H, m), 4.54 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.6, 6 4, 6.4, 4.0 Hz). _______________________ Example of Example of Reference 110 Reference 115 122XH-NMR (CDCh) δ: 0.19-0.38 (4H, m), 1.03-1.17 (3H, m), 1.32-1.54 (4H, m), 1.34 (3H, s), 1.56-1.84 (6H, m) , 1.90-2.56 (10H, m), 3.01-3.24 (4H, m), 3.63-3.75 (2H, m), 4.10-4.27 (2H, m), 4.57 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.5, 6.0, 6.0, 3.7 Hz).__________________________________________________________________ Example of Example of Reference 108 Reference 8 150 O~N (Abs) n x—4 i y® 1 y o'' 1 H i 0 FXX F X F P-N Γχ—x y. Me Ν^χΙχχ ), 1.30 (3H, s), 1.34-1.49 (2H, m), 1.54-1.85 (4H, m), 1.94-2.26 (6H, m), 2.26-2.42 (3H, m), 2.46-2.54 (1H , m), 2.70-2.79 (1H, m), 3.02-3.26 (4H, m), 3.613.74 (2H, m), 4.09-4.27 (2H, m), 4.56 (1H, d, J = 9.2 Hz ). 123 Me 9. O-N ® XX Ye N ΤΊ Η .......X F Reference Example 63 Reference Example 115 Me [Abs] 1 < N Me Me^ N τύ F [Abs] \ P—N Γ>· ·4 ií Me NXX Yxh 1H-NMR (CDCh) δ: 0.97-1.09 (6H, m), 1.32 (3H, s), 1.36-1.53 ​​(4H, m), 1.53-1.69 (3H, m), 1.69- 1.87 (4H, m), 1.91-2.04 (2H, m), 2.04-2.20 (3H, m), 2.20-2.28 (5H, m), 2.30-2.42 (2H, m), 2.62-2.77 (2H, m ), 2.82-2.95 (2H, m), 3.03-3.15 (2H, m), 3.63- 3.76 (2H, m), 4.03-4.18 (1H, m), 4.52 (1H, d, J = 7.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 124 Q \ Px [Abs] r>-4 ιϊ Me — L J h N XX F Reference Example 64 Reference Example 115 Q [Abs] X^i H2N,, / L F / XX F [Abs] \ P~N jL Me X NXX ΥχΗ 1H-NMR (CDCh) δ: 1.18-1.36 (5H, m), 1.36-1.54 (3H, m), 1.60-2.05(13H, m), 2.062.20 (2H, m), 2.21-2.30 (2H, m), 2.34-2.43 (1H, m), 2.45-2.66 (7H, m), 2.74-2.83 (1H, m), 3.01-3.16 (2H, m), 3.72-3.82 (1H, m), 3.72- 3.82 (1H, m), 4.09-4.23 (1H, m), 4·57 (1H, d, J = 7·2 Hz), 4·92 (1H, dddd, J =64.0, 6.0, 6.0, 3.6 Hz )· I. I Example of Reference 65 Example of Reference 115 ζζίταηη / ζζηζ / Ε / γίΛΐ 151 1H-NMR (CDCh) δ: 0.97-1.10 (6H, m), 1.21-1.35 (4H, m), 1.35-1.52 (2H, m), 1.621.76 (4H, m), 1.76-1.87 (2H, m), 1.87-2.22 (4H, m), 2.22-2.31 (2H, m), 2.31-2.42 (3H, m), 2.48-2.64 (3H, m), 2.64-2.80 (2H, m), 2.98- 3.09 (1H, m), 3.09-3.24 (3H, m), 3.58-3.70 (1H, m), 3.76-3.88 (1H, m), 4.07-4.24 (1H, m), 4.52 (1H, d, J = 8.0 Hz), 4.91 (1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). Reference Example 110 Reference Example 8 126 Me O~N ÍAbs) n 0-4 ji ) F Me (Ábs) F P-N Γ\_-4 || Me \^NH HCl (6H, m), 1.93-2.55 (9H, m), 3.02-3.24 (4H, m), 3.61-3.74 (2H, m), 4.11-4.27 (2H, m), 4.56 (1H, d, J = 9.2 Hz). Reference Example 66 Reference Example 115 Me —Me V / °~N M ® (S lí Me II Me )—Me σ [Abs] [Abs] P'N Ο·'4· || Me 127 F F ^-NMR (CDCh) δ: 1.00-1.12 (6H, m), 1.21-1.40 (5H, m), 1.40-1.59 (6H, m), 1.591.74 (4H, m), 1.74-1.84 (1H, m), 1.84-2.06 (2H, m), 2.08-2.22 (1H, m), 2.22-2.43 (8H, m), 2.43-2.65 (5H, m), 3.03-3.12 (1H, m) , 3.12-3.22 (1H, m), 3.63-3.73 (1H, m), 3.73-3.83 (1H, m), 4.07-4.23 (1H, m), 4.56 (1H, d, J = 8.0 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 86 Reference Example 115 Me Me f i---) Me xN~Me \ O~N (AbsJ - i>-4 i Ύ1® L > N h y Me N-Me [Abs] N [Abs] \ P-N O4 ΙΪ Me 128 o F— F F JH-NMR (CDCh) δ: 0.86 (6H, d, J = 6.8 Hz), 1.29-1.53 ​​(6H, m), 1.53-1.76 (4H, m), 1.76-2.08 (7H, m), 2.08-2.28 (6H, m), 2.32-2.41 (1H, m), 2.42-2.52 (1H, m), 2.522.63 (1H, m), 2.63-2.73 (1H, m) , 2.76-2.90 (3H, m), 3.02-3.17 (2H, m), 3.70 (2H, tt, J = 14.8, 4.0 Hz), 4.07-4.22 (1H, m), 4.55 (1H, d, J = 8.0 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz) 129 Reference Example 67 Reference Example 115 ζζίταηη / ζζηζ / Ε / γίΛΐ 152 / °N (Abs) Γ>4 ¿Me II Ν^Π Η Ϊ ° f Y / F Me^'N'^'Me [Abs] 'X F (Abs) P~N Γγ γ lí Me Y-NH 1H- NMR (CDCh) δ: 0.90-1.84 (20H, m), 1.84-2.04 (3H, m), 2.05-2.31 (5H, m), 2.322.43 (1H, m), 2.43-2.77 (6H, m) , 2.79-2.95 (1H, m), 3.03-3.19 (2H, m), 3.65-3.81 (2H, m), 4.08-4.24 (1H, m), 4.54 (1H, d, J = 7.9 Hz), 4.93 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 130 Me ¡Abs] __p / T jl Me Γ \ H 0 F F Reference Example 110 Commercial Product Me F Me^^x l 1Me l\^NH HCl ^-NMR (CDCh) δ: 0.16-0.48 (4H, m), 0.98-1.28 (4H, m), (2H, m), 1.50-1.89 (7H, m), 1.95-2.21 (5H, m), 2.22-2.65 (2H, 3.24 (1H, m), 3.25-3.41 ( 2H, m), 3.41-3.67 (3H, m), 4.10-4.2 J = 7.9 Hz), 7.16 (2H, d, J = 7.9 Hz), 7.21 (2H, d, J = 7.9 Hz .25 (3H, s), 1.30-1.50 m), 2.33 (3H,s), 3.117 (2H, m), 4.58 (1H, d, ). 131 Me ,Me Me N F UMe λ P~N (Abs) Γ>·'Ύ ¿ Me II ¡Ί η ϊ Saó F Reference Example 68 Reference Example 115 Me Jx ,Me Me N bMe ¡Abs] H2N,, / L F F [Abs] P~N |[ Me ΝγΥ Y-nh íH-NMR (CDCh) δ: 0.88 (3H, s), 0.92-0.98 (6H, m), 1.22-1.52 (8H, m), 1.60-1.84 (6H, m), 1.89-2.03 (2H, m), 2.04 (3H, s), 2.09-2.31 (4H, m), 2.31-2.41 (1H, m), 2.412.55 (3H, m), 2.70 -2.80 (1H, m), 3.00-3.23 (3H, m), 3.64-3.75 (1H, m), 3.75-3.85 (1H, m), 4.06-4.22 (1H, m), 4.58 (1H, d, J = 7.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 132 Me [Abs] y N 1---' < N Me 11 Me 1 I O SA!h H γ^ F Reference Example 94 Reference Example 115 Me (Ab§) |^^N'^x'Me °yNJ F [Abs] P-N |[ Me \ / NH ζζίταηη / ζζηζ / Ε / γίΛΐ 153 1H-NMR (CDCh) δ: 1.04 (6H, d, J = 6.7 Hz), 1.31 (3H, s), 1.41-2.05 (9H, m), 2.142.27 (3H, m), 2.31-2.59 (5H , m), 2.64-2.77 (1H, m), 2.85-2.96 (1H, m), 2.99-3.10 (2H, m), 3.46-3.74 (6H, m), 4.46-4.53 (1H, m), 4.53 -4.68 (1H, m), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 111 Reference Example 115 133 p P'N A A lí Me A νΆΙ / [Abs] A F -N F F [Abs] P P'N Α···α JÍ Me A nAa\. \^NH 1H-NMR (CDCh) δ: 0.57-0.69 (2H, m), 0.99-1.10 (2H, m), 1.33 (3H, s), 1.35-1.53 ​​(3H, m), 1.58-1.89 (4H , m), 1.91-2.20 (5H, m), 2.20-2.30 (2H, m), 2.32-2.41 (1H, m), 2.41-2.49 (1H, m), 2.51-2.61 (1H, m), 2.75 -2.94 (3H, m), 3.04-3.26 (4H, m), 3.65-3.75 (2H, m), 4.13-4.27 (2H, m), 4.58 (1H, d, J = 9.2 Hz), 4.92 (1H , dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 69 Reference Example 115 134 \ P-N ϊ>··4 Me^ N / le h y 0F^ F Me Me Me^ / N M-y [Abs] 00 A F [Abs] \ θ'-N A'A JÍ Me A nAa. \^NH ^-NMR (CDCh) δ: 0.14-0.34 (4H, m), 0.98-1.10 (3H, m), 1.18-1.37 (6H, m), 1.371.54 (3H, m), 1.54-1.74 (2H, m), 1.74-1.84 (2H, m), 1.84-2.03 (2H, m), 2.03-2.42 (12H, m), 2.46-2.57 (2H, m), 2.62-2.72 (1H, m) , 2.79-2.90 (1H, m), 3.01-3.20 (2H, m), 3.65-3.74 (1H, m), 3.74-3.85 (1H, m), 4.07-4.21 (1H, m), 4.55 (1H, m), d, J = 7.3 Hz), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 112 Reference Example 115 F3C 135 \ P~N a-a Me A [Abs] - A F •N ο'Ά / A F [Abs] V / °~N M A A JÍ Me A νΆΑ\ \ / NH ^-NMR (CDCh ) δ: 0.58-0.72 (2H, m), 0.93-1.02 (2H, m), 1.29-1.54 (4H, m), 1.33 (3H, s), 1.55-1.84 (4H, m), 1.90-2.03 ( 2H, m), 2.03-2.21 (2H, m), 2.21-2.30 (2H, m), 2.30-2.50 (3H, m), 2.55-2.82 (3H, m), 3.00-3.24 (4H, m), 3.65-3.75 (2H, m), 4.084.27 (2H, m), 4.56 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 136 Reference Example 70 Reference Example 115 ζζίταηη / ζζηζ / Ε / γίΛΐ 154 Me^ N \7 Mex N Y~7 [Abs) pY Ύ F [Abs] Ρ'Ν [>'4 i Y nYkY L^.nh \ P-n í>4 X Y N^Y le ® Xj H I 0 F-R / F Y- NMR (CDCh) δ: 0.52-0.66 (2H, m), 0.99-1.09 (2H, m), 1.16-1.36 (3H, m), 1.33 (3H, s), 1.36-1.53 ​​(3H, m), 1.53 -1.84 (5H, m), 1.84-2.03 (2H, m), 2.04-2.20 (2H, m), 2.21-2.31 (2H, m), 2.31-2.47 (5H, m), 2.47-2.60 (2H, m), 2.63-2.92 (4H, m), 3.043.19 (2H, m), 3.68-3.79 (2H, m), 4.08-4.23 (1H, m), 4.49-4.62 (1H, m), 4.92 ( 1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 87 Reference Example 115 137 F\ P~N Ν'^Ψ í----. Me Y 2 -ΝγΝγ\ 0 F F N-Me [Abs] N Η2Ν,,Λ. f—lx F [Abs] P-N r>..»4 iíMe ν'Ύ|Ύ ^-NMR (CDCh) δ: 0.13-0.33 (2H, m), 0.52-0.74 (2H, m), 0.90-1.14 ( 1H, m), 1.231.38 (5H, m), 1.38-1.55 (2H, m), 1.57-1.69 (2H, m), 1.69-1.87 (2H, m), 1.87-2.05 (4H, m), 2.10-2.27 (4H, m), 2.32-2.41 (2H, m), 2.41-2.62 (4H, m), 2.62-2.73 (2H, m), 2.90-3.04 (2H, m), 3.04-3.17 (2H , m), 3.52-3.75 (2H, m), 4.06-4.23 (1H, m), 4.51-4.64 (1H, m), 4.92 (1H, dddd, J =64.0, 6.0, 6.0, 3.6 Hz). Reference Example 87 Reference Example 8 138 P-N Γ>—Ύ II Μθ 1 (D \-Me [Abs] N Y F P-N nYR\ \^NH HCI Y-NMR (CDCh) δ: 0.05-0.24 (2H, m), 0.44-0.63 (2H, m), 0.80-1.00 (1H, m), 1.13 (4H, d, J = 6.0 Hz), 1.17-1.23 (4H, m), 1.24-1.50 (5H, m), 1.54- 1.86 (4H, m), 1.861.99 (2H, m), 2.11-2.24 (4H, m), 2.24-2.45 (4H, m), 2.52-2.73 (2H, m), 2.82-2.96 (2H, m ), 3.00-3.16 (2H, m), 3.58-3.72 (2H, m), 4.06-4.22 (1H, m), 4.55 (1H, d, J = 8.0 Hz). 139 Reference Example 123 Reference Example 8 ζζίταηη / ζζηζ / Ε / γίΛΐ 155 Me Me P~N r>-4 11 Me II H Y ^vrS o > F Me^^Me 0 P-n HCI 1H-NMR (CDCh) δ: 1.01 (6H, d, J = 6.4 Hz), 1.16-1.24 (6H , m), 1.30 (3H, s), 1.541.70 (3H, m), 1.81-1.88 (2H, m), 2.09-2.31 (5H, m), 2.34-2.53 (6H, m), 2.53-2.63 (1H, m), 2.67-2.76 (2H, m), 3.04-3.18 (2H, m), 3.62-3.72 (1H, m), 3.72-3.88 (2H, m), 4.19 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 4.68 (1H, d, J = 6.1 Hz). 140 „ CF3 Me^ ^\ / ó N \7 F''- P~N [Abs] NY^ H Y 0 F Reference Example 71 Reference Example 115 .. CF3 Me^ ¿ N \7 [Abs] <¥ X F [Abs] P-N Γ^4· jl Me L^NH ^-NMR (CDCh) δ: 0.57-0.64 (2H, m), 0.87-0.93 (2H, m), 1.10-1.53 ​​(9H, m), 1.541. 73 (4H, m), 1.74-1.84 (1H, m), 1.84-1.91 (1H, m), 1.91-2.11 (2H, m), 2.11-2.30 (7H, m), 2.31-2.40 (1H, m ), 2.45-2.55 (2H, m), 2.55-2.69 (3H, m), 2.80-2.87 (1H, m), 3.02-3.19 (2H, m), 3.65-3.83 (2H, m), 4.06-4.21 (1H, m), 4.53 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 4.83-5.00 (1H, m). 141 Me^ - \7 7 P~N [Abs] YY Γ>4 JL Me <—> 1 Η I ¥ II 0 F ¥ / F Reference Example 72 Reference Example 115 Me^ N 577 ® Λ uÓ F [Abs ] O-N [Ρ'Ύ jí Me N YNH ^-NMR (CDCh) δ: 0.00-0.06 (2H, m), 0.42-0.49 (2H, m), 0.72-0.83 (1H, m), 1.191.42 (3H , m), 1.31 (3H, s), 1.42-1.82 (13H, m), 1.89-2.02 (1H, m), 2.05-2.16 (1H, m), 2.16-2.28 (7H, m), 2.30-2.40 (1H, m), 2.51-2.60 (1H, m), 2.72-2.85 (1H, m), 2.99-3.09 (1H, m), 3.09-3.18 (1H, m), 3.20-3.26 (1H, m) , 3.36-3.41 (1H, m), 3.653.74 (1H, m), 3.77-3.85 (1H, m), 3.97-4.10 (1H, m), 4.67 (1H, d, J = 7.3 Hz), 4.90 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 142 Reference Example 73 Reference Example 115 ζζίταηη / ζζηζ / Ε / γίΛΐ 156 Me, - \7 P~N [Abs] ¥¥ r>-< ι^θ — o N γΊ h Y F Me^ N Y7 [Abs) Ύ F [Abs] \ P'N lí Me \^NH ^-NMR (CDCh) δ: 0.01-0.22 (2H, m), 0 1.52 (6H, m), 1.52-1.87 (13H, m), 1.89¿ (4H, m), 3.33-3.50 (1H, m), 3.60- 3.72 m), 4.65 (1H, d, J = 7.9 Hz), 4.91 (1H, c .39-0.64 (2H, m), 0.77-0.97 (1H, m), 1.13'.03 (1H, m), 2.03-2.72 (10H, m), 3.01-3.32 1H, m), 3.74-3.87 (1H, m), 3.95-4.12 (1H, ddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 143 F -pMe \ 0~N (Abs) n Me r ώό F Reference Example 113 Reference Example 115 F __ —^Me [Abs] Μθ TÓ F [Abs] P-N |í Me \ / NH ^-NMR (CDCh ) δ: 1.17-1.86 (18H, m), 2.42 (1H, m), 2.44-3.03 (3H, m), 3.04-1 (2H, m), 4.60 (1H, d, J = 9.2 Hz), 4.91 ( L.88-2.20 (5H, m), 2.20-2.30 (2H, m), 2.303.24 (4H, m), 3.61-3.75 (2H, m), 4.09-4.28 1H, dddd, J = 63.6, 6.0, 6.0, 3.6Hz). 144 Me 1N'_\ \ O~N (AbS / ^X V Γ>·'4 JL Me \ J N γΊ h v ......¡Y F Reference Example 74 Reference Example 115 Mex N—\ [Abs] / \ JP , m), 1.58-1.87 (5H, m), 1.89-2.01 (2H, m), 2.06-2.16 (1H, m), 2.16-2.30 (8H, m), 2.30-2.40 (1H, m), 2.46 -2.79 (6H, m), 3.03-3.19 (2H, m), 3.65-3.78 (2H, m), 4.02-4.16 (1H, m), 4.61 (1H, d, J = 7.3 Hz), 4.90 (1H , dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 145 Mex N—\ \ p-.N ¡Abs) / ^\ > t>4 1 \ J ΎΊ η s YY 0 F F Reference Example 75 Example of Reference 115 Mex N—\ ® V Ύ F [Abs] A. O-N [>i4 ¿Me \ / NH 1H-NMR (CDCh) δ: 0.05-0.19 (2H, m), 0.47-0.60 (2H, m), 0.83-0.98 (1H, m), 1.211.53 (10H, m), 1.53-2.03 (7H, m), 2.07-2.19 (1H, m), 2.19-2.66 (13H, m), 2.68-2.83 (2H , m), 3.03-3.15 (2H, m), 3.62-3.80 (2H, m), 4.01-4.18 (1H, m), 4.59 (1H, d, J = ζζίταηη / ζζηζ / Ε / γίΛΐ 157 7.9 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 120 Reference Example 115 146 \ P'N Γ>'4 V Me^Me [Abs] le II Me F Me^'Me [Abs] Me P ίό F [Abs] P'N r>·^ jL Me L^NH , 1.89-2.13 (3H, m), 2.17-2.28 (2H, m), 2.29-2.58 (7H, m), 2.582.69 (1H, m), 2.75-2.99 (7H, m), 2.99-3.09 ( 1H, m), 3.34-3.46 (2H, m), 4.35-4.49 (1H, m), 4.89 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 121 Reference Example 8 147 4 A2 Me^Me [Abs] e L J Η V 0 p Me^ Me Me^^Me 0 N h2n% Me / S Me p-N \^NH HCl ^-MRI (CD3OD) δ : 0.86 (3H, s), 0.90 (3H, s), 1.01 (3H, d, J = 6.8 Hz), 1.02 (3H, d, J = 6.8 Hz), 1.10-1.33 (6H, m), 1.31 ( 3H, s), 1.35-1.49 (2H, m), 1.55-1.72 (3H, m), 1.84-1.93 (1H, m), 2.13-2.28 (3H, m), 2.30-2.59 (8H, m), 2.66-2.75 (2H, m), 3.093.18 (2H, m), 3.28-3.35 (1H, m), 3.53 (1H, d, J = 11.6 Hz), 3.67-3.79 (2H, m). Reference Example 76 Reference Example 115 148 \ P'N r>4 i Me ,Me __ Me N [Abs] 1 Λ H i F Me Á ,Me Me N [Abs] NZ τώ F [Abs] P'N ^ >4 iMe \^NH 1H-NMR (CDCh) δ: 1.15-1.30 (6H, m), 1.33 (3H, s), 1.37-1.57 (3H, m), 1.57-1.85 (6H, m), 1.85- 2.03 (3H, m), 2.11-2.30 (3H, m), 2.30-2.61 (4H, m), 3.10-3.22 (2H, m), 3.22-3.42 (1H, m), 3.47-3.68 (4H, m ), 3.68-3.77 (1H, m), 3.77-3.84 (1H, m), 4.04-4.25 (1H, m) 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). 149 Reference Example 77 Reference Example 115 ζζίταηη / ζζηζ / Ε / γίΛΐ 158 ^-NMR (CDCh) δ: 0.02-0.19 (2H, m), 0.44-0.59 (2H, m), 0.75-0.90 (1H, m), 1.121.28 (1H, m), 1.32 (3H, s) , 1.40-1.55 (2H, m), 1.55-1.70 (3H, m), 1.70-1.82 (2H, m), 1.84-2.04 (4H, m), 2.08-2.29 (8H, m), 2.98-3.20 ( 4H, m), 3.46-3.56 (2H, m), 3.663.76 (2H, m), 4.08-4.23 (1H, m), 4.59-4.73 (1H, m) 4.91 (1H, dddd, J = 64.0, 6.0, 6.0, 4.0Hz). 150 Example of Example of Reference 114 Reference 115 JH-NMR (CDCh) δ: 1.32-1.55 (6H, m), 1.35 (3H, s), 1.58-1.86 (6H, m), 1.91-2.11 (3H, m), 2.11-2.21 (1H, m) , 2.22-2.31 (2H, m), 2.32-3.05 (6H, m), 3.06-3.24 (3H, m), 3.64-3.76 (2H, m), 4.08-4.28 (2H, m), 4.30-4.35 (2H, m), 4.44-4.51 (2H, m), 4.60 (1H, d, J = 8.5 Hz), 4.93 (1H, dddd J = 63.6, 6.0, 6.0, 3.6 Hz)._________ Example of Example Reference 122 Reference 115 151 ^-NMR (CDCh) δ: 1.07 (6H, d, J = 5.5 Hz), 1.14-1.25 (6H, m), 1.31 (3H, s), 1.311.43 (2H, m), 1.43-1.79 (4H , m), 1.83-1.93 (1H, m), 2.13-2.26 (4H, m), 2.26-2.82 (12H, m), 3.01-3.16 (2H, m), 3.29-3.42 (1H, m), 3.59 -3.76 (2H, m), 5.80-6.06 (1H, brs) AND. Example of Reference 78 Example of Reference 115 152 159 1H-NMR (CDCh) δ: 0.90-1.12 (6H, m), 1.22-1.53 ​​(7H, m), 1.54-2.05 (7H, m), 2.082.20 (1H, m), 2.20-2.29 (2H, m), 2.30-2.40 (1H, m), 2.48-3.04 (10H, m), 3.04-3.17 (2H, m), 3.66-3.80 (2H, m), 4.02-4.17 (1H, m), 4.72 ( 1H, s), 4.90 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 125 Reference Example 115 of Me^^Me Me^Me 153 0 \ O~N (Abs) Me f F o 0 [Abs] 0^0 X F \ P-N Γ>··4 V [Abs] le \^ NH ^-NMR (CDCh) δ: 0.89-1.17 (6H, m), 1.33 (3H, s), 1.42-1.69 (6H, m), 1.69-1.89 (2H, m), 1.91-2.04 (1H, m ), 2.04-2.14 (1H, m), 2.14-2.82 (8H, m), 2.99-3.13 (2H, m), 3.28-3.77 (6H, m), 4.20-4.35 (1H, m), 4.68-4.80 (1H, m), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 4.94 (1H, d, J = 8.5 Hz). Reference Example 88 Reference Example 115 of Me O—n Íabs) λ N 1' r N Me Me 1 J Me [Abs] [Abs] 154 '~Οή0 F F 'r>-4 V N'X / le \^NH ^-NMR (CDCh) δ: 1.03-1.21 (6H, m), 1.35 (3H, s), 1.41-1.90 (8H, m), 1.91-2.61 (11H, m), 2.61-2.71 (1H, m) , 2.71-3.04 (4H, m), 3.05-3.21 (2H, m), 3.64-3.79 (2H, m), 4.11-4.27 (1H, m), 4.63 (1H, d, J = 9.8 Hz), 4.93 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Example 126 Reference Example 115 of 155 Me \ O-N Θ Χ-,ζ Me 0 1 j N γΊ H°=t ...... F Me (Abs) θ Ή F \ P-n ϊ>4 v N'X [Abs] / le ^^.NH !H-NMR (CDCh) δ: 0.93-1.14 (6H, m), 1.33 (3H, s), 1.43-1.54 (1H, m), 1.54-1.81 (5H, m ), 1.82-2.32 (11H, m), 2.32-2.45 (2H, m), 2.71-2.85 (1H, m), 2.96-3.24 (6H, m), 3.66-3.82 (2H, m), 4.67-4.80 (1H, m), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 4.93 (1H, d, J = 9.2 Hz). 156 Reference Example 124 Reference Example 115 ζζίταηη / ζζηζ / Ε / γίΛΐ 160 Ú-NMR (CDCh) δ: 0.98-1.38 (10H, m), 1.40-1.78 (10H, m), 1.89-2.11 (3H, m), 2.162.32 (2H, m), 2.32-2.42 (1H, m), 2.43-3.44 (9H, m), 3.54-3.77 (2H, m), 4.89-5.26 (2H, m), 4.93 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). ζζίταηη / ζζηζ / Ε / γίΛΐ The chemical names from Example 82 to Example 155 are listed below. Example 82: N-{(lS,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-¡l]cyclohexyl}-4-{5[(lR, 2R)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-l-carboxamide Example 83: N-[(1R,65)-2,2-difluoro-6-{[l-(propan-2-yl)p¡períd¡n-4-yl]oxy}cyclohex¡l ]-4{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡perid¡na-l- carboxamide Example 84: 4-(5-cyclopropyl-l,2,4-oxadiazol-3-l)-N-[(lR,6S)-2,2-difluoro-6-{[l(propan-2 -¡l)p¡pend¡n-4-yl]oxy}cyclohex¡l]-4-met¡lp¡perídina-l-carboxamide Example 85: 4-(5-cyclopropyl-l,2,4-oxadilazole-3-yl)-N-{(lR,6S)-2,2-difluoro-6-[5(propan-2 -¡l)-l,2,4-oxadiazol-3-¡l]cyclohex¡l}-4-met¡lp¡perídina-l-carboxamide Example 86: N-{(lR,6S)-2,2-difluoro-6-[5-(propan-2-yl)-l,2,4-oxadiazol-3¡l]cyclohex¡l}- 4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-methylpiper¡dina-l-carboxam gives Example 87: N-[(lR,6S)-2,2-difluoro-6-{[3-(propan-2-¡l)-l,2,4-t¡ad¡azol-5¡l]ox ¡}cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡ lp¡perína-lcarboxamide Example 88: N-[(lR,6S)-2,2-difluoro-6-{[l-(propan-2-¡l)-lH-pyrazol-4yl]ox¡}cyclohexyl]-4-{5- [(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 89: N-[(lR,6S)-2,2-difluoro-6-{[l-(propan-2-¡l)azetidin-3-¡l]ox¡}c¡clohex¡ l]-4{5-[(lS,2S)-2-fluoroc¡clopropyl]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡perídine-l-carboxam¡ gives Example 90: 4-(5-cyclopropyl-l,2,4-oxadíazol-3-íl)-N-[(lR,6S)-2,2-difluoro-6-{[l(propan -2-¡l)-lH-pyrazol-4-¡l]ox¡}c¡clohex¡l]-4-met¡lp¡perína-l-carboxamide Example 91: N-[(lR,6S)-6-{benzyl[(3S)-l-(propan-2-¡l)pyrrolidin-3-yl]amino}-2,2difluoroc¡clohexyl] -4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 92: N-[(1R,65)-2,2-difluoro-6-{[2-(propan-2-¡l)pyrimid¡n-4-¡l]ox¡} cyclohex¡l]-4{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxadiazol-3-¡l}-4-methylpiperidine-l-carboxamide Example 93: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-¡l)-lH-l,2,3-triazol-l161 ¡l]cyclohexyl} -4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxadiazol-3-¡l}-4-methylpiperidine-l-carboxamide Example 94: N-{( lR,6S)-2,2-difluoro-6-[4-(2-methylpropyl)-lH-l,2,3-triazol-l¡l]cyclohex¡l}-4-{5- [(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxad¡azol-3-yl}-4-methylpiperdine-l-carboxamide Example 95: N-[(lR,6S)-2,2-difluoro-6-{met¡l[(3S)-l-(propan-2-¡l)pyrrolídin-3¡l]am ¡no}cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met ¡lp¡perídina-lcarboxamide Example 96: N-[(lR,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-yl)amino]pyrrolidin-l¡l}c¡clohex¡l] -4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡perid¡na-l- carboxamide Example 97: 4-(5-cyclobutíl-1,2,4-oxadiazol-3-íl)-N-{(lR,6S)-2,2-difluoro-6-[4(propan-2-íl )piperazin-l-yl]cyclohexyl}-4-methylpiperdina-l-carboxamide Example 98: N-[(lR,6S)-2,2-difluoro-6-{[(lR,3S,5S)-8-(propan-2-yl)-8azab¡cyclo[3.2.1] octan-3-¡l]oxy¡}cyclohexyl]-4-{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxadiazol-3-¡l}-4methylpiperidine- l-carboxamide Example 99: 4-(5-cyclopropyl-1,2,4-oxadiazol-3-¡l)-N-[(lR,6S)-2,2-difluoro-6-{(3S)-3[ methyl(propan-2-yl)amino]pyrrolidin-l-yl}cyclohexyl]-4-methylpiperidine-l-carboxamide Example 100: N-[(lR,6S)-2,2-difluoro-6-{[(lR,5S,8R)-3-(propan-2-yl)-3azab¡cyclo[3.2.1] octan-8-¡l]oxy¡}cyclohexyl]-4-{5-[(lS,2S)-2-fluoroc¡clopropyl]-l,2,4-oxadiazol-3-¡l}-4methylpiperidine- l-carboxamide Example 101: N-[(lR,6S)-2,2-difluoro-6-{4-[(propan-2-yl)oxy]píperídin-l-yl}cyclohexyl]4 -{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-íl}-4-methyllp¡perína-l-carboxamide Example 102: 4-(5-cyclobutyl-l,2,4-oxadiazol-3-yl)-N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l(propan- 2-¡l)pyrrol¡din-3-yl]ox¡}c¡clohex¡l]-4-met¡lp¡peridína-l-carboxamide Example 103: N-[(lR ,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-yl)pyrrol¡din-3¡l]ox¡}cyclohex¡l]-4 -ethyl-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}piper¡dina-lcarboxamide Example 104: N-[(lR,6S)-2,2-difluoro-6-{[(lR,5S,8S)-3-(propan-2-yl)-3azabicyclo[3.2. l]octan-8-yl]ox¡}cyclohexyl]-4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-¡l}-4methylpiperidine-l -carboxamide Example 105: N-[(lR,6S)-2,2-difluoro-6-{[(lR,3R,5S)-8-(propan-2-yl)-8azabicyclo[3.2. l]octan-3-¡l]ox¡}cyclohex¡l]-4-{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxad¡azol-3- ¡l}-4methylpiperidine-l-carboxamide Example 106: N-[(lR,6S)-2,2-difluoro-6-{[(lR,5S,6S)-3-(propan-2-yl)-3azab¡cyclo[3.1.0] hexan-6-¡l]ox¡}cyclohexyl]-4-{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxadiazol-3-¡l}-4methylpiperidine- l-carboxamide Example 107: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(2-met¡lprop¡l)pyrro¡din-3ζζίταηη / ζζηζ / Ε / γίΛΐ 162 ¡l]ox¡}cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxadiazol-3-yl}-4- methylpiperdina-lcarboxamide Example 108: N-[(lR,6S)-2,2-difluoro-6-{[(3R,4R)-4-methoxy-l-(propan-2-¡l)pyrroli¡d¡ n3-¡l]oxy}cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l} -4-methylpiperidine-lcarboxamide Example 109: N-[(lR,6S)-2,2-difluoro-6-{[4-met¡l-l-(propan-2-yl)piperidin-4¡l]ox¡}c¡clohex¡l] -4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxadiazol-3-¡l}-4-methylpiperid¡na-lcarboxamide Example 110: N-{(lR,6S)-2,2-difluoro-6-[(2S)-2-methyl-4-(propan-2-yl)piperazin-l¡l]cyclohex¡l} -4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol·3-¡l}-4-met¡lp¡perídine-l- carboxamide Example 111: N-{(lR,6S)-2,2-difluoro-6-[(2R)-2-methyl-4-(propan-2-¡l)p¡peraz¡n-l¡l]cyclohex ¡l}-4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methyllp¡perídine-l-carboxamide Example 112: N-[(lR,6S)-2,2-difluoro-6-{(3R)-3-[methyl(propan-2-yl)amino]pyrrolidin-l¡l}c¡clohex¡l] -4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-methylpiper¡na-l- carboxamide Example 113: N-[(lR,6S)-2,2-difluoro-6-{metll[(3R)-l-(propan-2-yl)pyrrolidin-3¡l]am¡no}cyclohexyl] -4-{5-[(lS,2S)-2-fluorocyclopropíl]-1,2,4-oxadiazol-3-íl}-4-methylpiperidine-lcarboxamide Example 114: N-[(lR,6S)-2,2-difluoro-6-{4-[methyl(propan-2-yl)amino]píperid¡n-l¡l}c¡clohexyl]-4 -{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxadiazol-3-¡l}-4-methylpiperid¡na-l-carboxamide Example 115: N-[(lR,6S)-6-{(3S)-3-[c¡cloprop¡l(met¡l)amino]pyrrol¡n-l-¡l}-2,2d¡ fluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocycloprop¡l]-1,2,4-oxadiazol-3-¡l}-4-methylpiperidine-lcarboxamide Example 116: 4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-yl)-N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l( 2-methylprop¡l)pyrrolídin-3-¡l]oxy}cyclohexyl]-4-met¡lp¡perídine-l-carboxamide Example 117: N-[(lR,6R)-2,2-difluoro-6-{[4-(propan-2-yl)piperaz¡n-lyl]met¡I}cyclohexyl]-4-{5-[ (lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 118: N-[(lR,6S)-6-{[(3S)-l-(cycloprop¡lmethyl)pyrrolidin-3-yl]oxy}-2,2d¡fluoroc¡ clohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡per¡ dna-lcarboxamide Example 119: 4-(5-cycloprop¡l-l,2,4-oxadiazol-3-¡l)-N-[(lR,6S)-6-{[(3S)-l-(2,2dimet¡ lprop¡l)pyrrol¡n-3-¡l]ox¡}-2,2-d¡fluoroc¡clohex¡l]-4-met¡lpiper¡dina-l-carboxamide Example 120: N-[(lR,6S)-6-{[(3S)-l-(2,2-dimethylprop¡l)pyrrol¡din-3-¡l]ox¡}- 2,2difluoroc¡clohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡clopropyl]-1,2,4-oxad¡azol-3-yl}-4-methyllp¡per d¡na-lcarboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ 163 Example 121: N-[(lRz6S)-2,2-difluoro-6-({(3S)-l-[(l-methylcycloprop¡l)methyl]pyrrolidin3-¡l}oxy )cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-1,2,4-oxad¡azol-3-¡l}-4-met¡lp perídina-lcarboxamide Example 122: N-[(lRz6S)-6-{[(3S)-l-(cycloprop¡lmet¡l)pyrrol¡din-3-¡l]ox¡}-2.2d¡ fluoroc¡clohex¡l]-4-(5-c¡clopropyl-l,2,4-oxad¡azol-3-¡l)-4-methyl¡lp¡perína-l-carboxamide Example 123: N-[(lR,6S)-2,2-difluoro-6-{met¡l[l-(propan-2-¡l)piper¡d¡n-4¡l]am¡no}cyclohex ¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l / 2,4-oxad¡azol-3-¡l}-4-methylpi¡perdina -lcarboxamide Example 124: N-{(lR,6S)-2,2-difluoro-6-[4-(pyrrolídin-l-yl)piperidín-l-yl]cyclohexyl}-4{5-[ (lS,2S)-2-fluoroc¡cloprop¡l]-l,2z4-oxad¡azol-3-¡l}-4-methylpi¡perdine-l-carboxamide Example 125: N-{(lRz6S)-2z2-d¡fluoro-6-[5-(propan-2-¡l)hexah¡drop¡nOlo[3,4-c]p¡rrol2(lH)-¡l ]cyclohex¡l}-4-{5-[(lSz2S)-2-fluoroc¡cloprop¡l]-lz2z4-oxad¡azol-3-¡l}-4-methylpiper¡dina-lcarboxamide Example 126: 4-(5-cycloprop¡l-lz2z4-oxadiazol-3-¡l)-N-[(lR,6S)-2z2-difluoro-6-({(3S)-l[(l- methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-methylpiperidina-l-carboxamide Example 127: N-{(lR,6S)-2z2-difluoro-6-[2-(propan-2-¡l)-2z8-diazaspiro[4.5]decan-8¡l]cyclohex¡l} -4-{5-[(lSz2S)-2-fluorocycloprop¡l]-lz2z4-oxad¡azol-3-¡l}-4-met¡lp¡perídine-l-carboxamide Example 128: N-[(lRz6S)-2z2-difluoro-6-{(3S)-3-[methyl(2-methylpropyl)amino]pyrrolidinyl-yl}cyclohexyl] -4-{5-[(lSz2S)-2-fluorocyclopropyl]-lz2z4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 129: N-{(lRz6S)-6-[4-(diethylamino)piperidin-l-yl]-2,2-difluorocyclohexíl}-4-{5[(lSz2S)-2-fluorocycloprop ¡l]-lz2z4-oxad¡azol-3-¡l}-4-met¡lp¡per¡dina-l-carboxamide Example 130: N-[(lR,6S)-2,2-difluoro-6-({(3S)-l-[(l-methylcyclopropyl)methyl]pyrrolidin3-l}oxy)cyclohex¡l]-4-methyl¡l-4-(4-methylphen¡l)p¡perina-l-carboxamide Example 131: N-[(lRz6S)-2z2-difluoro-6-{4-methyl-4-[methyl(propan-2-yl)amino]p¡per¡dinl-yl}c¡ clohexyl]-4-{5-[(lSz2S)-2-fluorocyclopropyl]-lz2z4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 132: N-{(lRz6S)-2z2-difluoro-6-[4-(propan-2-yl)p¡peraz¡na-lcarbonyl]cyclohex¡l}-4-{5-[(lSz2S)-2 -fluoroc¡cloprop¡l]-lz2z4-oxad¡azol-3-¡l}-4-met¡lp¡per¡na-lcarboxamide Example 133: N-[(lRz6S)-2z2-difluoro-6-«(3S)-l-[(l-fluorocyclopropyl)methyl]pyrrolidin3-¡l}ox¡)cyclohex¡l]-4-{5 -[(lSz2S)-2-fluoroc¡cloprop¡l]-lz2z4-oxad¡azol-3-¡l}-4-methylp¡perína-lcarboxamide Example 134: N¿(lRz6S)-2z2-difluoro-6-(4-{methyl[(lmet¡lc¡cloprop¡l)met¡l]amino}p¡pend¡n-l-¡l)cyclohex ¡l]-4-{5-[(lSz2S)-2-fluoroc¡cloprop¡l]-lz2z4zzfronn / zznz / E / YiAi 164 oxadiazol-3-yl}-4-methylpiperidine-l-carboxamide Example 135: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-{[l(trifluoromethyl)c¡cloprop¡l]methyl}pyrrolidine-3- il]ox¡}cyclohex¡l]-4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4oxad¡azol-3-yl}-4-methylp¡períd¡ na-l-carboxamide Example 136: N-[(lR,6S)-2,2-difluoro-6-(4-{[(lfluorocycloprop¡l)methyl](methyl)amino}p¡perídin-l -yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4oxadiazol-3-íl}-4-methylpiperidine-l-carboxamide Example 137: N-[(lR,6S)-6-{(3S)-3-[(cycloprop¡lmethyl)(methyl)amino]pyrrolidin-l-¡l}-2, 2d¡fluorocyclohex¡l]-4-{5-[(1S,2S)-2-fluorocycloprop¡l]-1,2,4-oxadiazol-3-¡l}-4-methylpiperidine-lcarboxamide Example 138: N-[(lR,6S)-6-{(3S)-3-[(cyclopropylmethyl)(methyl)amino]pyrrolidin-l-yl}-2,2d fluoroclohexyl]-4-(5-cyclopropyl-l,2,4-oxadíazol-3-l)-4-methylpiperidine-l-carboxamide Example 139: / 'ac-4-(5-cycloprop¡l-l,2,4-oxad¡azol-3-¡l)-N-{(lR / 2R,6S)-2-fluoro-6-[ 4(propan-2-¡l)p¡perazin-l-¡l]c¡clohex¡l}-4-met¡lp¡perídina-l-carboxam¡da Example 140: N-{(lR,6S)-2,2-difluoro-6-[4-(methyl{[l(trifluoromethyl)c¡clopropyl]methyl}amino)p¡per¡din-l-yl ]cyclohex¡l}-4-{5-[(lS,2S)-2-fluoroc¡clopropyl]l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡perídina- l-carboxamide Example 141: N-[(lR,6S)-6-{(lR,3R,5S)-3-[(cyclopropylmethyl)(methyl)amino]-8azab¡acid[3.2.1]octan-8 -yl}-2,2-difluorocyclohexíl]-4-{5-[(1S,2S)-2-fluorocyclopropíl]-1,2,4-oxadiazol3-yl}-4-methylplper dna-l-carboxamide Example 142: N-[(lR,6S)-6-{(lR,3S,5S)-3-[(cyclopropylmethyl)(methyl)amino]-8azabicyclo[3.2.1]octan-8-yl}- 2,2-difluoroc¡clohexyl]-4-{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxad¡azol3-¡l}-4-methylpiperidine-l-carboxam¡ gives Example 143: N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(2-fluoro-2-met¡lprop¡l)pyrrolídin-3yl]ox ¡}cyclohexyl]-4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 144: N-[(lR,6S)-6-{(4S)-4-[(cycloprop¡lmethyl)(methyl)amino]azepan-l-yl}-2,2d¡fluoroc¡clohex¡l ]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-yl}-4-methylpiper¡dina-lcarboxamide Example 145: N-[(lR,6S)-6-{(4R)-4-[(cyclopropylmethyl)(methyl)amino]azepan-l-yl}-2,2difluorocíclohexyl]-4-{5-[ (lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 146: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-l-¡l]cyclohex¡l}-4-{5[( lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-N,4-dimet¡lp¡perína-l-carboxam¡ gives Example 147: 4-(5-cyclopropyl-l,2,4-oxadíazol-3-íl)-N-{(lSz6S)-2,2-dimethyl-6-[4 zzfronn / zznz / E / YiAi 165 (propan-2-yl)piperazin-l-¡l]cyclohexyl}-4-methylpiperidine-l-carboxamide Example 148: N-[(lR,6S)-2,2-difluoro-6-{3-[methyl(propan-2-yl)amino]azetidin-l¡l}cyclohex¡l]-4 -{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadíazol-3-yl}-4-methylperídine-l-carboxamide Example 149: N-[(lR,6S)-6-{3-[(cyclopropylmethyl)(methyl)amino]azetidin-l-yl}-2,2d¡fluoroc¡clohex¡l]- 4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-methylp¡per¡na-lcarboxamide Example 150: N-[(lR,6S)-2,2-difluoro-6-({(3S)-l-[(3-met¡loxetan-3-¡l)met¡l]p¡rrOlid¡n3 -¡l}ox¡)cyclohex¡l]-4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l} -4-methyl!per!dyna-lcarboxamide Example 151: Λ^c-4-(5-c¡cloprop¡l-l,2,4-oxad¡azol-3-¡l)-4-methyl¡l·N-{(lS,2S)-2-[ 4(propan-2-¡l)p¡peraz¡n-l-¡l]c¡cloheptyl}piper¡na-l-carboxamide Example 152: N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)-l,4-diazepan-l-yl]cyclohexyl}4-{5-[( lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡perína-l-carboxamide Example 153: (1S,2R)-3,3-difluoro-2-[(4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4oxad¡azol-3-yl}-4 -methylpiperidine-l-carbonyl)amino]cyclohexyl 4-(propan-2-yl)piperazine-l-carboxylate Example 154: N-[(lS,6S)-2,2-difluoro-6-{[l-(propan-2-yl)p¡períd¡n-4yl]sulfanyl}cyclohexyl]-4- {5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}-4-methylpiperidine-lcarboxamide Example 155: N-{(lS,6S)-2,2-difluoro-6-[l-(propan-2-¡l)piper¡dina-4sulfon¡l]cyclohex¡l}-4- {5-[(lS,2S)-2-fluorocíclopropíl]-1,2,4-oxadíazol-3-íl}-4-methylpipendina-lcarboxamide. The compound of Reference Example 124 above which is a diastereomixture and its intermediates to prepare the compound can be obtained as a single enantiomer by optical resolution with chiral column chromatography or by crystallization with an acid having a chiral center. Furthermore, the compound of Reference Example 124 can also be prepared as a single enantiomer using optically active epoxide as a starting material. Therefore, when Reference Example 124 as a Starting Material A is further determined through separation or asymmetric synthesis, the diastereomixture of Example 156 can be prepared as each diastereomer. Furthermore, the compound of Example 156 which is a diastereomixture can be obtained as a single enantiomer by optical resolution with chiral column chromatography or by crystallization with an acid having a chiral center. Therefore, the two diastereomers of Example 156 can be separated as each diastereomer. The compound of Example 156 is a diastereomixture comprising two different diastereomers. These diastereomers can be separated through their process or by resolution ζζίταηη / ζζηζ / Ε / γίΛΐ 166 optics with chiral column chromatography. It means that the two different diastereomers were prepared substantially. No. Chemical structure of diastereomer Chemical name 156-A Me-^Me (Abs) 1 4 O'N |^N> «y ^V'Ai 0 F-v 4-<5-[(lS,2S)-2-fluorocyclopropyl ]-l,2,4oxadiazol-3-íí}-N-{(lR,2S,6S)-2-fluoro-6-[4(propan-2-yl)piperazin-l-yl]cyclohexyl}-4methylpiperidine -l-carboxamide 156-B / —Me^ ^Me (Abs) γ F<. °~N Λ Γ> ·ν li Me II κ N γΊ Η V o 4-<5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4oxadiazol-3-¡l}-N-{( 15,2R,6R)-2-fluoro-6-[4-(propan-2-yl)p¡perazin-l-¡l]cyclohexyl}-4methylpiperidine-l-carboxamide EXAMPLES 157 - 160 The compounds of Examples 157-160 shown in the table below were prepared according to the process in Example 17 using the compound of Reference Example 80 and each appropriate commercial aldehyde or ketone compound. 157 158 Example Spectral data____________________________________ ^-NMR (CDCh) δ: 0.84 (6H, d, J = 6.0 Hz), 1.181.35 (4H, m), 1.35-1.54 (3H, m), 1.60-1.84(8H, m), 1.83 -2.04 (2H, m), 2.04-2.31 (11Η, m), 2.312.41 (1H, m), 2.45-2.56 (1H, m), 2.61-2.71 (1H, m), 2.77-2.87 (1H, m), 3.01-3.20 (2H, m), 3.653.75 (1H, m), 3.75-3.86 (1H, m), 4.06-4.22 (1H, m), 4.55 (1H, d, J = 8.0 Hz) , 4.91 (1H, ddd, J =63.6, 6.0, 6.0, 3.6 Hz). ^-NMR (CDCh) δ: 0.06-0.13 (2H, m), 0.47-0.55 (2H, m), 0.80-0.91 (1H, m), 1.19-1.36 (6H, m), 1.36-1.53 ​​(4H, m), 1.53-1.84 (3H, m), 1.84-2.03 (2H, m), 2.04-2.21 (2H, m), 2.21-2.45 (10H, m), 2.46-2.58 (2H, m), 2.64- 2.71 (1H, m), 2.81-2.89 (1H, m), 3.04-3.19 (2H, m), 3.67-3.79 (2H, m), 4.07-4.22 (1H, m), 4.55 (1H, d, J = 7.9 Hz), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). ζζίταηη / ζζηζ / Ε / γίΛΐ 167 159 160 ^-NMR (CDCh) δ: 1.15-1.35 (5H, m), 1.35-1.53 ​​(3H, m), 1.53-1.74 (4H, m), 1.74-2.21 (14H, m), 2.21-2.30 (2H, m), 2.30-2.43 (2H, m), 2.44-2.57 (2H, m), 2.61-2.72 (1H, m), 2.74-2.88 (1H, m), 3.00-3.20 (3H, m), 3.65- 3.82 (2H, m), 4.05-4.21 (1H, m), 4.54 (1H, d, J = 8.0 Hz), 4.91 (1H, dddd, J =64.0, 6.0, 6.0, 3.6 Hz). ^-NMR (CDCh) δ: 1.08-1.83 (16H, m), 1.842.03 (3H, m), 2.07-2.43 (9H, m), 2.45-2.76 (5H, m), 2.86-2.98 (1H, m), 3.06-3.20 (2H, m), 3.623.77 (2H, m), 4.08-4.23 (1H, m), 4.53 (1H, d, J = 7.9 Hz), 4.93 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6Hz). The chemical names from Example 157 to Example 160 are listed below. Example 157: N-[(lR,6S)-2,2-difluoro-6-{4-[methyl(2-methylprop¡l)amino]piper¡din-l¡l}cyclohex¡l] -4-{5-[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol·3-¡l}-4-methylp¡per¡na- l-carboxamide Example 158: N-[(lR,6S)-6-{4-[(cycloprop¡lmethyl)(methyl)amino]p¡perídin-l-¡l}-2,2difluoroc¡clohexyl] -4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-yl}—4-methylpiperidine-lcarboxamide Example 159: N-[(lR,6S)-6-{4-[cyclobut¡l(met¡l)amino]p¡perídin-l-¡l}-2,2d¡fluoroc¡clohex¡ l]-4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadíazol-3-íl}-4-methylperídine-l10 carboxamide Example 160: N-[(lR,6S)-6-{4-[eth¡l(met¡l)amino]p¡perid¡n-l-¡l}-2,2-d¡fluoroc¡clohex¡ l]4-{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡perídine-l-carboxam gives EXAMPLE 161 N-[(lR,6S)-2,2-Difluoro-6-{[(3S)-l-(propan-2-¡l)pinOl¡d¡n-3-¡l]amino}c¡ clohex¡l]-4-{5[(lS,2S)-2-fluoroc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡períd na-l-carboxamide To a mixture of Reference Example 90 (175 mg) and ethanol (1.3 mL) was added 168 palladium on carbon (6.4 mg) at room temperature, and the mixture was stirred under a hydrogen atmosphere. After the reaction was completed as judged by LC-MS, the reaction mixture was filtered with Celite, and concentrated in vacuo. The obtained residue was then purified by HPLC (eluate: acetonitrile / water / TFA) to give the title compound (44.1 mg). iH-NMR (CDCh) δ: 1.03-1.31 (2H, m), 1.13 (6H, d, J = 6.0 Hz), 1.34 (3H, s), 1.381.88 (13H, m), 1.91-2.23 (3H , m), 2.27 (2H, d, J = 13.2 Hz), 2.33-2.42 (1H, m), 2.42-2.54 (1H, m), 2.95-3.21 (2H, m), 3.32-3.54 (1H, brs ), 3.58-3.80 (2H, m), 3.91-4.08 (1H, m), 4.65 (1H, d, J = 9.2 Hz), 4.93 (1H, dddd, J = 63.6, 6.4, 6.4, 4.0 Hz). ζζίταηη / ζζηζ / Ε / γίΛΐ REFERENCE EXAMPLE 1 / ac-(lS,2S)-2-[4-(Propan-2-¡l)p¡perazin-l-¡l]c¡clohexan-l-am¡na Step (i): To a mixture of compound 1 (1.13 g) and dichloromethane (2 mL), 1-isopropylpiperazine (1.14 g) was added at room temperature, and the mixture was stirred for 17 hours. After the reaction was completed judging from the consumption of the starting material, diethyl ether was added to the reaction mixture. The precipitate was removed by filtration, and the filtrate was concentrated in vacuo to give a crude product. The crude product obtained was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 2 (1.82 g). LCMS: [M+H]7Rt (min): 256 / 0.48 Step (ii): Palladium / carbon (0.95 g) was added to a mixture of compound 2 (1.14 g), acetic acid (2.04 mL), and ethanol (15 mL) at room temperature, and the mixture was stirred under a hydrogen atmosphere for 18 hours. After the reaction was completed as judged by LC-MS, the reaction mixture was filtered with Celite, and concentrated in vacuo. Next, the obtained residue was purified by silica-amino gel column chromatography (eluate: chloroform) to give compound 3 of 169 titer (0.370 g). LCMS: [M+H]+ / Rt (min): 226 / 0.31 ζζίταηη / ζζηζ / Ε / γίΛΐ REFERENCE EXAMPLE 2 Rac-4-(4-Methylphenyl)-N-[(lS,2S)-2-(p¡peraz¡n-l-¡l)cyclohex¡l]p¡per¡dina1-carboxamide dihydrochloride Step (i): Title compound 4 (1.28 g) was prepared in the same manner as Step (i) in Reference Example 1 using Compound 1 (1.17 g) and 1-Boc-piperazine (1.72 g). Step (i): To a solution of Compound 4 (593 mg) in ethanol (9 mL) was added palladium hydroxide (266 mg) at room temperature, and the mixture was stirred under a hydrogen atmosphere. After the reaction was completed as judged by LC-MS, the reaction mixture was filtered with Celite, and the filtrate was concentrated in vacuo to give the title compound 5 (560 mg). Step (iii): To a mixture of compound 5 (370 mg), triethylamine (0.91 mL), and dichloromethane (5 mL) was added 4-nitrophenyl chloroformate (316 mg) at 0°C, and the mixture was stirred for 2 hours. Then, 4-(4-methylphenyl)piperdine (297 mg) was added to the reaction mixture at 0°C, and stirring was continued at room temperature. After the reaction was over judging by the 170 consumption of the reaction intermediate, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 6 ( 435mg). ζζίτοηη / ζζηζ / Ε / γίΛΐ Step (iv): To a mixture of compound 6 (430 mg) and chloroform (3 mL), hydrogen chloride / dioxane solution (4 M, 2.22 mL) was added at 0°C, and the mixture was stirred for 16 hours. The reaction mixture was then concentrated in vacuo to give the title compound 7 (310 mg). LCMS: [M+H]+ / Rt (min): 385 / 0.71 REFERENCE EXAMPLE 3 zac-(lR,2S)-2-(4-ethyllp¡peraz¡n-l-¡l)cyclohexan-l-amine Step (i): To a mixture of compound 8 (312 mg) and acetic acid (5 mL), platinum (IV) oxide (86 mg) was added, and the mixture was stirred at 70°C under a hydrogen atmosphere for 6 hours. The reaction mixture was then filtered with Celite, and the filtrate was concentrated in vacuo to give a crude product. The crude product obtained was purified by silicaamino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 9 (9 mg). LCMS: [M+H]+ / Rt (min): 212 / 0.15 REFERENCE EXAMPLE 4 Rac-(lR,2S,6S)-2-Methoxy-6-[4-(propan-2-¡l)piperaz¡n-l-¡l]cyclohexan1-amine trihydrochloride 171 15ζζίταηη / ζζηζ / Ε / γίΛΐ Step (i): Title compound 11 (424 mg) was prepared in the same manner as Step (i) in Reference Example 3 using Compound 10 (407 mg). LCMS: [M+H]+ / Rt (min): 146 / 0.15 Step (i): To a mixture of Compound 11 (424 mg), triethylamine (1.22 mL), and acetonitrile (10 mL) was added BoczO (765 mg) at room temperature, and the mixture was stirred at room temperature. After the reaction was completed as judged by LC-MS, water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 12 (310 mg ). LCMS: [M+H]+ / Rt (min): 246 / 0.78 Step (iii): To a mixture of compound 12 (141 mg), triethylamine (0.160 mL), and THF (3 mL) was added ethanesulfonyl chloride (0.160 mL) under ice temperature, and the mixture was warmed to room temperature and stirring was continued. . After the reaction was completed as judged by LC-MS, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the residue obtained was purified by silica gel column chromatography (eluate: hexane / ethyl acetate). 172 to give title compound 13 (180 mg). LCMS: [M+H]+ / Rt (min): 338 / 0.86 Step (iv): To a mixture of compound 13 (155 mg), 1-isopropylpiperazine (236 mg), and 1,4dioxane (4 mL), potassium carbonate (76 mg) was added at room temperature, and the mixture was stirred for 13 hours by heating at 150°C with a microwave device. Then, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 14 ( 17mg). LCMS: [M+H]+ / Rt (min): 356 / 0.81 Step (v): Title compound 15 (16.8 mg) was prepared in the same manner as Step (iv) in Reference Example 2 using Compound 14 (16.3 mg). LCMS: [M+H]+ / Rt (min): 256 / 0.32 ζζίταηη / ζζηζ / Ε / γίΛΐ REFERENCE EXAMPLE 5 / ac-(lS,2S)-2-[4-(Propan-2-yl)piperazin-l-yl]cyclopentane-l-amine Step (i): To a mixture of compound 16 (315 mg), triethylamine (0.289 mL), and THF (5 mL) ethanesulfonyl chloride (0.15 mL) was added, and the mixture was stirred at room temperature for 15 hours. After the reaction was completed judging from the consumption of the starting material, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the residue obtained was purified by 173 silica-amino gel column chromatography (eluate: ethyl acetate / hexane) to give title compound 17 (140 mg). LCMS: [M+H]7Rt (min): 231 / 0.44 Step (i): To a mixture of compound 17 (136 mg) and DMF (4 mL) sodium azide (77 mg) was added, and the mixture was stirred at 80°C for 3.5 hours. After the reaction was completed judging from the consumption of the starting material, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo to give the title compound 18 (137 mg). LCMS: [M+H]+ / Rt (min): 238 / 0.42 Step (iii): To a mixture of compound 18 (42.4 mg), hydrogen chloride / ethyl acetate solution (4.0 M, 0.711 mL), and ethanol (2.8 mL) was added palladium / carbon (202 mg), and the mixture was stirred under hydrogen atmosphere for 8 hours. After the reaction was completed as judged by LC-MS, methanol and aqueous sodium bicarbonate were added to the reaction mixture, and the mixture was filtered with Celite and extracted with chloroform / methanol (6 / 1). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: chloroform / methanol) to give the title compound 19 (98.7 mg ). LCMS: [M+H]7Rt (min): 212 / 0.15 ζζίταηη / ζζηζ / Ε / γίΛΐ REFERENCE EXAMPLE 6 / '<?c-(lR,6S)-2,2-Difluoro-6-[4-(propan-2-yl)p¡peraz¡n-l-¡l]cyclohexan-l-ol Step (i): 174 To a mixture of compound 20 (688 mg) and ethanol (20 mL), 1-isopropylpiperazine (723 mg) was added at room temperature, and the mixture was stirred for 9 hours while heating to 80°C. The reaction mixture was cooled to room temperature, and then concentrated in vacuo. And, the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 21 (830 mg). LCMS: [M+H]+ / Rt (min): 263 / 0.35 ζζίταηη / ζζηζ / Ε / γίΛΐ REFERENCE EXAMPLE 7 / ac-(lR,2S)-3,3-Difluoro-2-[4-(propan-2-¡l)p¡peraz¡n-l-¡l]cyclohexan-l-am na Step (i): To a mixture of DMSO (0.081 mL) and dichloromethane (2 mL), oxalyl chloride (0.075 mL) was added at -78°C, and the mixture was stirred for 20 minutes. Next, a solution of compound 21 (150 mL) in dichloromethane (2 mL) was added to the reaction mixture, and the mixture was further stirred at −78°C for 30 minutes. Triethylamine (0.398 mL) was added to the reaction mixture, and the mixture was heated to 0°C. Next, the mixture was stirred for 30 minutes, and sodium borohydride was added thereto. The mixture was stirred for 30 minutes. And, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, 175 was concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: chloroform / methanol) to give the title compound 22 (27 mg). LCMS: [M+H]7Rt (min): 263 / 0.38 Step (i): To a mixture of compound 22 (27 mg), triethylamine (0.029 mL), and THF (2 mL) was added ethanesulfonyl chloride (0.015 mL), and the mixture was stirred at room temperature. After the reaction was completed judging from the consumption of the starting material, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: chloroform / methanol) to give the title compound 23 (23 mg ). LCMS: [M+H]+ / Rt (min): 354 / 0.65 Step (iii): Title compound 24 (16.0 mg) was prepared in the same manner as Step (i) in Reference Example 5 using Compound 23 (23.4 mg). LCMS: [M+H]+ / Rt (min): 288 / 0.60 Step (iv): To a mixture of compound 24 (14 mg), THF (1 mL), and water (1 mL), triphenylphosphine (25.6 mg) was added at room temperature, and the mixture was stirred for 4.5 hours while heating to 50°C. Then, the reaction mixture was cooled to room temperature, and aqueous hydrochloric acid was added thereto. The mixture was washed with ethyl acetate, and aqueous sodium bicarbonate was added to the aqueous layer. The mixture obtained was extracted with chloroform / methanol (3 / 1). The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo to give the title compound 25 (7.8 mg). LCMS: [M+H]+ / Rt (min): 262 / 0.31 REFERENCE EXAMPLE 8 ζζίταηη / ζζηζ / Ε / γίΛΐ 4-(5-C¡c¡cloprop¡l-l,2,4-oxad¡azol-3-¡l)-4-met¡lp¡perídina monohydrochloride 176 Step (i): To a solution of compound 26 (50.0 g) in ethanol (446 mL), 50% aqueous hydroxylamine (132 mL) was added, and the mixture was stirred at 70°C for 8 hours. The reaction mixture was cooled to room temperature, and water (892 mL) was added to the reaction mixture. The mixture was stirred at room temperature for 30 minutes. The precipitated white crystal was collected on a filter, the obtained crystal was suspended in water (344 mL) again, and the suspension was stirred at room temperature for 30 minutes. The precipitated white solid was collected on a filter and dried to give the title compound 27 (52.3 g). LCMS: [M+H]+ / Rt (min): 258 / 0.52 (Method C) Step (i): To a mixture of compound 27 (52.3 g), cyclopropanecarboxylic acid (18.4 g), HATU (85 g), and THE (406 mL) in an ice bath, triethylamine (142 mL) was slowly added dropwise, and the mixture was stirred. at room temperature for 12 hours. Ethyl acetate (406 mL) was added to the reaction mixture, and the mixture was washed with water (406 mL) and brine (406 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 28 (59.1 g). LCMS: [M+H]+ / Rt (min): 326 / 0.77 (Method C) Step (i!): A mixture of compound 28 (59.1 g), DBU (54.2 mL), and toluene (727 mL) was stirred 177 under reflux for one hour. The reaction mixture was cooled to room temperature, and washed with water (727 mL). The organic layer was concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 29 (54.5 g). LCMS: [M+H]+ / Rt (min): 308 / 1.11 Step (iv): Title compound 30 (35.3 g) was prepared in the same manner as Step (iv) in Reference Example 2 using Compound 29 (54.5 g). LCMS: [M+H]+ / Rt (min): 208 / 0.30 (Method C) ζζίταηη / ζζηζ / Ε / γίΛΐ REFERENCE EXAMPLES 9 TO 12' The compounds of Reference Examples 9 to 12' shown in the table below were prepared according to the process in Reference Example 8 above, using each appropriate starting compound instead of cyclopropanecarboxylic acid in Step (i) in he Reference Example 8. Reference Example Starting Compound Chemical Structure Instrumental Analytical Data 9 O Me P'N HCl ^NH LCMS: [M+H]+ / Rt (min): 196 / 0.32 (Method C) 10 O and oh F F. O-N γγ xm F Y. HCI ^NH LCMS: [M+H]+ / Rt (min): 218 / 0.44 11 [Abs] o F. .Y V OH P'N Λ ¡Abs] Me HCI \^,NH LCMS: [ M+H]+ / Rt (min): 226 / 0.29 (Method C) 12 [Abs] q Me,, ,Ύ \7 OH o-f N HCl Vle \^NH LCMS: [M+H]+ / Rt (min ): 222 / 0.46 (Method C) 12' [Abs] o Me^ OH "\SO-N .Y HCl le ^NH LCMS: [M+H]+ / Rt (min): 222 / 0.46 (Method C) 178 Reference Example 9: 4-(5-ethyl-1,2,4-oxad¡azol-3-yl)-4methylpiperidine monohydrochloride Reference Example 10: 4-[5-(difluoromethyl)-l,2,4-oxadiazol-3yl]-4-methylpiperidine monohydrochloride Reference Example 11: 4-{5-[(lS,2S)-2-fluorocyclopropyl]l,2,4-oxadiazol-3-yl}-4-met¡lp¡peridine monohydrochloride Reference Example 12: 4-Methyl-4-{5-[(1R,2S)-2methylcyclopropyl]-1,2,4-oxad¡azol-3-yl}piperidine monohydrochloride Reference Example 12': 4-Methyl-4-{5-[(1S,2R)-2methylc¡cloprop¡l]-1,2,4-oxad¡azol-3-yl}p¡per monohydrochloride ¡d¡na ζζίταηη / ζζηζ / Ε / γίΛΐ REFERENCE EXAMPLE 13 4-(6-{[4-(5-cycloprop¡l-l,2,4-oxadiazol-3-¡l)-4-met¡lp¡peridine-lcarbon¡l]amino}cyclohex-l- rac-fer-Butyl en-l-yl)-3,6-d¡hydropyr¡dina-l(2H)-carboxylate Step (i): To a mixture of compound 35 (192 mg), cerium(III) chloride heptahydrate (309 mg), and methanol (3 mL) was added sodium borohydride (51.4 mg) under ice temperature, and the mixture was stirred at same temperature for 3 hours. Aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with chloroform / methanol (6 / 1). The organic layer dried 179 on anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 36 (120 mg). LCMS: [M+H]7Rt (min): 280 / 0.97 Step (i): To a mixture of compound 36 (115 mg), triethylamine (0.143 mL), and THF (2 mL) was added ethanesulfonyl chloride (0.058 mL) under ice temperature, and the mixture was stirred for 30 minutes. Sodium azide (107 mg) was then added to the reaction solution. The mixture was warmed to room temperature, and then the mixture was stirred. After the reaction was completed judging from the consumption of the reaction intermediate, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 37 (80 mg ). LCMS: [M+H]+ / Rt (min): 305 / 1.25 Step (iii) Title compound 38 (35 mg) was prepared in the same manner as Step (iv) in Reference Example 7 using Compound 37 (73 mg). LCMS: [M+H]+ / Rt (min): 279 / 0.74 Step (iv) Title compound 39 (14.0 mg) was prepared in the same manner as Step (iii) in Reference Example 2 using Compound 38 (14.4 mg). LCMS: [M+H]+ / Rt (min): 512 / 1.14 REFERENCE EXAMPLE 14 Rac-(lR,6S)-2,2-Difluoro-6-[4-(propan-2-¡l)piperazin-l-¡l]cyclohexanζζίταηη / ζζηζ / Ε / γίΛΐ trihydrochloride 1-amine zzfronn / zznz / E / YiAi Step (i): Title compound 41 (1.59 g) was prepared in the same manner as Step (i) in Reference Example 4 using Compound 40 (1.69 g). LCMS: [M+H]+ / Rt (min): 252 / 0.73 Step (i): To a mixture of Compound 41 (1.5 g) and THF (30 mL) potassium fer-butoxide (1.01 g) was added under ice temperature, and the mixture was stirred at the same temperature for 20 minutes. Next, tosyl chloride (1.37 g) was added to the reaction mixture under ice temperature, and the reaction mixture was further stirred for 2.5 hours. Water was added to the reaction mixture under ice temperature, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue obtained was dissolved in 1,4-dioxane (30 mL), and tosyl chloride (1.37 g) was added to the solution under ice temperature. The solution was heated to 100°C and stirred for 30 minutes. The reaction solution was cooled to room temperature, and aqueous ammonium chloride was added to the reaction solution. The mixture was extracted with chloroform / ethanol (3 / 1). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 42 (1.09 g ). LCMS: [M+H]+ / Rt (min): 234 / 1.01 Step (iii): 181 A mixture of compound 42 (1.09 g), 1-isopropylpiperazine (0.899 g), and ethanol (10 mL) was stirred for 8 hours by heating to 120°C with a microwave device. Next, the reaction solution was concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: ethyl acetate / hexane) to give the title compound 43 (1.32 g). . LCMS: [M+H]+ / Rt (min): 362 / 0.74 Step (iv): Title compound 44 (1.40 g) was prepared in the same manner as Step 10 (iv) in Reference Example 2 using Compound 43 (1.31 g). LCMS: [M+H]+ / Rt (min): 262 / 0.19 REFERENCE EXAMPLES 15 TO 17 The compounds of Reference Examples 15 to 17 shown in the table below were prepared according to the process in Reference Example 14 above, using an optically active isomer of compound 40 (as Material A) instead of compound 40 in the Step (i) in Reference Example 14 and each appropriate starting compound (as Material B) instead of 1-isopropylpiperazine in Step (i¡) in Reference Example 14. ζζίταηη / ζζηζ / Ε / γίΛΐ Reference example Material A Material B Chemical structure Instrumental analytical data 15 [Abs] nh2 F Me^^Me O N H [Abs] । j I 3HCI F LCMS: [M+H]+ / Rt (min): 262 / 0.19 15' [Abs] nh2 X) F Me^^Me N H Me Me (---) / N\ [Abs] r η - 3HCI F / X / F LCMS: [M+H]+ / Rt (min): 262 / 0.19 (Method C) 182 ζζίταηη / ζζηζ / Ε / γίΛΐ Reference Example 15: (lR,6S)-2,2-difluoro-6-[4-(propan-2yl)piperazin-l-yl]cyclohexan-l-amine trihydrochloride Reference Example 15': (lS,6R)-2,2-difluoro-6-[4-(propan-2-yl)p¡peraz¡n-l5 ¡l]cyclohexan-l-amine Reference Example 16: (lR,6S)-2,2-difluoro-6-[6-(propan-2-yl)-3,6diazab¡cyclo[3.1.1]heptan-3-yl]c¡ clohexan-l-amine Reference Example 17: (lR,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8diazabicyclo[3.2.1]octan-8-íl]cyclohexan-l -amine 10 REFERENCE EXAMPLE 18 (lR,6S)-2,2-Difluoro-6-[4-(propan-2-yl)píperazin-l-yl]cyclohexan-l-amine ζζίταηη / ζζηζ / Ε / γίΛΐ Step (i): To a mixture of compound 48 (5.94 g), sodium bicarbonate (13.2 g), and THF (131 mL) was added 2-nitrobenzenesulfonyl chloride (10.5 g) at room temperature, and the mixture was stirred at the same temperature for 16 hours. Aqueous sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The obtained residue was dissolved in THF (131 mL), and triethylamine (11 mL) and methanesulfonyl chloride (3.67 mL) were added to the solution under ice temperature. The mixture was stirred. After the reaction was completed judging from the consumption of the starting material, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue obtained was dissolved in acetonitrile (393 mL), and potassium carbonate (16.3 mg) was added to the solution. The mixture was stirred for one hour while heating to 80°C. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 49 (9.25 g ). LCMS: [M+H]+ / Rt (min): 319 / 0.94 Step (i): A mixture of compound 49 (7.1 g), 1-isopropylpiperazine (3.56 mL), and toluene (22.3 mL) was stirred for one hour while heating to 110°C. After the reaction was over judging by 184 consumption of the starting material, the reaction mixture was concentrated in vacuo, and the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 50 ( 9.79g). LCMS: [M+H]7Rt (min): 447 / 0.68 Step (iii): To a mixture of benzenethiol (0.530 mL) and toluene (11.2 mL), sodium hydride (55%, 0.215 g) was added under ice temperature, and the mixture was warmed to room temperature and stirred for 10 minutes. Next, a solution of compound 50 (1 g) in toluene (9 mL) was added to the reaction mixture, and the mixture was stirred by heating to 60°C. After the reaction was completed judging from the consumption of the starting material, the reaction solution was cooled to 0°C, and 40% aqueous sodium hydroxide was added to the reaction mixture. The mixture was extracted with toluene. 5 M hydrochloric acid was added to the organic layer under ice temperature, and the aqueous layer was extracted from the mixture. To the aqueous layer obtained, 40% aqueous sodium hydroxide was added, and the mixture obtained was extracted again with toluene. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 51 ( 0-47g). LCMS: [M+H]+ / Rt (min): 262 / 0.17 REFERENCE EXAMPLE 19 2-(4-Methylpiperidin-4-yl)-4,5,6,7-tetrahydro-l,3-benzoxazole Step (i): A mixture of compound 52 (120 mg), 2-chlorocyclohexanone (68.9 mg), and DMF (1.5 mL) was stirred for 11 hours by heating to 130°C with a microwave device. Next, hydrogen chloride / l,4-dioxane solution (0.25 mL) was added to the reaction solution, and the mixture was stirred for 6 hours by heating to 130°C with a microwave device. The reaction solution was concentrated in vacuo, and the residue obtained was dissolved in ethanol. 15% aqueous sodium hydroxide (2 mL) was added to the solution, and the mixture was stirred for 3 hours by heating to 150°C with a 185 microwave device. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 53 ( 14 mg). LCMS: [M+H]+ / Rt (min): 221 / 0.57 REFERENCE EXAMPLE 20 4-(5-cyclopropyl-1,2-oxazol-3-1)-4-methylpiperidine monohydrochloride Step (i): To a mixture of compound 54 (900 mg), sodium acetate (650 mg), and methanol (5 mL) was added hydroxylamine hydrochloride (550 mg), and the mixture was stirred at room temperature for 24 hours. The reaction solution was cooled to 0°C, and water was added thereto. The mixture was extracted with chloroform, and the organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo to give the title compound 55 (1.23 g). Step (ii): To a mixture of compound 55 (416 mg) and DMF (4 mL) was added N-chlorosuccinimide (252 mg), and the mixture was stirred for 3 hours. The reaction solution was cooled to 0°C, and water (6 mL) was added thereto. The precipitated solid was collected on a filter, and dried to give the title compound 56 (326 mg). Step (i!): 186 To a mixture of ethynylcyclopropane (117 mg) and toluene (5 mL) were added Compound 56 (326 mg) and sodium bicarbonate (198 mg), and the mixture was stirred at room temperature. After the reaction was completed judging from the consumption of the starting material, water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo. The obtained residue was then purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 57 (348 mg). LCMS: [M+H]+ / Rt (min): 307 / 1.13 Step (iv): Title compound 58 (307 mg) was prepared in the same manner as Step (iv) in Reference Example 2 using Compound 57 (337 mg). LCMS: [M+H]+ / Rt (min): 207 / 0.49 REFERENCE EXAMPLE 21 60 61 zzfronn / zznz / E / YiAi Step (i): To a solution of Compound 59 (1.46 g) in THF (30 mL) was added isobutyl chloroformate (819 mg) and diisopropylethylamine (3.88 g) under ice temperature, and the mixture was stirred for one hour. 2-Aminophenol (655 mg) was added to the reaction mixture under ice temperature, and the mixture was stirred for 6 hours by heating to 70°C. The reaction solution was directly purified by silica-amino gel column chromatography (eluate: ethyl acetate / hexane) to give the title compound 60 (710 mg). LCMS: [M+H]+ / Rt (min): 335 / 2.28 (Method B) Step (ii): A mixture of Compound 60 (204 mg) and acetic acid (1.10 mL) was stirred for 2 hours. 187 by heating to 90°C, and concentrated in vacuo. The residue obtained was dissolved in chloroform (2 mL), and trifluoromethanesulfonic acid (2.1 mL) was added to the solution. The mixture was stirred at room temperature for one hour. The reaction solution was concentrated in vacuo, ethyl acetate and sodium bicarbonate were added to the residue. The mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: ethyl acetate / hexane) to give the title compound 61. (99mg). LCMS: [M+H]+ / Rt (min): 217 / 1.36 (Method B) REFERENCE EXAMPLE 22 4-cyclopentyl-4-methylpiperdine monohydrochloride Step (i): To a mixture of compound 62 (700 mg) and THF (14 mL), lithium diisopropylamide (2 M, 5.18 mL) was added at -78°C, and the mixture was stirred at the same temperature for 2 hours. Bromocyclopentane (1.23 mL) and potassium iodide (478 mg) were added to the reaction mixture, and the mixture was warmed to room temperature. The mixture was stirred overnight, and then water was added to the mixture. The mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: ethyl acetate / hexane) to give the title compound 63 (468 mg ). LCMS: [M+H]+ / Rt (min): 312 / 1.26 Step (ii): 188 To a mixture of lithium aluminum hydride (104 mg) and THF (3 mL), Compound 63 (371 mg) and THF (6 mL) were added under ice temperature, and the mixture was stirred for 4 hours. After the reaction was completed judging by the consumption of the starting material, water (0.104 mL), 15% aqueous sodium hydroxide (0.104 mL), and then water (0.312 mL) were added to the reaction mixture at 0°C, and the mixture was stirred. The reaction mixture was filtered. The filtrate was concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: ethyl acetate / hexane) to give the title compound 64 (320 mg). LCMS: [M+H]+ / Rt (min): 284 / 1.06 Step (iii): To a mixture of Compound 64 (314 mg), triethylamine (0.309 mL), and THF (5 mL) was added methanesulfonyl chloride (0.104 mL), and the mixture was stirred at room temperature. After the reaction was completed judging from the consumption of the starting material, water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: ethyl acetate / hexane) to give the title compound 65 (290 mg ). LCMS: [M+H]+ / Rt (min): 362 / 1.15 Step (iv): To a mixture of compound 65 (278 mg) and THF (3 mL) was added lithium triethylborohydride (0.99 M, 1.55 mL), and the mixture was stirred at room temperature. Then, the reaction solution was heated to 70°C. After the reaction was completed judging from the consumption of the starting material, the reaction solution was cooled to 0°C, and aqueous ammonium chloride was added to the reaction solution. The mixture was extracted with chloroform, and the organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The obtained residue was then purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 66 (100 mg). LCMS: [M+H]+ / Rt (min): 268 / 1.42 Step (v): Title compound 67 (58.5 mg) was prepared in the same manner as Step (iv) in Reference Example 2 using Compound 66 (90 mg). LCMS: [M+H]+ / Rt (min): 168 / 0.62 ζζίταηη / ζζηζ / Ε / γίΛΐ 189 REFERENCE EXAMPLE 23 ζζίταηη / ζζηζ / Ε / γίΛΐ 4-(4,4-Difluoroc!clohexyl)-4-methylperidine monohydrochloride The compound of Reference Example 23 shown in the table below was prepared according to the process in Reference Example 22 above, using 1,1-difluoro4-iodocyclohexane instead of bromocyclopentane in Step (i) in the Reference Example 22. Reference Example Chemical Structure Instrumental Analytical Data 23. F HCl H 1 1Me LCMS: [M+H]+ / Rt (min): 218 / 0.57 REFERENCE EXAMPLE 24 4-(5-cyclopropyl-1,3,4-thiadiazol-2-1)-4-methylperidine monohydrochloride Step (i): To a mixture of Compound 59 (399 mg), cyclopropanecarbohydrazide hydrochloride (269 mg), and DMF (5 mL) were added HATU (686 mg) and diisopropylethylamine (1.15 mL), and the mixture was stirred at room temperature for 3 hours. . Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 69 (520 mg ). LCMS: [M+H]+ / Rt (min): 326 / 0.74 190 Step (i!): To a mixture of Compound 69 (255 mg) and toluene (6 mL) Lawesson's reagent (349 mg) was added, and the mixture was stirred under reflux for one hour. The reaction solution was cooled to 0°C, and aqueous sodium bicarbonate was added to the reaction solution. The mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica gel column chromatography (eluate: hexane / ethyl acetate) and then by silica gel column chromatography. -amino (eluate: hexane / ethyl acetate) to give the title compound 70 (102 mg). LCMS: [M+H]+ / Rt (min): 324 / 1.08 Step (iii): Title compound 71 (78 mg) was prepared in the same manner as Step (iv) in Reference Example 2 using Compound 70 (92 mg). LCMS: [M+H]7Rt (min): 224 / 0.45 REFERENCE EXAMPLE 25 ζζίταηη / ζζηζ / Ε / γίΛΐ 4-(5-cyclopropyl-1,3-thiazol-2-yl)-4-methylperidine monohydrochloride Step (i): Title compound 72 (796 mg) was prepared in the same manner as Step (i) in Reference Example 24 using Compound 59 (718 mg) and 2-amino1-cyclopropylethane-l-one hydrochloride (400 mg). LCMS: [M+H]+ / Rt (min): 325 / 0.83 191 Step (ii): To a mixture of Compound 72 (127 mg), pyridine (0.063 mL), and toluene (3 mL) Lawesson's reagent (205 mg) was added, and the mixture was stirred under reflux for 14 hours. The reaction solution was cooled to room temperature, and then aqueous sodium bicarbonate was added to the reaction solution. The mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the obtained residue was purified by silica-amino gel column chromatography (eluate: hexane / ethyl acetate) to give the title compound 73 ( 76.3 mg). LCMS: [M+H]+ / Rt (min): 323 / 1.43 Step (iii): Title compound 74 (66.5 mg) was prepared in the same manner as Step (iv) in Reference Example 2 using Compound 73 (77 mg). LCMS: [M+H]+ / Rt (min): 223 / 0.67 REFERENCE EXAMPLE 26 4-(2-cyclopropyl-l,3-thiazol-4-yl)-4-methylpiperidine monohydrochloride ζζίταηη / ζζηζ / Ε / γίΛΐ 77 Step (i): A solution of Compound 75 (532 mg) and cyclopropanecarbothioamide (168 mg) in methanol (6 mL) was stirred under reflux for 2.5 hours. The reaction mixture was allowed to cool to room temperature, and then saturated aqueous sodium bicarbonate was added to the reaction mixture. The mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo, and then the ...

Claims

CLAIMS (1) or a pharmaceutically acceptable salt thereof wherein R1 is an optionally substituted Ce-io aromatic carbocyclyl group, an optionally substituted 5- to 10-membered aromatic heterocyclyl group, an optionally substituted C3-6 saturated carbocyclyl group, an optionally substituted 4- to 10-membered saturated heterocyclyl group, or cyano; L1 and L2 are each independently a single bond, methylene (which may be optionally substituted with the same or different one or more Ci 4 alkyl groups), -NR8-, -C(=O)-, -OC(=O)-, -SO-, -SO2-, -S-, or oxygen atom; R2 is a hydrogen atom, hydroxy group, halogen atom, cyano, or optionally substituted C1-4 alkyl group; or when L1 is a single bond, R1 and R2 can combine together as a spiro ring to form an optionally substituted C3-6 saturated carbon ring or an optionally substituted 4- to 10-membered saturated heteroring;R3 and R4 are each independently hydrogen atom, halogen atom, cyano, -(C=O)NR5R6, carboxy group, -(C=O)O-R7, optionally substituted Ci-4 alkyl, or optionally substituted Ci-4 alkoxy, wherein R3 and R4 may be attached to the same carbon atom if chemically possible; or when R3 and R4 are attached to different carbon atoms, R3 and R4 may be taken together via a C1-6 alkylene to form a fused ring or a bridged ring; R5 to R7 are each independently hydrogen atom, halogen atom, or optionally substituted C1-4 alkyl; R8 is each independently hydrogen atom or optionally substituted C1-4 alkyl; n is an integer from 1, 2, 3, or 4;ring G is an optionally substituted Cs-ium aromatic carbocyclyl group, an optionally substituted 5- to 10-membered aromatic heterocyclyl group, an optionally substituted C3-6 saturated carbocyclyl group, or an optionally substituted 4- to 10-membered saturated heterocyclyl group; A1 is an oxygen atom or a sulfur atom; A2 is an oxygen atom or -NR8-; A3 is -CH-, a nitrogen atom, or a carbon atom; and the bond accompanied by a dashed line is each independently a single or double bond.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, further characterized in that in R2-R8, the optionally substituted Ci-4 alkyl substituent is the same as or different from one or more substituents selected from the group consisting of a halogen atom, hydroxy group, Ci-4 alkoxy, Ce-10 aromatic carbocyclyl group, and C3-7 cycloalkyl; and the optionally substituted Ci-4 alkoxy substituent is the same as or different from one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, and C3-7 cycloalkyl; in R1, the optional substituent is an optionally substituted Ce-10 aromatic carbocyclyl group, an optionally substituted 5- to 10-membered aromatic heterocyclyl group, or an optionally substituted C3-6 saturated carbocyclyl group.and optionally substituted saturated heterocyclyl group of 4 to 10 members is each independently substituted with at least one substituent selected from the group consisting of hydrogen atom, halogen atom, hydroxy group, Ce-ium aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkyl, Ci-4 alkoxy, and C3-7 cycloalkyl), Ci-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Ci-4 alkoxy, and C3-7 cycloalkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, Ci-4 alkoxy, and cycloalkyl from C3-7),C1-6 alkylamino (the alkyl group of which may be optionally substituted with a halogen atom, hydroxy group, or C3-7 cycloalkyl), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl optionally substituted with the same or different one or more halogen atoms, and C3-7 cycloalkyl), and 5- to 10-membered aromatic heterocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, alkyl of C1-4, C1-4 alkoxy, and C3-7 cycloalkyl); and in ring G,The optional substituent of the optionally substituted Ce-io aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and optionally substituted 4- to 10-membered saturated heterocyclyl group is each independently at least one substituent selected from the group consisting of a halogen atom, a C1-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a hydroxy group, a Ci4 alkoxy, and a C3-7 cycloalkyl), a C6-10 aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a hydroxy group, a Ci4 alkoxy, and a C3-7 cycloalkyl), and a C6-10 aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a hydroxy group, a Ci4 alkoxy group, and a C3-7 cycloalkyl group). halogen, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl),C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C3-7 cycloalkyl), C1-6 alkylamino (the alkyl group of which may be optionally substituted with halogen atom, hydroxy group, or C3-7 cycloalkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), and C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl); or when there are plural optional substituents,Two of them can be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring.

3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, further characterized in that at R2-R7, the optionally substituted Ci-4 alkyl substituent is the same as or different from one or more substituents selected from the group consisting of a halogen atom and a Cu alkoxy; and the optionally substituted Ci-4 alkoxy substituent is the same as or different from one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkyl; at R1, the optionally substituted Ce-ium aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and optionally substituted 4- to 10-membered saturated heterocyclyl group is each independently at least one substituent selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxy group,aromatic C6-10 carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkoxy, and C3-7 cycloalkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, C1-4 alkoxy, and C3-7 cycloalkyl halogen, hydroxy group,C1-4 alkyl optionally substituted with the same or different one or more halogen atoms, and C3-7 cycloalkyl), and 5- to 10-membered aromatic heterocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, Cu alkyl, C1-4 alkoxy, and C3-7 cycloalkyl); and in ring G, the optional substituent of the optionally substituted Ce-io aromatic carbocyclyl group, optionally substituted 5- to 10-membered aromatic heterocyclyl group, optionally substituted C3-6 saturated carbocyclyl group, and optionally substituted 4- to 10-membered saturated heterocyclyl group is each independently at least one substituent selected from the group consisting of a halogen atom,C1-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkoxy), Ce-io aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), C1-6 alkylamino (the alkyl group of which may be optionally substituted with a halogen atom, a hydroxyl group, or C3-7 cycloalkyl),and a C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy); or when there are plural optional substituents, two of them may be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring.

4. The compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, further characterized in that R1 is selected from the following formulas (a-1) to (a-4): (1a-1) X1 - X7 are each independently a nitrogen atom or CRa6; Q1 and Q2 are an oxygen atom, -NRa7-, or a sulfur atom; Ral - Ra7 are each independently (if they are plurals of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, Ce-io aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy),C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), or aromatic heterocyclyl group of 5 to 10 members; wherein Ra4 and Ra5 may be attached to the same carbon atom if chemically possible; and when X1 and X3 are both CRa6,The two Ra6 atoms can be taken together with the carbon atoms to which each is attached to form a 6-membered carbon ring that fuses with the 5-membered ring comprising X1, X2, and X3; and q1 is an integer of 1 or 2.

5. The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, further characterized in that ring G is selected from the following (lb-1) to (lb-14): ζζίταηη / ζζηζ / E / γίΛΐ 252 (1b-3) (1b-4) zzfronn / zznz / E / YiAi (1b-9) (1b-13) wherein W1, W3, W5, W6, W7, W11, W12, W13, W15, W16, W17, W19, and W25 are each independently a nitrogen atom or CRb4; W2, W4, W8, W9, W10, W14, W18, W20, W21, W22, W23, and W24 are NRb5, oxygen atom, or CRb6Rb7; Rbl - Rb7 are each independently (if there are 5 plurals of CRb4, each Rb4 is also independently), hydrogen atom, -N(Rb8)Rb9, Ci-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom,C3-7 cycloalkyl group that may be optionally substituted with the same or different one or more substituents selected from group 253 consisting of a halogen atom and a C1-4 alkyl (said C1-4 alkyl may be substituted with a halogen atom), and a C1-4 alkoxy), Ce-ium aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), 5- to 10-membered aromatic heterocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and C1-4 alkyl),C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy); wherein Rbl and Rb2 may be attached to the same carbon atom if chemically possible; or Rbl and Rb2 may be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a ported ring; and Rb8 and Rb9 are each independently hydrogen atom, Ci 6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, Ci-4 alkoxy,C3-7 cycloalkyl that may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkyl (said C1-4 alkyl may be substituted with a halogen atom), and a 5- to 10-membered aromatic heterocyclyl group), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkyl), a 5- to 10-membered aromatic heterocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), or a C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a hydroxy group, a C1-4 alkyl,and C1-4 alkoxy); or Rb8 and Rb9 can be taken together with the nitrogen atom to which they are attached to form a saturated nitrogen-containing heterocycle of 3 to 7 members.

6. The compound according to any of claims 1 to 5 of formula (2): or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the following formulas (a-1) to (a-4): wherein X1 - X7 are each independently a nitrogen atom or CRa6; Q1 and Q2 are an oxygen atom, -NRa7-, or a sulfur atom; Ral - Ra7 are each independently (if they are plurals of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, Ce-io aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy),C3-6 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, Cu alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), or a 5- to 10-membered aromatic heterocyclyl group; wherein Ra4 and Ra5 may be attached to the same carbon atom if chemically possible; and where X1 and X3 are both CRa6,The two Ra6 atoms can be taken together with the carbon atoms to which each is attached to form a 6-membered carbon ring that fuses with the 5-membered ring comprising X1, X2, and X3; and q1 is an integer of 1 or 2; L1 and L2 are each independently a single bond, -CH2-, or oxygen atom; R2 is a hydrogen atom, hydroxy group, halogen atom, cyano, or optionally substituted 255 Ci-4 alkyl; R3 and R4 are each independently hydrogen atom, halogen atom, C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkoxy, and C3-7 cycloalkyl), or C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl,and C3-7 cycloalkyl); wherein R3 and R4 can be attached to the same carbon atom if chemically possible; and when R3 and R4 are attached to different carbon atoms in the ring, R3 and R4 can be taken together via a C1-6 alkylene to form a fused ring or bridged ring; ring G is selected from the following (lb-1) to (lb-4): (1b-1) (1b-2) (1b-3) (1b-4) wherein W1, W3, W5, W6, and W7 are each independently a nitrogen atom or CRb4; W2, W4, and W8 are NRb5, an oxygen atom, or CRb6Rb7; Rbl - Rb7 are each independently (if they are plurals of CRb4, each Rb4 is also independently), hydrogen atom, C1-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy),aromatic C6-10 carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl,and C1-4 alkoxy); wherein Rbl and Rb2 can be attached to the same carbon atom if chemically possible; or Rbl and Rb2 can be taken together via a C1-6 alkylene to form a chemically possible bicyclic structure selected from a fused ring, a spiro ring, and a bridged ring; A1 is an oxygen atom or a sulfur atom; A2 is an oxygen atom or -NH-; and A3 is -CH-, a nitrogen atom, or a carbon atom.

7. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, further characterized in that R1 is selected from the following formulas (la-1), (la-2), and (la-3-1): ζζίταηη / ζζηζ / E / γίΛΐ wherein X1 - X6 are each independently a nitrogen atom or CRa6; Q1 and Q2 are an oxygen atom, -NRa7-, or a sulfur atom; and Ral - Ra3, Ra6, and Ra7 are each independently (if they are plurals of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, Ce-io aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy),C37 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), or 5- to 10-membered aromatic heterocyclyl group; Wherein, when X1 and X3 are both CRa6, the two Ra6 can be taken together with the carbon atoms to which each is attached to form a 6-membered carbon ring that fuses with the 5-membered ring comprising X1, X2, and X3.

8. The compound according to claim 6 or 7 or a pharmaceutically acceptable salt thereof, further characterized in that ring G is selected from the following (lb-1), (lb-2), and (lb-4): (1b-1) (1b-2) (1b-4) wherein W1, W3, W5, W6, and W7 are each independently a nitrogen atom or CRb4; W2 and W4 are NRb5 or CRb6Rb7; and Rbl, Rb2, and Rb4 - Rb7 are each independently (if they are plurals of CRb4, each Rb4 is also independently), hydrogen atom, C1-6 alkyl (which 257 may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), Cb-io aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy),C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkyl), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), or C3-7 cycloalkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy); or Rbl and Rb2 may be attached to the same carbon atom if chemically possible; or Rbl and Rb2 may be taken together via a Ci-e alkylene to form a bridged bicyclic structure.

9. The compound according to any of claims 6 to 8 or a pharmaceutically acceptable salt thereof, further characterized in that ring G is selected from the following (lb-1) and (lb-2): (1b-2) ζζίταηη / ζζηζ / E / γίΛΐ wherein W1 and W3 are nitrogen atom or CRb4; W2 and W4 are NRb5 or CRb6Rb7; and Rbl, Rb2, and Rb4 - Rb7 are each independently hydrogen atom, C1-6 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), Cs io aromatic carbocyclyl group (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, C1-4 alkyl, and C1-4 alkoxy), C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl),C3-7 cycloalkyl (which may optionally be substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy), or C3-7 cycloalkoxy (which may optionally be substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy); wherein Rbl and Rb2 may be attached to the same carbon atom if chemically possible; or Rbl and Rb2 may be taken together via a C1-6 alkylene to form a bridged bicyclic structure. 258, 10. The compound according to any one of claims 1 to 9 of formula (3): (3) or a pharmaceutically acceptable salt thereof, wherein R1 is the following formula (la-1), (la-2), or (la-3-1): wherein X1 - X6 are each independently a nitrogen atom or CRa6; Q1 and Q2 are an oxygen atom or a sulfur atom;Ral - Ra3 and Ra6 are each independently (if plurals of CRa6, each Ra6 is also independently), hydrogen atom, halogen atom, C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, and C1-4 alkoxy), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), cyano, or C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy);wherein when X1 and X3 are both CRa6, the two Ra6 can be taken together with the carbon atoms to which each is attached to form a 6-membered carbon ring that fuses with the 5-membered ring comprising X1, X2, and X3; L1 and L2 are each independently a single bond or oxygen atom; R2 is a hydrogen atom, halogen atom, or Ci-4 alkyl that can optionally be substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a hydroxyl group; R3 and R4 are each independently a halogen atom; ring G is the following (lb-1), (1b 2-1), (lb-2-2), or (lb-2-3): 259 Rb5 (1b-1-1) ζζίταηη / ζζηζ / E / γίΛΐ where Rb5 is a hydrogen atom, or a Ci-6 alkyl that may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkoxy; and A1 is an oxygen atom or a sulfur atom.; 11. The compound according to any of claims 4 to 10 or a pharmaceutically acceptable salt thereof, further characterized in that R1 is formula (la2), and Ral is hydrogen atom, halogen atom, C1-4 alkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkoxy), C3-7 cycloalkyl (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom, hydroxy group, C1-4 alkyl, and C1-4 alkoxy), or C1-4 alkoxy (which may be optionally substituted with the same or different one or more substituents selected from the group consisting of halogen atom and C1-4 alkyl).

12. The compound according to claim 10 to 11 or a pharmaceutically acceptable salt thereof, further characterized in that R1 is formula (la-2), and X4 and X5 are both nitrogen atoms.

13. The compound according to any of claims 10 to 12 or a pharmaceutically acceptable salt thereof, further characterized in that ring G is of the formula (lb-1-1), and Rb5 is an alkyl of Ci-4 that may be optionally substituted with the same or different one or more halogen atoms.

14. The compound according to any one of claims 10 to 12 or a pharmaceutically acceptable salt thereof, further characterized in that ring G is of the formula (lb-2-1), and Rb5 is a hydrogen atom, or a C1-4 alkyl group which may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkoxy group.

15. The compound according to any one of claims 1 to 12 of formula (4): 260 1): F (4) or a pharmaceutically acceptable salt thereof, wherein R1 is the following (la-2- ζζίταηη / ζζηζ / E / γίΛΐ where Q2 is an oxygen atom or a sulfur atom; Ra2 is a C37 cycloalkyl group (which may optionally be substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy) or a cycloalkoxy group (which may optionally be substituted with the same or different one or more substituents selected from the group consisting of a halogen atom, a C1-4 alkyl, and a C1-4 alkoxy); R2 is a C1-4 alkyl; ring G is the following (lb-1-1) or (lb-2-1): Rb5 (1b-1-1) Rb5 (1 b-2-1) wherein Rb5 is a C1-4 alkyl that may be optionally substituted with the same or different one or more substituents selected from the group consisting of a halogen atom and a C1-4 alkoxy;and L2 is a single bond or oxygen atom. 15; 16. The compound according to claim 15 or a pharmaceutically acceptable salt thereof, further characterized in that Ra2 is a C37 cycloalkyl group that can be optionally substituted with the same or different one or more substituents 261 selected from halogen atoms, and R2 is a methyl group.

17. The compound according to claim 15 or 16 or a pharmaceutically acceptable salt thereof, further characterized in that Ra2 is a cyclopropyl group that may optionally be substituted with the same or different one or more substituents selected from halogen atoms, and R2 is a methyl group.

18. The compound according to any of claims 15 to 17 or a pharmaceutically acceptable salt thereof, further characterized in that ring G is of the formula (lb-2-1), and Rb5 is an isopropyl group.

19. The compound according to any of claims 15 to 17 or a pharmaceutically acceptable salt thereof, further characterized in that ring G is of the formula (lb-1-1), and Rb5 is an α-sobutyl group.

20. The compound according to any of claims 15 to 17 or a pharmaceutically acceptable salt thereof, further characterized in that ring G is of the formula (lb-1-1), Rb5 is an isopropyl group, and L2 is an oxygen atom.

21. The compound according to any of claims 15 to 20 or a pharmaceutically acceptable salt thereof, further characterized in that Q2 is an oxygen atom.

22. The compound of claim 1 or a pharmaceutically acceptable salt thereof, further characterized because it is selected from the following compound names or structures: 4-(5-cyclopropyl-l,2-oxazol-3-yl)-N-{(lS,6R)-2,2-d¡fluoro-6-[4(propan-2-yl)piperazin-l-yl]cyclohexyl}-4-methylpiperid¡na-l-carboxamide F 4-(5-c¡cloprop¡ll,2,4-oxad¡azol-3-¡l)-N-{(lS,6R)-2,2-difluoro-6-[4-(propan-2¡l)piperaz¡nl-¡l]c¡clohexil}-4-methylp¡l-cardiac-cardiac-26 ζζίταηη / ζζηζ / Ε / γίΛΐ 4-(5-cyclopropyl-l,2,4-oxad¡azol-3-yl)-N-{(lR,6S)-2,2-d¡fluoro-6-[4-(propan-2¡l)piperaz¡nl-¡l]c¡clohex¡l}-4-methylp¡amp¡amp¡l 4-(5-cyclopropyl-l,2-oxazol-3-yl)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-lyl]c¡clohexil}-4-met¡lp¡per¡d¡na-l-carboxamide 4-(5-cycloprop¡ll,2z4-oxad¡azol-3-¡l)-N-{(lR,6S)-2,2-d¡fluoro-6-[3-(propan-2-¡l)-3,8d¡azabic¡chlo[3.2.1]octane-8-yl]cyclohex¡l}-4-methylp¡perid¡na-l-carboxamide 263 zzfronn / zznz / E / YiAi F N-{(lR,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazab¡c¡chlo[3.2.1]octane-8¡l]c¡clohex¡l}-4-met¡l-4-(4-meth¡lphen¡l)p¡d-carb 4-(5-cyclopropyl-l,2-oxazol-3-yl)-N-{(lR,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8- N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2-yl)p¡peraz¡nl-yl]c¡clohexil}-4-{5-[(lS ,2S)-2fluorocycloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-methylp¡per¡dine-l-carboxamide Me^ ^Me 264 N-{(lR,6S)-2,2-d¡fluoro-6-[4-(propan-2-¡l)p¡peraz¡nl-yl]cyclohex¡l}-4-met¡l-4 -{5[(lS,2R)-2-meth¡lcyclopropyl]-l,2,4-oxad¡azol-3-yl}piper¡d¡na-l-carboxyne Me^ .Me ζζίταηη / ζζηζ / Ε / γίΛΐ N-{(lR,6S)-2,2-d¡fluoro-6-[4-(propan-2-¡l)p¡perazin-l-yl]c¡clohex¡l}-4-met¡l-4-{55 [(lR,2S)-2-met¡lc¡clopropyl]-l,2,4-oxad¡azol-3-yl}piperid¡na-l-carboxamida Me^ ^Me rac-4-(5-cycloprop¡ll,2,4-oxadiazol-3-¡l)-N-{(lR,6S)-2,2-d¡fluoro-6-[4-(propan-2yl)piperaz¡nl-¡l]c¡clohexil}-4-met¡lpiperid¡na-l-carbot¡oam¡da Me^ ^Me 10 4-(5-cycloprop¡ll,2,4-oxadiazol-3-yl)-N-{(lR,6S)-2,2-difluoro-6-[4-(propan-2¡l)piperazin-l-¡l]c¡clohex¡l}-4-methylpiper¡d¡na-l-carbotioamida. 265 ζζίταηη / ζζηζ / Ε / γίΛΐ.

23. The compound of claim 1 or a pharmaceutically acceptable salt thereof, further characterized because it is selected from the following compound names or structures: 4-(5-c¡cloprop¡ll,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-2,2-d¡fluoro5 6-{[(3R)-l-(propan-2-¡l)p¡rrol¡d¡n-3-¡l]ox¡}c¡clohex¡l]-4-met¡lpiper¡d¡na-l-carboxam¡da N-[(lR,6S)-2,2-d¡fluoro-6-{[(3R)-l-(propan-2-yl)p¡nOl¡d¡n-3-¡l]ox¡}c¡clohex¡l]-4-met¡l4-(4-meth¡lphenyl)piperidine-l-boxamide 10 4-(5-c¡cloprop¡ll,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-2,2-d¡fluoro-6-{[(3S)-l-( propane-2¡l)p¡rrol¡n-3-¡l]ox¡}c¡clohex¡l]-4-methylp¡per¡d¡na-l-carboxam¡da 266 ζζίταηη / ζζηζ / Ε / γίΛΐ N-[(lR,6S)-2,2-difluoro-6-{[(3S)4-(propan-2-yl)p¡rrol¡din-3-¡l]oxy}c¡clohex¡l]-4-{5 [(lS,2S)-2-fluorooc¡chlopropyl]-l,2,4-oxad¡azol-3-¡l}-4-met¡lpiper¡d¡na-l-carboxam¡da 5 N-[(lR,6S)-2,2-difluoro-6-{[(3R)-l-(propan-2-¡l)p¡rrOl¡n-3-¡l]ox¡}c¡clohex¡l]-4-{5[(lS,2S)-2-clopropyl,¡l,2]4-oxad¡azol-3-yl}-4-meth¡lpiper¡d¡na-l-carboxam¡da N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-l)p¡rrolidin-3-¡l]ox¡}c¡clohex¡l]-4-m ethyl4-{5-[(lR,2S)-2-met¡lcycloprop¡l]-l,2,4-oxad¡azol·3-¡l}p¡per¡d¡na-l-carboxamide 267 4-(5-cycloprop¡ll / 2,4-oxad¡azol-3-yl)-N-[(lRz6S)-2 / 2-d¡fluoro-6-<[(3Sz4S)-4-fluo ro-l(propan-2-yl)pyrrole¡d¡n-3-yl]oxy}c¡clohex¡l]-4-methylpiperid¡na-l-carboxam¡da 4-(5-c¡cloprop¡l·l,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-6-{[(3R)-4,4-d¡fluoro-l-(propane-25 il)pyrrolid¡n-3-¡l]ox¡}-2,2-difluorooc¡clohex¡l]-4-methylpiper¡dyne-l-carboxamide., 24. The compound of claim 1 or a pharmaceutically acceptable salt thereof, further characterized because it is selected from the following compound names or structures: il]c¡clohex¡l}-4-{5-[(lR,2R)-2-fluorooc¡cloprop¡l]-l,2,4-oxad¡azol·3-¡l}-4-met¡lp¡per¡na-l-carboxam¡da N-[(lR,6S)-2,2-d¡fluoro-6-{met¡l[(3S)-l-(propan-2-¡l)p¡rrol¡din-3-¡l]amino}c¡clohex¡l]4 -{5-[(lS,2S)-2-fluorooc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡per¡na-l-carboxam¡da 268 Me Me ζζίταηη / ζζηζ / Ε / γίΛΐ N-[(lR,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-¡l)amino]pyrrole¡d¡nl-¡l}cyclohexyl]4 -{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡dine-l-carboxam¡da 5 4-(5-cyclobutyl-l,2,4-oxadiazol-3-yl)-N-{(lR,65)-2,2-difluoro-6-[4-(propan-2¡l)p¡peraz¡nl-¡l]c¡clohex¡l}-4-methylpiper¡l-carboxylate 4-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-N-[(lR,65)-2,2-difluoro-6-{(3S)-3-[methyl(propan2-¡l)am¡no]p¡rrol¡nl-¡l}c¡clohex¡l]-4-met¡lp¡perid¡na-l-carboxam¡da 269 Me ζζίταηη / ζζηζ / Ε / γίΛΐ N-{(lR,6S)-2,2-difluoro-6-[(2S)-2-met¡l-4-(propan-2-¡l)p¡perazine-l-¡l]c¡clohexil}-4- {5[(lS,2S)-2-fluorooc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lp¡per¡d¡na-l-carboxam¡da F N-{(lR,6S)-2,2-difluoro-6-[(2R)-2-methyl-4-(propan-2-yl)piperazin-l-yl]c¡clohexil}-4- {5[(lS,2S)-2-fluorooc¡cloppro¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lpiper¡d¡na-l-carboxamide Mex ^Me N-[(lR,6S)-2,2-difluoro-6-{(3R)-3-[met¡l(propan-2-yl)amino]p¡rrol¡d¡nl-¡l}c¡clohexil]4 -{5-[(lS,2S)-2-fluorooc¡cloprop¡l]-l,2,4-oxadiazol-3-¡l}-4-met¡lp¡per¡dyne-l-carboxam¡da May 270 N-[(lR,6S)-2,2-difluoro-6-{4-[methyl(propan-2-¡l)am¡no]piper¡d¡nl-yl}c¡clohexil]-4-{ 5[(lS,2S)-2-fluorooc¡chlopropyl]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡na-l-carboxam¡da ζζίταηη / ζζηζ / Ε / γίΛΐ Me N-[(lR,6S)-6-{(3S)-3-[c¡clopropyl(met¡l)amino]p¡rrolidin-l-¡l}-2,2-d¡fluorolidin-l-cl {5-[(lC,2C)-2-fluorocycloprop¡l]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡d¡na-l-carboxam¡da N-[(lR,6S)-2,2-difluoro-6-{(3S)-3-[meth¡l(2-meth¡lpropyl)amino]pyrrol¡d¡n-lyl}cyclohex¡l]- 4-{5-[(lS,2S)-2-fluorooc¡cloprop¡l]-l,2,4-oxad¡azole·3-¡l}-4-methylp¡per¡na-l-carboxam¡da 10 N-[(lR,6S)-2,2-difluoro-6-(4-{met¡l[(l-met¡lc¡cloprop¡l)met¡l]am¡no}p¡per¡d¡nl¡l)c¡clohex¡ l]-4-{5-[(lS,2S)-2-fluorooc¡chloprop¡l]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡na-l-carboxam¡da 271 N-[(lR,6S)-2,2-difluoro-6-(4-{[(l-fluorocyclopropyl)met¡l](methyl)amino}piper¡d¡nl¡l)c¡clohex l]-4-{5-[(lS,2S)-2-fluorooc¡chloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-rnet¡lpiper¡dine-l-carboxam¡da 5 N-[(lR,6S)-6-{(3S)-3-[(cycloprop¡lmet¡l)(met¡l)am¡no]pyrrolidin-l-yl}-2,2difluorocyclohex¡ l]-4-{5-[(lS,2S)-2-fluorooc¡clopropyl]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡na-lcarboxamide N-[(lR,6S)-6-{(3S)-3-[(c¡cloprop¡lmethl)(meth¡l)am¡no]p¡rrol¡d¡nl-¡l}-2,210 difluoroc¡clohex¡l]-4-(5-cyclopropyl-l,2,4-oxadiazol-3-¡l)-4-met¡lp¡per¡dina-l-carboxam¡da 272 ζζίταηη / ζζηζ / Είγγ zac-4-(5-c¡cloprop¡ll,2,4-oxadiazol·3-¡l)-N-{(lR,2R,6S)-2-fluoro-6-[4-(propane-2¡l)piperaz¡nl-¡l]c¡clohex¡l}-4-met¡lpiper¡d¡na-l-carboxam¡da 5 N-{(lR,6S)-2,2-difluoroO-6-[4-(propan-2-¡l)-l,4-d¡azepan-l-¡l]c¡clohex¡l}-4-{5[(l S,2S)-2-fluorooc¡chlopropyl]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡na-l-carboxam¡da 4-{5-[(lS,2S)-2-fluorooc¡clopiOpyl]-l,2,4-oxad¡azol-3-¡l}-N-{(lR,2S,6S)-2-fluo ro-6-[4(propan-2-¡l)p¡peraz¡nl-¡l]c¡chlohex¡l}-4-met¡lpiper¡d¡na-l-carboxam¡da 273 4-{5-[(lS,2S)-2-fluorooc¡cloprop¡l]-l,2,4-oxad¡azol-3-¡l}-N-{(lS,2R,6R)-2-fluo rO-6-[4(propan-2-yl)p¡peraz¡nl-yl]c¡clohexyl}-4-meth¡lpiper¡d¡na-l-carboxam¡da ζζίταηη / ζζηζ / Ε / γίΛΐ N-[(lRz6S)-2z2-d¡fluoro-6-{4-[met¡l(2-methylprop¡l)amino]piper¡d¡nl-yl}c¡clohex]-4¡5 {5-[(lS,2S)-2-fluorocycloprop¡l]-lz2,4-oxad¡azol-3-¡l}-4-methylp¡per¡d¡na-l-carboxamide N-[(lR,6S)-6-{4-[(c¡cloprop¡lmeth¡l)(meth¡l)amino]p¡per¡d¡nl-¡l}-2,2-difluorocyclohex¡l]4-{5-[(lS,2S)-2-fluorooc¡l-clops¡l,2,]4-oxad¡azol-3-¡l}-4-methylpiperid¡na-l-carboxamide 10 N-[(lRz6S)-6-{4-[c¡clobut¡l(met¡l)am¡no]p¡per¡d¡nl-¡l}-2,2-difluoroOC¡clohex¡l]-4-{5 [(lSz2S)-2-fluorocycloprop¡l]-lz2z4-oxad¡azol-3-¡l}-4-met¡lpiperidine-l-carboxam¡da 274 ζζίταηη / ζζηζ / Ε / γίΛΐ N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(propan-2-yl)pyrrol¡d¡n-3-¡l]amino}cyclohex¡l]-4-{ 5[(lS,2S)-2-fluorooc¡chloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-rnet¡lpiper¡d¡na-l-carboxam¡da 5, 25. The compound of claim 1 or a pharmaceutically acceptable salt thereof, further characterized because it is selected from the following compound names or structures: N-[(lR,6S)-2,2-difluoro-6-{[l-(propan-2-yl)p¡per¡d¡n-4yl]ox¡}cyclohexyl]-4-{5-[(lS,2S)-2-fluorocyclopropyl]-l,2,4-oxadiazol-3-methylcarpidyne-4-lboxamide) F 4-(5-c¡cloprop¡ll,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-2,2-d¡fluoro-6-{[l-(pr opan-2¡l)piper¡d¡n-4-¡l]ox¡}c¡clohex¡l]-4-methylp¡per¡d¡na-l-carboxam¡da 275 Me ζζίταηη / ζζηζ / Ε / γίΛΐ 4-(5-cyclobutyl-l,2,4-oxadiazol-3-yl)-N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-( propane-2¡l)p¡rrol¡n-3-yl]ox¡}c¡clohex¡l]-4-methylpiper¡d¡na-l-carboxamide May 5 N-[(lR,6S)-2,2-d¡fluoro-6-{[(3S)-l-(propan-2-¡l)p¡rrolidin-3-¡l]ox¡}c¡clohex¡l]-4-e t¡l-4{5-[(lS,2S)-2-fluorocycloprop¡l]-l,2,4-oxadiazol-3-yl}p¡peridine-l-carboxam¡da N-[(lR,6S)-2,2-d¡fluoro-6-{[(3S)-l-(2-met¡lpropyl)p¡rrolidin-3-¡l]ox¡}c¡clohexil]-4-{5[(lS,2S)-2-fluorooc¡l,l,l,2 / 4-oxad¡azol-3-yl}-4-methylp¡per¡d¡na-l-carboxamide Me 10 F 4-(5-cycloprop¡ll,2,4-oxad¡azol-3-¡l)-N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(2methylpropyl)p¡rrol¡d¡n-3-yl]oxy}cyclohex¡l-peridyne-pyridine-4] ζζίταηη / ζζηζ / Ε / γίΛΐ N-[(lR,6S)-6-{[(3S)-l-(c¡cloprop¡lmethl)p¡rrol¡d¡n-3-¡l]oxy}-2,2-d¡fluorooc¡clohex¡l]-4 -{5[(lS,2S)-2-fluorooc¡cloprop¡l]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡dine-l-carboxam¡da F. F 4-(5-cyclopropyl·lz2z4-oxad¡azol-3-yl)-N-[(lRz6S)-6-{[(3S)-l-(2z2d¡meth¡lpropy l)p¡rrol¡d¡n-3-¡l]ox¡}-2 / 2-d¡fluorooc¡clohex¡l]-4-met¡lpiper¡d¡na-l-carboxam¡da N-[(lR,6S)-6-{[(3S)-l-(2,2-dimethylpropyl)p¡rrol¡d¡n-3-¡l]ox¡}-2,2-d¡fluorooc¡clohex¡l]-410 {5-[(lS,2S)-2-fluorooc¡cloprop¡l]-l,2z4-oxad¡azol-3-¡l}-4-met¡lp¡per¡na-l-carboxam¡da Me Til N-[(lR,6S)-2,2-difluoro-6-({(3S)-l-[(l-met¡lc¡clopropyl)methyl]pyrrol¡d¡n-3yl}oxy)c¡clohex¡ l]-4-{5-[(lS,2S)-2-fluorooc¡clopropyl]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡na-lcarboxamide ζζίταηη / ζζηζ / Ε / γίΛΐ F 5 N-[(lR,6S)-6-{[(3S)-l-(c¡cloprop¡lmet¡l)p¡rrol¡d¡n-3-yl]ox¡}-2,2-d¡fluoroOC¡clohe x¡l]-4-(5cycloprop¡ll,2,4-oxadiazol-3-¡l)-4-met¡lp¡per¡dyne-l-carboxam¡da 4-(5-cycloprop¡ll,2,4-oxad¡azol-3-yl)-N-[(lR,6S)-2,2-d¡fluoro-6-({(3S)-l-[(lmeth¡lcyclopropyl)methyl]p¡rrolidin-3-yl}cyclohexyl-period-amyl-carpida] 10 F N-[(lR,6S)-2,2-difluoro-6-({(3S)-l-[(l-fluorocyclopropyl)met¡l]p¡rrol¡d¡n-3yl}oxy)c¡clohex l]-4-{5-[(lS,2S)-2-fluorooc¡chlopropyl]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡d¡na-lcarboxamide 278 N-[(lR,6S)-2,2-d¡fluoro-6-(4-{methyl[(l-met¡lcyclopropyl)methyl]amino}piper¡d¡nl¡l)c¡clohex¡ l]-4-{5-[(lS,2S)-2-fluorooc¡chloprop¡l]-l,2,4-oxad¡azol-3-yl}-4-met¡lp¡per¡na-l-carboxam¡da N-[(lR,6S)-2,2-difluoro-6-{[(3S)-l-(2-fluoro-2-methylprop¡l)p¡rrolid¡n-3¡l]ox¡}c¡clohex¡l] -4-{5-[(lS,2S)-2-fluorooc¡chloprop¡l]-l,2,4-oxad¡azol-3-¡l}-4-met¡lpiper¡na-lcarboxamide., 26. A medicament for the treatment of an orexin receptor-related disease, comprising the compound of any of claims 1 to 25 or a pharmaceutically acceptable salt thereof.

27. A medicinal product for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, hypersomnia associated with Lewy body dementia, hypersomnia syndrome involving daytime hypersomnia (e.g., Kleine-Levin syndrome, major depression accompanied by hypersomnia, Lewy body dementia, Parkinson's disease, progressive supranuclear palsy, Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome, Niemann-Pick disease type C, cerebral contusion, cerebral infarction, brain tumor, muscular dystrophy, multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barré syndrome, Rasmussen's encephalitis, Wernicke's encephalopathy, limbic encephalitis, Hashimoto's encephalopathy), coma, loss of consciousness, obesity (e.g., malignant mast cells, extrinsic obesity,hyperinsulin obesity, hyperplasmic obesity, pituitary obesity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, childhood obesity, upper body obesity, dietary obesity, gonadal obesity, systemic mastocytosis, primary obesity, central obesity), insulin resistance syndrome, Alzheimer's disease, impaired consciousness such as coma, side effect or complication caused by anesthesia, sleep disturbance, sleep problems, insomnia, intermittent sleep, nocturnal myoclonus, REM sleep disruption, jet lag, jet lag syndrome, shift worker sleep disorder, dyssomnia, sleep terrors, depression, major depression, sleepwalking, enuresis, sleep disorder, Alzheimer's sunset syndrome, circadian rhythm-associated disorder, fibromyalgia, condition resulting from decreased sleep quality, bulimia, obsessive eating disorder,Obesity-related diseases, hypertension, diabetes, elevated plasma insulin level / insulin resistance, hyperlipidemia, endometrial cancer, breast cancer, prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart rhythm, arrhythmia, myocardial infarction, congestive heart failure, heart failure, coronary heart disease, cardiovascular disease, sudden death, polycystic ovary syndrome, craniopharyngioma, Prader-Willi syndrome, Froehlich syndrome, growth hormone deficiency, short stature, Turner syndrome, children suffering from acute lymphoblastic leukemia, syndrome X, reproductive hormone abnormality, decreased fertility, infertility, hypogonadism in men, dysfunction of sexual / reproductive function such as hirsutism in women,fetal defect associated with obesity in maternity, gastrointestinal motility disorder such as obesity-related gastroesophageal reflux, obesity hypoventilation syndrome (Pickwickian syndrome), respiratory disease such as respiratory distress, inflammation such as systemic vascular inflammation, arteriosclerosis, hypercholesterolemia, hyperuricemia, lower back pain, gallbladder disease, gout, kidney cancer, secondary risk of obesity such as risk of left ventricular hypertrophy, migraine, headache, neuropathic pain, Parkinson's disease, psychosis, schizophrenia, facial flushing, night sweats, disease of the genital / urinary system, disease associated with sexual function or fertility, persistent depressive disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder,zzfronn / zznz / E / YiAi 280 obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, anxiety disorder, acute neurological and psychiatric disorder such as brain deficiency developed after cardiac bypass surgery or heart transplantation, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head injury, periparturient hypoxia, cardiac arrest, hypoglycemic nerve injury, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, eye damage, retinopathy, cognitive impairment, muscle spasm, tremor, epilepsy, disorder associated with muscle spasm, delirium, amnesic disorder, age-related cognitive decline, schizoaffective disorder, paranoia, drug addiction, movement disorder, chronic fatigue syndrome, fatigue,drug-induced parkinsonian syndrome, Tourette syndrome, chorea, myoclonus, tic, restless leg syndrome, dystonia, dyskinesia, attention deficit hyperactivity disorder (ADHD), conduct disorder, urinary incontinence, withdrawal syndrome, trigeminal neuralgia, hearing loss, tinnitus, nerve injury, retinopathy, macular degeneration, vomiting, cerebral edema, pain, bone pain, arthralgia, toothache, cataplexy, or traumatic brain injury, comprising the compound of any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof.

28. A medicament for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with Lewy body dementia, comprising the compound of any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof.

29. A method for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with Lewy body dementia, comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof to a patient in need thereof.

30. The use of the compound as claimed in any of claims 1 to 25 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-like symptoms, hypersomnia associated with Parkinson's disease, or hypersomnia associated with Lewy body dementia.